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When I first entered the study of hormone action, 
some 25 years ago, there was a widespread feeling 
among biologists that hormone action could not be 
studied meaningfully in the absence of organized cell 
structure. 
However, as I reflected on the history of 
biochemistry, it seemed to me there was a real 
possibility that hormones might act at the molecular 
level. 
o Earl W. Sutherland, Nobel Address, 1971 
  





During the last two and a half decades, a large body of research has been amassed which indicate that 
various compounds capable of inducing hormone-like responses in humans and animals are present within 
the environment.  These natural and synthetic molecules, termed endocrine disruptors, have been implicated 
in a variety of developmental, reproductive and physiological abnormalities which have been shown to 
converge on the endocrine system.  Given that endocrine disrupters are comprised of a diverse group of 
molecules with dissimilar chemical structures, general screening techniques are not feasible for effective 
environmental monitoring.  A primary method of action by which these exogenous molecules affect the 
homeostatic regulation of the endocrine system is believed to be via the modulation of gene transcription.  
It is now well established that many endocrine disrupting compounds act upon a principal group of 
transcription factors, the nuclear receptors, by chance interaction with the ligand-binding domains of these 
proteins. 
The current consensus is that endocrine disruptors pose a significant, long-term environmental risk to the 
well-being of both humans and wildlife.  Resultantly, there is a growing need for the development of 
technologies that can be employed in the rapid assessment of environmental samples for the presence of 
detrimental xenobiotics.  In the view of this need, this dissertation describes membrane-based biological 
devices which may ultimately form the basis of novel assays which may be used for the rapid detection of 
endocrine disrupting compounds in remote geographical locations.  Specifically, this study describes: 
1. A review of the development of in vitro membrane-based immunoassays used in rapid diagnostics, 
point-of-care analysis and over-the-counter devices for the detection of diseases, environmental 
contaminants, drugs of abuse and adulterants in food and water supplies.  
2. The heterologous expression and purification of highly functional recombinant forms of the alpha 
isoform of the human oestrogen receptor ligand-binding domain. 
3. The characterisation of the ligand-binding properties of these receptor molecules regarding the 
natural ligand, 17β-oestradiol, other hormones and several known endocrine disruptors by 
saturation and competitive radioligand-binding methods. 
4. Immobilisation of the receptor proteins onto a synthetic support via chelation chemistry and the 
determination of endocrine active compound sequestration to the biofunctionalised membrane. 
5. The establishment, selection and propagation of immortal murine hybridoma cell strains derived 
from antigen-stimulated B-cells fused to Sp2/0-Ag14 murine myeloma cells. 
6. The purification of monoclonal antibodies raised against a defined epitope on the human oestrogen 
receptor alpha ligand-binding domain surface. 
7. Covalent labelling of purified monoclonal antibodies with colloidal gold nanoparticles in 
preparation for the development of a novel immunochromatographic device. 
  





Die teenwoordigheid van natuurlike en sintetiese chemiese middels wat oor die vermoë beskik om die 
aksies van hormone in die mens en dier na te boots was ’n belangrike focus in navorsing gedurende die 
laaste twee en ’n halwe dekades.  ’n Verskeidenheid van ontwikkelings-, reproduktiewe- en fisiologiese 
abnormaliteite ontstaan as gevolg van die aksies van hierdie molekule, genaamd endokriene-ontwrigters, op 
die natuurlike funksionering van die endokriene-sisteem.  Gegewe dat die groep chemiese middels waaruit 
endokriene-ontwrigters bestaan ’n diverse oorsprong het lei dit daartoe dat algemene analitiese tegnieke nie 
altyd geskik is vir effektiewe omgewingsmonitering is nie.  Die modulasie van geentranskripsie is een van 
die metodes wat voorgestel word as ’n metode waarop hierdie eksogene molekule die homeostatiese 
regulering deur die endokriene-sisteem ontwrig.  ’n Algemene wyse waarop vele endokrien-ontwrigtende 
stowwe geentranskripsie beïnvloed is deur interaksie met die hormoon-bindings loki van ’n belangrike 
groep transkripsiefaktore, die nukluêre reseptore. 
Die huidige konsensus is dat endokriene ontwrigters ’n beduidende, langtermyn omgewingsrisiko vir die 
welsyn van mense, sowel as diere inhou.  Gevolglik is daar 'n toenemende behoefte aan die ontwikkeling 
van tegnologieë vir die vinnige nasporing van nadelige xenobiotika in omgewingsmonsters.  In die lig van 
dié behoefte beskryf hierdie proefskrif membraangebaseerde biologiese toestelle wat uiteindelik die basis 
kan vorm van nuwe toetse vir die spoedige opsporing van endokriene ontwrigtende verbindings in afgeleë 
geografiese areas.  Meer spesifiek beskryf hierdie studie: 
1. 'n Oorsig oor die ontwikkeling van in vitro membraan-gebaseerde immunoessaïs wat gebruik word 
in vinnige diagnostiese analise, punt-van-sorg-analise en oor-die-toonbank-toestelle vir die 
deteksie van siektes, omgewingsbesoedeling, dwelms en nadelige bymiddels in kos- en 
waterbronne. 
2. Die heteroloë uitdrukking en suiwering van hoogs funksionele rekombinante vorme van die alfa-
isoform van die menslike estrogeenreseptor ligandbindende domein. 
3. Die karakterisering van die ligandbindingseienskappe van hierdie reseptorproteïene ten opsigte 
van die natuurlike ligand, 17β-estradiol, ander hormone en verskeie bekende endokriene 
ontwrigters deur versadiging en mededingende radioligand-bindingsmetodes. 
4. Immobilisering van die reseptorproteïene op 'n sintetiese membraan deur middel van kelering, 
gevolg deur toetsing van binding aan die biofunksionele membraan deur verbindings met bekende 
endokriene aktiwiteite. 
5. Die vestiging, seleksie en vermeerdering van hibried muissellyne wat gevorm is deur die 
versmelting van antigeengestimuleerde B-selle met die Sp2/0-Ag14 muis miëlomasellyn. 
6. Die suiwering van monoklonale teenliggaampies wat vervaardig is om 'n gedefinieerde epitoop op 
die alfa-isovorm van die menslike estrogeenreseptor se ligandbindingsdomein te herken. 
7. Kovalente binding van gesuiwerde monoklonale teenliggaampies aan kolloïdale goud-
nanopartikels in voorbereiding vir die ontwikkeling van 'n nuwe immunochromatografiese toestel.  
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Figure 4.2 Proposed immunochemical EDC detection system, based on conformational changes to the nuclear 
receptor LBD tertiary structure following ligand binding.  Monoclonal antibodies, selected for 
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Figure 4.11 Titrations of anti-αII hybridoma culture supernatants.  (A) ELISA plate indicating the extremely high 
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Water quality and availability is intrinsic to public health and greatly impacts on the sustainable 
development and economic progress of a country.  Between 1990 and 2015, more than 2.6 billion people 
have gained access to improved sources of drinking water (1).  Nevertheless, within the developing world, 
where economic progress is limited, a variety of water related issues threaten the global gains formulated 
under the United Nations (UN) Millennium Development Goals in relation to improved access to safer 
drinking water (2).  Water quality assurance programs in Third World countries are often circumscribed by 
a lack of scientific skill and knowledge, resulting in the contamination of water supplies by industrial 
chemicals, pesticides and biological waste.  Moreover, many persistent chemicals capable of disrupting the 
biochemical processes of the endocrine system are imported into developing countries as agricultural aids 
or agents for pathogen control (3). 
The occurrence of endocrine disrupting compounds (EDCs), pharmaceutical and personal care products 
(PPCPs) within the environment is believed to be detrimental to public health and, within industrialised 
countries, trace level detection of synthetic biologically active chemicals has received much attention (4–
13).  In developing countries, however, due to poor waste disposal practices and a lack of infrastructure to 
effectively test and treat contaminated water, people are increasingly being exposed to pesticides and other 
EDCs.  Considering the many deleterious effects that have been linked to EDC exposure, continual 
assessment of the environmental impact of chemical and pharmaceutical discharge at specific locations, 
such as water and sewage treatment facilities, industrial zones and rural water access points, which may 
affect the lives of people and animals, is a necessity.  Still, any action plan aimed at the successful 
management of EDCs, or the formulation and implementation of strategies for environmental remediation, 
would ultimately require methods capable of rapid and cost-effective detection of problematic compounds.  
In contrast to the developing world, industrialised countries have access to the infrastructure and knowledge 
base needed to implement various analytical techniques for the continual monitoring of specific EDCs.  In 
vitro assays are extremely relevant in the rapid detection of small molecules and assessment of their 
endocrine disruptive capabilities.  Yet, internationally agreed and validated testing methods capture only a 
limited range of the known spectrum of EDCs and most of these assays still necessitate access to a 
laboratory and other forms of expensive infrastructure, while requiring multiple reaction steps and 
prolonged incubation periods prior to generation of a result.  There is thus a growing need for the 
development of a rapid and economical EDC detection system that may be used in situ with a low demand 
for technical capabilities.  Such a system must not require specialised equipment yet must be able to detect 
a range of different molecules without the need for complex end-points and/or additional steps such as 
chemical derivatisation or the maintenance of test animals.  Ideally, therefore, EDCs should be identified by 
their biological mode of action and not by specific molecular structures. 




The first requirement in the design of such a novel system, capable of the simultaneous detection of a 
variety of chemicals which occur at low concentrations, is the ability to selectively sequester and 
concentrate molecules with analogous biological effects.  A main site of convergence for many EDCs is at 
genetic regulatory points controlled by the nuclear receptor superfamily of transcription factors.  Despite 
the vast and diverse regulatory roles which they govern, nuclear receptors share remarkable structural and 
functional organisation.  In general, these molecules are modular in nature (14) and consist of a single 
polypeptide chain that may be delineated into four or five segregate domains.  The centrally located 
deoxyribose nucleic acid (DNA)-binding domain (DBD) recognises highly specific DNA sequences which, 
upon binding of the receptors, mediate activation or repression of gene transcription via an array of 
transcription factor recruitment events.  The DBD is linked by a hinge domain of variable length to a 
ligand-binding domain (LBD), located within the C-terminal half of the polypeptide.  It is this domain that 
is the target for various hormonal and non-hormonal ligands.  Furthermore, depending on the structure of 
the ligand, it is the LBD that mediates which coregulatory elements are recruited and thus is central in the 
direction of specificity of the biological response.  The biological actions mediated by nuclear receptors are 
therefore governed, in part, by chance interaction with cognate ligands which fit into the ligand-binding 
pocket (LBP) of the LBD.  Thus, to be able to selectively concentrate small molecules which can mediate 
such actions via the oestrogen receptor (ER) without the need for prior knowledge of their chemical 
identity, we have transferred the genetic material encoding the LBD of the human alpha isoform of this 
receptor (hERα LBD) to the genome of a recombinant baculovirus (15).  Two different constructs were 
made, both of which are expressed as histidine-tagged fusion proteins following infection of a suitable 
insect host cell: one, a 30.5 kDa protein containing only the LBD of ERα, known as the E-domain 
(hERαLBD), and a 35.2 kDa analogue consisting of the hERαLBD plus 42 additional C-terminal amino 
acid residues constituting the F-domain of ERα (hERαLBD-f). 
The availability of recombinant forms of nuclear receptors enables the binding of structurally diverse EDCs 
with the ability to elicit analogous biological effects, thereby facilitating the concentration of said EDCs to 
measurable levels.  By employing conventional and modern binding assay methods, that utilise specialised 
equipment which mostly require fluorescent or radioactive tracers, EDC equivalents to cognate receptor 
ligands may be evaluated and quantified (16–18).  However, these in vitro methods require the use of 
apparatus that is generally only available to research institutions or agencies with funds available to conduct 
such intricate and complicated tests.  Furthermore, even though nonseparation methods have been devised 
based on the process of scintillation proximity counting (19), most traditional binding experiments utilising 
soluble receptor proteins require some form of partitioning of bound from unbound ligands prior to reading 
of the result.  The techniques which have been developed to facilitate this separation step, generally require 
physical adsorption of unbound ligand to dextran-coated charcoal (DCC) or ligand-bound protein to 
hydroxyapatite, followed by centrifugation or filtration.  These methods are typically time-consuming and 
cumbersome and are ill-suited to routine high-throughput screening (HTS) assays.  Recent advances in our 
laboratory have enabled the directed immobilisation of proteins containing histidine-fusion tags to a 




specialised synthetic immobilised metal affinity membrane (IMAM) via chelation chemistry (20).  Thus, by 
retaining recombinant hERα LBD to the membrane, we have enabled the specific sequestration of small 
molecules which can bind the protein, together with a facile means to separate bound from unbound ligand.  
The next challenge is to design a system which can be used to indicate binding of EDCs to the membrane-
immobilised receptors that does not rely on the use of dangerous radioisotopes or sensitive devices for 
measurement.  Ideally, the method should enable a visual result as output that may be interpreted without 
extensive knowledge of the molecular principles behind the test.  Thus, in this thesis, two novel in vitro 
membrane-based methodologies, applicable in achieving this this goal, will be introduced. 
Nuclear receptors undergo changes in conformation when a ligand, natural or synthetic, occupies the 
receptor LBD (21–23).  In vivo, this initiates a cascade of molecular events which result in the activation 
and control of many cellular functions.  Of importance, the change in the tertiary and quaternary structure 
of the receptor results in a concomitant change in the profile of surface accessible amino acids.  Antibodies 
are proteins produced in the bodies of animals in response to invasion by a foreign antigen, which it binds 
to and which it neutralises; they are, by definition, extremely discriminatory in their molecular binding 
interactions.  Since the surface accessibility of antigenic determinants available for antibody-binding will 
differ between alternative three-dimensional protein conformations, an immunochemical probe may be 
capable of discriminating between ligand-bound (either agonist (the holo form) or antagonists) and apo-
receptor (unliganded) states.  A dipstick test for the immunochemical detection of oestrogenic EDCs based 
on the conformation change which occur in the hERα LBD following ligand-binding would therefore 
consist of a biofunctionalised IMAM and a means to visualise such a three-dimensional alteration.  The 
possibility of designing a membrane-based dipstick test which exploits these characteristics was 
investigated by immunising BALB/c mice with purified hERαLBD bound to 17β-oestradiol (E2), thus 
raising populations of cells that secrete antibodies against the holo form of receptor LBD.  In addition, 
peptide antigens which are either related to the hERα LBD or which have been reported in literature to 
interact with the LBD (24, 25), have also been used as immunogens.  Antibody-secreting spleen cells were 
subsequently harvested and fused to a murine myeloma cell line for the generation of immortal hybrid cell 
populations. 
Immunoassay dipstick tests are multi-step assays requiring consecutive transfer of the membrane from one 
reagent vial to the next, with intermittent wash steps.  Conversely, lateral flow immunochromatographic 
assay (LFIA) devices are self-contained, mostly qualitative or semi-quantitative tests utilising differential 
interaction of reagents within delineated capillary flow systems.  Several LFIA are available for the 
detection of compounds that are known to be disruptive of the endocrine system.  These assays are, 
however, highly specific towards individual compounds or, in rare cases, have been adapted to multiplexed 
assays which detect several defined chemicals within a single unit.  Since structurally diverse EDC affect 
biological actions via binding to nuclear receptor (NR) LBDs, a practical alternative may be the assembly 
of a LFIA based on receptor-ligand interactions.  There are several potential iterations by which such an 
LFIA may function; in general exploiting competitive binding of cognate ligands to recombinant receptor 




LBDs, release of biorecognition molecules from temporary storage and visualisation of binding reactions 
by the formation of a coloured line at a test zone on the device strip. 
The health threat posed by EDCs affects all individuals, in both an urban and rural context, and demands 
regular, reliable, rapid and cost-effective methods of detection.  Yet, considering the global disparity in 
wealth and resources, too few communities have the infrastructure or expertise for continual analysis of 
water or food samples for EDCs by laboratory-based techniques.  A rapid point-of-care (POC) device 
intended to serve as a baseline screening method will be especially useful in rural municipalities where 
infrastructure may be old, inadequate or simply lacking.  With the goal to develop a membrane-based POC 
assay for environmental EDC monitoring, the aims of this study are: 
1. To investigate the in vitro ligand-binding properties of an isolated steroid-binding protein. 
2. To establish a method to selectively concentrate potential ligands onto biofunctionalised 
membranes. 
3. To investigate the feasibility of using monoclonal antibodies to visually indicate protein-ligand 
interaction. 
4. To refine existing and novel designs of membrane-based EDC detection devices. 
The rest of this dissertation will thus be presented as follows: 
In Chapter 2 an overview of the technology used for rapid, on-site diagnostics and environmental 
monitoring with the use of hand-held paper and membrane devices will be discussed.  The evolution of 
relatively simple membrane-based immunochemical dipstick tests and their origins from intricate 
laboratory-based methods is outlined.  An overview of the principles and requirements involved in LFIA 
fabrication is given with a focus on the materials involved for the manufacture of such devices. 
In Chapter 3 the characterisation of heterologously expressed hERα LBD is approached by radioligand 
binding assays.  The section will start with a brief overview of the production and purification of these 
proteins within the baculovirus expression vector system.  The binding parameters, KD and Bmax, for both 
proteins were determined to allow comparison of the efficacy of binding and affinity for the natural ligand, 
E2.  By means of competitive binding assays, inhibitory binding constants for several xenobiotic 
compounds were determined.  Finally, the ability to immobilise recombinant receptors to a novel chelation 
membrane is presented.  Following biofunctionalisation of the membrane, the protein retains ligand-binding 
capabilities and can thus serve to selectively sequester and concentrate compounds with ER-binding 
capabilities. 
Chapter 4 addresses the production of monoclonal antibodies against the hERα LBD.  Following the fusion 
of B cells obtained from immunised mice with a murine myeloma cell line by means of polyethylene glycol 
mediated cell fusion, several hybridoma cell strains were established by the limiting dilution technique.  
The difficulties associated with an immunological approach to indicate receptor conformation are briefly 
outlined and an alternative solution to the design of a novel EDC detection system is introduced. 




In Chapter 5 the purification of antibodies from hybridoma culture media is approached by affinity 
chromatography.  The immunoglobulins were subsequently titrated and conjugated to gold nanoparticles to 
facilitate visualisation of the hERα LBD without the need for additional enzymatic substrates or reagents.  
It is shown that the conjugate-antibodies not only retained epitope-recognition following covalent 
attachment to the gold colloid, but that the complex can migrate across a lateral axis to be captured by a 
second anti-hERα antibody.  This is an important requirement for the establishment of a method for EDC 
detection which utilises lateral flow to separate bound from free ligand. 
In conclusion, Chapter 6 presents a general overview of the strategies investigated in the study.  The results 
are discussed considering future directions which may be considered for the assembly of a functional 
membrane-based EDC detection system and possible improvements to the hypotheses introduced in 
previous chapters are presented. 





Membrane-based rapid immunodiagnostic tests: 
Evolution, assembly and function 
2.1 INTRODUCTION 
The radioimmunoassay (RIA) was the first in vitro assay designed for the rapid, quantitative detection of 
specific biomolecules in complex matrices.  Originating from the work of Yalow and Berson (26), RIA had 
found widespread application as an extremely valuable diagnostic tool in clinical practice and in the 
detection of small molecules, peptides and proteins from a wide variety of sources.  However, since 
radioactive substances are used during the procedure, the main limitations of RIA are imposed by its tracer 
component.  Depending on the isotope employed, radiolabelled tracers may be extremely short lived.  The 
half-life of the 131I radioisotope used for the labelling of insulin by Yalow and Berson (27), for instance, is a 
mere 8.04 days.  Furthermore, depending on the activity of the compound in question, at the very least the 
use of radioisotopes must be confined to licenced type C laboratories (28), which adds additional 
complications to the procedures required for their use and disposal.  The principles of RIA, to a certain 
extent, have formed the basis of one of the most well-known and prolific methods of sample analysis, the 
enzyme-linked immunosorbent assay (ELISA).  As first described by Engvall and Perlmann in 1971 (29, 
30), ELISAs are performed in a plate-based format and are used as qualitative or quantitative means to 
detect a variety of molecules using antigens or antibodies adsorbed to polystyrene by passive mechanisms.  
Resultantly, the technique is highly amenable to settings requiring HTS methodologies.  Within the first 
decade following its advent, ELISAs were developed for the detection and quantification of a variety of 
hormones, drugs, serum components, oncofoetal proteins, viral and other infectious diseases, auto-immune 
diseases and parasitic diseases (31, 32).  Nevertheless, although simple and economical to perform, the 
procedure requires sophisticated equipment such as specialised plate washers and spectrophotometers that 
must be regularly maintained and necessitates a constant supply of electricity and skilled technicians.  
Moreover, ELISAs are generally ill suited for small laboratories with limited funds to invest in 
infrastructure, and where only a small number of samples may require analysis at any given time.  As an 
alternative assay format, membrane-based analytical techniques provide several advantages over the 
ELISA.  The high surface areas and binding capacities of membranes permits excellent concentration of 
analytes for visualisation with a variety of labels.  Furthermore, reagents required for membrane-based 
diagnostics are normally compatible with dry storage without refrigeration and are therefore well-suited to 
environments outside of traditional laboratory settings. 
  




2.2 DOT IMMUNOASSAYS 
The dot immunoassay (DIA), or dot-ELISA, is a highly versatile solid-phase immunoassay for antigen or 
antibody detection which require only sparing amounts of reagents, a low level of technical abilities and 
limited infrastructure.  Expanding upon the DNA dot hybridisation method developed by Kafatos et al. 
(33), Hawkes et al. (34) described a procedure of dot immunobinding in which minute volumes of 
monoclonal antibodies (mAbs) were directly applied to nitrocellulose (NC).  Initially developed to replace 
traditional ELISAs for the screening of hybridoma clones for antigen-specific antibodies, the procedure 
presented some attractive advantages over conventional immunoassays; the technique utilises extremely 
small amounts of antigen, allows easy screening of multiple antigens simultaneously and viewing of dot 
colour reactions against a white background enables the detection of positive responses which are not 
readily apparent by traditional ELISA (35).  While developing a DIA for visceral leishmaniasis, Pappas et 
al. (36) submitted that soluble parasite antigen extracts, standardised to protein concentration prior to 
overnight microtiter plate adsorption, may not adhere completely to the plastic.  With an approximation of 
only 10% soluble protein being retained on the plate surface (37), the actual antigen concentration in an 
ELISA assay well after washing is unknown and variable.  On the other hand, NC has a high binding 
capacity for proteins equal to, or more than 100 μg/cm2 (38).  By applying whole parasites or defined 
quantities of solubilised protein to NC membranes, the potential hazards associated with traditional ELISAs 
performed in microtiter plates, which include antigen loss during washing, destruction of labile antigens 
during solubilisation and differential antigen adherence to plate materials, are avoided since whole parasites 
and protein bind avidly to the NC matrix. 
The procedure to conduct a membrane-based ELISA, as originally described (34), is very similar to the 
traditional plate-based formats, with the main divergence pertaining to the initial preparation of the reagent 
dots on the solid support.  First, a rectangular grid comprising 4 mm squares is drawn onto NC with pencil 
and the membrane is washed with distilled water and left to dry.  Alternatively, commercially available 
membrane with pre-printed grids may be used.  Second, a small drop of antigen solution at the required 
concentration is dotted to the centre of each square and dried.  The membrane is washed, the individual 
squares cut and placed facing upward in the wells of a 96-well microtiter plate.  The procedure further 
allows for the simultaneous screening of multiple antigens using the same antibody with NC strips carrying 
antigen arrays incubated in a suitable vessel during the succeeding steps.  After antigen preparation, the 
dotted membrane is incubated with a solution containing horse or bovine serum, casein, triethanolamine, or 
other agents to block the nonspecific antibody binding sites on both the NC filter and assay chamber.  The 
process is completed as with a normal ELISA.  Following incubation with antibodies and enzyme 
conjugates, with intermittent wash steps, the signal is developed with a suitable substrate which results in 
the formation of a coloured precipitate dot that may be analysed visually or by means of scanning 
densitometry. 
  




2.2.1 Chromogenic substrates 
The antibodies used during DIA may be labelled with a variety of enzymes which give visual representation 
of antigen presence upon addition of a suitable substrate.  Most commonly, horseradish peroxidase (HRP) 
or alkaline phosphatase (AP) is conjugated to detection or secondary antibodies.  Whichever reporter is 
applied, whether HRP, AP or lesser used enzymes such as catalase, β-galactosidase, glucose oxidase or 
acetylcholinesterase, the choice of substrate is determined by the instrumentation available for 
quantification, if required.  Chromogenic substrates used in immunoblotting, where HRP is the reporter, 
require the addition of peroxide to facilitate the enzymatic reaction.  Yet, hydrogen peroxide exhibits an 
extremely short shelf life at the concentrations needed.  Traditionally, peroxides were therefore added to the 
reaction buffer along with the substrate immediately prior to use; normally, these preparations provided 
short working times of only a few hours.  Nowadays, improved commercially available precipitating HRP-
substrates are manufactured to utilise concentrated peroxides in stabilising buffers which greatly increases 
shelf life and provides consistent results.  Most often, when the reporter employed during ELISA is an 
HRP-conjugate, 3,3’,5,5’-tetramethylbenzidine (TMB) is used as a substrate to form a dark blue water-
soluble product diamine/diimine charge complex by two-step oxidation of the aromatic amines at positions 
4 and 4’of the compound (39).  The final oxidation product of TMB, 3,3',5,5'-tetramethylbenzidine diimine, 
is only stable under very acidic conditions.  Therefore, sulphuric acid is often added to halt the HRP-
mediated reaction and stabilise the yellow diimine which can be measured by spectrophotometry at 450 nm 
(Figure 2.1).  Under mildly acidic conditions, however, in the presence of additives such as ammonium 
heptamolybdate (40, 41) or ammonium paratungstate (42), the diimine can be precipitated from solution 
and deposited on the membrane of an immunobinding assay. 
Figure 2.1 A schematic representation of the two-step irreversible conversion of TMB to the its diimine form.  
Oxidation of the colourless benzidine (1) is catalysed by HRP in the presence of H2O2 to yield a cation 
free-radical as first oxidation product (2), which reversibly converts to the two-electron diimine which 
forms a complex with the parent diamine (3).  The blue oxidation product can be converted under very 
acidic conditions to a stable yellow oxidation product with a characteristic absorbance maximum at 
450 nm. 
Another HRP substrate commonly used in membrane-based immunoassays, related to TMB, is 3,3’-
diaminobenzidine (DAB), a derivative of benzene.  In the presence of HRP and peroxide, water-soluble 
DAB is oxidised to a deep brown precipitate that is insoluble in aqueous and organic solvents (43) 
(Figure 2.2).  An interesting characteristic of the DAB precipitate is its ability to form complexes with 




metals such as nickel, copper, silver and cobalt (44).  These complexes are darker in colour than that of the 
DAB precipitate alone, thus the addition of metal salts to membranes following substrate conversion may 
be used to enhance the sensitivity of the immunobinding assay with a high signal to noise ratio (45).  
Moreover, the addition of imidazole to the reaction buffer has been suggested to induce the formation of a 
third electron transfer site in HRP (46), further increasing its catalytic activity and resulting in an 
approximate fivefold increase in the signal generated by DAB oxidation alone (46, 47). 
 
Figure 2.2 A schematic representation of the two-step oxidation of DAB to yield an insoluble product.  In the presence 
of H2O2, HRP catalyses the one-electron oxidation of DAB (1) to form a quinone iminium cation radical 
(2), which upon further oxidation polymerises to form a complex brown precipitate (3). 
Significant drawbacks to the routine use of DAB, however, is its potent mutagenic potential and the 
requirement of a fume cupboard for its use (48).  Sodium hypochlorite is commonly utilised in many 
laboratories as a neutralisation method; however, it is not effective in removing the mutagenic properties of 
DAB.  Instead, the use of excess HRP and hydrogen peroxide for complete precipitation, or degradation 
with a potassium permanganate-sulphuric acid procedure are effective ways of neutralising this toxic 
compound (49).  A less harmful chromogenic substrate used in HRP-mediated immunoblotting is 4-chloro-
1-naphthol (4CN) (Figure 2.3).  Although readily visible to the naked eye, the alcohol-soluble blue to blue-
purple precipitate is not as sensitive or stable as TMB or DAB.  However, the compound is especially 
useful in applications where sequential staining is performed to visualise several antigens in one assay (48).  
Often 4CN and DAB are combined to produce a single substrate mixture.  The combination of HRP 
substrates greatly increases the sensitivity of the obtained signal without the need for additional 
enhancement steps.  With up to or greater than tenfold improvements in chromogen formation (50) the dark 
black precipitate is ideal for photographic reproduction. 
 
Figure 2.3 The oxidation of 4CN (1) to yield a purple coloured precipitate (2). 
  




For the development of immunoblots in which AP is used as the reporter enzyme, nitro blue tetrazolium 
(NBT) is often used.  The catalytic activity of AP reduces the heterocyclic organic tetrazolium salt to NBT-
diformazan, a deep purple-coloured water-insoluble product which is linear and stable over a wide dynamic 
range.  An alternative AP substrate often employed in immunoblotting techniques is 5-bromo-4-chloro-3-
indolyl phosphate (BCIP).  The hydrolysis of BCIP by AP results in the deposition of an indigo precipitate 
on the membrane.  An ideal system for the chromogenic development of applications which utilise AP is a 
combination of NBT and BCIP (Figure 2.4).  Following dephosphorylation of the halogenated indolyl 
phosphate, the indoxyl intermediate undergoes tautomerisation which, under alkaline conditions, results in 
the formation of a dehydroindigo dimer product.  The hydrogen ions released during dimerisation causes 
reduction of NBT to yield the deeply purple diformazan (51).  This reaction proceeds at a steady rate, 
allowing accurate control of its relative sensitivity.  NBT/BCIP characteristically produces sharp band 
resolution with little background staining of the membrane. 
Figure 2.4 The formation of water-insoluble salts from BCIP and NBT, mediated by AP.  Dephosphorylation of BCIP 
(1) leads to the formation of an indoxyl intermediate (2) which undergoes tautomerisation under alkaline 
conditions to form a dimerised indigo dye precipitate (3).  The hydrogen ions released during dimerisation 
cause the reduction of NBT (4), yielding an insoluble purple NBT diformazan (5). 
2.2.2 Improvements to dot immunoassay execution 
A drawback to the original DIA procedure is that it necessitates antigen discs to be cut and placed in flat-
bottomed microtiter plates for analysis.  This requirement is especially disadvantageous in HTS 
methodologies such as assays of large numbers of hybridoma supernatants for the presence of specific 
antibodies.  Bennett and Yeoman (52) introduced a modification to the technique using a single NC 
membrane cut to fit atop of a 96-well microtiter plate to address the prerequisite for membrane disc 
preparation prior to DIA.  Antigen application is achieved by spotting dots on the sheet corresponding to 
the centre of each well on the plate.  Following blocking of the membrane, the sheet is placed on the 
microtiter plate containing test samples and sealed with a layer of Parafilm (Beemis Company, Inc.; 
formerly produced by the American Can Company).  Next, three sheets of Whatman 3MM paper are added, 
and a microtiter plate lid is clamped onto the assembly with four spring-type binder clamps (Figure 2.5).  




Once clamped, the assembly is inverted and placed on a rotary shaker for the first incubation with the 
primary antibody containing samples.  Next, the membrane is washed, incubated with enzyme-conjugated 
antibodies, washed again and developed with a suitable chromogenic substrate. 
 
Figure 2.5 Schematic representation of the modified dot-ELISA proposed by Bennet and Yeoman.  A single sheet of 
antigen dotted nitrocellulose is clamped onto a microtiter plate containing 100 μL to 250 μL sample liquid.  
The components of the assay are: (1) 96-well microtiter plate; (2) spotted nitrocellulose membrane; (3) 
Parafilm; (4) Whatman 3MM chromatography paper; (5) microtiter plate lid.  Source: (52). 
Besides the advantage of not having to cut the membrane into individual squares, each which need to be 
manipulated separately during the assay procedure, the method described above utilises a single sheet in 
which all reactions occur simultaneously for the same period.  Moreover, the technique allows for 
comparisons of specific immunoreactivities to background reactivity, whilst also enabling comparison to 
areas of the membrane which were not exposed to the primary antibody.  The adaptation of the original dot-
ELISA to the single sheet method is easily achieved with readily available and inexpensive laboratory 
equipment.  Nevertheless, the adjusted assay procedure decreases the functionality of the assay outside of 
the laboratory environment by the inclusion of additional required materials. 
A more high-tech adaptation of the method described by Bennet and Yeoman (52) involves the use of a 
specialised vacuum manifold to perform DIA by microfiltration.  Several companies have designed 
dedicated apparatus for the screening of unfractionated or purified proteins on membranes in a dot format.  
The most well-known of these vacuum manifolds are the MultiScreen®HTS produced by Merck, the 
Whatman® Minifold® I system manufactured by GE Healthcare and the Bio-Dot® microfiltration apparatus 
produced by Bio-Rad.  The MultiScreen®HTS vacuum manifold is designed for use with specialised 96-well 
and 384-well filter and collection plates.  In contrast to this, the Minifold® and Bio-Dot® systems require 
the assembly of the apparatus to house a membrane sheet between two parts of the vacuum manifold 
assembly (Figure 2.6).  The assay can be conducted in either a 96-well format, or in a 48-well slot format.  
The slot format focuses the applied samples in a thin line instead of a circle enabling improved 
densitometric quantification, if required.  Furthermore, these systems provide consistent reagent and buffer 
application which can be performed with standard multichannel pipettes without the need for removal of the 
membrane between steps.  A drawback to these systems, however, is the need for a vacuum pump to draw 
liquids through the membrane. 





Figure 2.6 Schematic diagrams of the Bio-Dot® and Bio-Dot® SF apparatus assemblies (Bio-Rad).  (1) Sample 
template; (2) gasket; (3) gasket support plate; (4) vacuum manifold; (5) membrane; (6) filter paper (three 
sheets).  Figure adapted from Bio-Rad apparatus instruction manuals (53, 54). 
An alternative to these methods which simplifies DIA for laboratory and field use utilises disposable 96-
well NC plates (55).  As above, the use of such plates also abrogates the need for preparation of individual 
antigen discs which need to be transferred to microtiter plate wells and manipulated separately.  Moreover, 
individual spots can be applied directly to the plate wells and reagents used in laboratory settings can be 
conveniently removed by means of commercially available plate suction devices; in the field, reagents may 
be removed from the plate by rapid inversion.  Furthermore, antigen-prepared plates can easily be 
transported and used in remote geographical areas.  However, at an approximate cost of US$20 per plate 
which cannot be reused, the test may be critically expensive for use in the developing world.  Moreover, the 
use of a premanufactured 96-well plate limits the ability to tailor experiments for small numbers of samples. 
2.2.3 Dipstick dot-ELISA 
Even with the improvements made to the dot-ELISA format discussed above, the technique still required 
the use of a plate format for execution.  Although well suited for HTS applications, the bulky microtiter 
plates are less effective for use in non-laboratory settings.  In 1983, Pappas et al. (36) first introduced the 
concept of a dot-ELISA dipstick as a potential improvement for rapid screening of sera from large numbers 
of individuals for endemic diseases.  Due to its portability, low cost, conservative reagent requirements, 
sensitivity and dearth of necessity for sensitive equipment or electricity, dipsticks are especially useful for 
serodiagnostic use in developing countries or geographically remote areas.  In these locations, where the 
implementation of clinical immunodiagnostic tests are limited by dependence on refrigeration or ultrapure 
water (56), NC strips prepared with antibodies or antigens to serve as diagnostic tests which yield rapid 
results are invaluable aides.  However, the fragile nature of the membranes makes them unacceptable for 
use outside of the laboratory.  Nitrocellulose filter discs dotted with antigens or antibodies can be affixed to 




flat, flexible plastic strips such as polyester or polyvinyl chloride using water-insoluble glue (Figure 2.7) to 
circumvent this critical shortcoming.  Furthermore, multiple antigens can be applied to the NC disc 
enabling the simultaneous assaying of serum and environmental samples for a number of diseases, 
pathogenic vectors or other factors of interest (57). 
 
Figure 2.7 Schematic representation of a dipstick used in a dipstick dot-ELISA format.  Situation of the antigen (Ag) 
at the end of the strip permits immersion of the test zone in different reagent solutions without physical 
interaction.  Coating of the top end of the plastic dipstick with a matt white surface allows easy labelling of 
the test with identifiable information, allowing storage of the strip as a permanent record of the result.  
Figure reproduced from (58). 
Multiple antigen disc-containing dipsticks can be successively dipped in optimally diluted patient serum or 
sample liquid, enzyme conjugate and substrate to simultaneously screen for several infectious agents or 
environmental contaminants.  In addition, the use of a membrane allows for the inclusion of controls to 
which the assay may be standardised.  Moreover, since the assay is not conducted in microtitration wells, 
the necessity to keep the membrane smaller than a certain size is no longer a requirement; with the only 
limitation on size being imposed by the volumes of reagent and wash reservoirs. 
2.2.4 Immunoblot assay formats 
Depending on the antigen of interest, membrane-based DIA and dipstick tests can be conducted in multiple 
ways (Figure 2.8).  In the simplest format, antigen within a sample is adsorbed directly to the assay 
membrane via passive interactions.  Following appropriate blocking and washing steps, the spotted 
membrane is incubated with detection antibodies that recognise and bind to the antigen.  Since the detection 
antibody has been labelled with a suitable enzymatic reporter, the reaction can be visualised or detected 
directly by the addition of a preferred substrate.  This method is known as a direct DIA.  Due to a rise in 
infectious disease in farmed Penaeid shrimp, Penaeus vannamei, Zhang et al. (59) investigated the 
immunology of these invertebrates to establish strategies of aquaculture disease control since the animals 
lack adaptive immune systems.  By utilising proteomic and immunological methods, the researchers  
 





Figure 2.8 Diagrammatic representation of common ELISA formats.  In the indirect format, the antigen of interest is 
adsorbed to the plate surface.  In this arrangement the antigen is bound by a primary recognition antibody, 
which in turn is detected by a species-specific secondary antibody-conjugate.  Alternatively, if the antigen 
is large enough to present multiple epitopes for antibody recognition, a sandwich ELISA captures the 
antigen from the sample solution to be detected by matched antibodies as in the indirect format.  In a 
special type of assay, the competitive ELISA, the reporter enzyme is conjugated to a purified antigen.  The 
sample, containing unconjugated antigen, is incubated with the labelled antigen and compete for binding to 
a capture antibody; the signal generated in this format is inversely proportional to sample antigen 
concentration.  In a similar format, the blocking ELISA, antibodies in a sample fluid inhibits the binding of 
enzyme-labelled primary anti-antigen antibodies.  Thus, positive results are also recorded as a reduction in 
observable signal. 
identified an immunoglobulin-like conserved domain at the C-terminal of a 75 kDa haemocyanin protein 
extracted from the haemolymph.  Serial dilutions of shrimp and human sera spotted on NC reacted 
positively with goat anti-human IgG following direct incubation with the antibody conjugate.  Direct DIA is 
simple to perform since few steps are required.  However, because the antigen immobilisation is not 
specific a degree of background noise and loss of sensitivity may be incurred.  Also, every assay that is 
developed requires the conjugation of the specific primary antibody to a reporter molecule. 
As an alternative, polyclonal secondary enzyme-labelled and species-specific antibodies can be used to 
detect the antigen-bound primary antibody in an indirect assay.  In the same study, Zhang et al. (59) 
compared the results obtained between direct and indirect DIA.  In both assays, the staining intensity of 
shrimp serum was weaker than that of the human serum.  Nevertheless, the sensitivity of detection was 
greatly increased in the indirect DIA.  Indirect ELISAs are more sensitive than direct ELISAs since more 
than one labelled secondary antibody can bind to the antigen bound primary antibody.  Furthermore, the 
indirect format allows greater flexibility and economy since different primary antibodies can be detected by 




a single labelled species-specific secondary antibody or antibody binding-protein such as protein A or 
protein G.  While this type of immunoassay is especially useful in the screening and titration of hybridoma 
culture supernatants for specific antibodies (34, 52, 60, 61), it is also highly applicable to the detection of 
infectious diseases in serum samples.  Roldán et al. (62) developed an indirect DIA for the detection of 
human toxocariasis and compared it to a conventional plate-based ELISA.  Not only was the dot-ELISA 
found to be an effective method for the serological diagnosis of the disease, it was also asserted that the 
method was amenable to the development of a field detection system.  Even though the sensitivity of both 
assays were similar, the DIA required significantly less antigen, Toxocara larvae excretion-secretion, than 
the plate-based assay at 0.2 ng total protein per dot as compared to 1.25 μg per microtitration well.  When 
utilising the dot-ELISA to determine the frequency of the disease in a rural population from Cajamarca, 
Peru, significant associations were observed between seropositivity as determined by the assay, risk factors 
and signs and symptoms of infection (63).  An indirect DIA requiring application of the sample directly to 
untreated NC membrane prior to blocking was produced by Anand et al. (64).  The test could effectively 
diagnose rotaviral infection following analysis of stool samples.  Traditionally, rotavirus detection was 
approached by molecular techniques such as ribonucleic acid (RNA) polyacrylamide gel electrophoresis 
(PAGE) or observation of rotavirus particles by electron microscopy, which require expensive equipment 
and highly skilled personnel.  Considering its utility outside of the laboratory or clinical environment, the 
rotavirus DIA is much more applicable as an alternative diagnostic methodology since it is comparatively 
easy to perform, more economical and requires less technical ability.  The ease of use, sensitivity and rural 
application of indirect dot-ELISA have recently spurred the development of various membrane-based 
assays for the detection of other infectious diseases caused by parasitic (65–67), fungal (68), bacterial (69–
73) protozoan (74) and viral (75, 76) vectors.  The first dipstick based on an indirect DIA was introduced by 
Pappas et al. (57) in 1986 for the detection of a variety of parasite antigens in human sera.  An interesting 
adaptation to the technology was developed by Coelho et al. (77) for the simultaneous detection of malaria, 
Chagas disease and syphilis-specific IgG.  The multiparametric dipstick dot-ELISA was assembled by 
dotting 1-μL volumes of soluble antigens relating to Trypanosoma cruzi, Treponema pallidum, Plasmodium 
vivax and P. falciparum onto single NC membranes.  Once blocked and incubated with test serum, strips 
were developed with anti-human IgG and developed with 4CN.  The multiplexed test strip yielded 99% 
specificity for Chagas disease and 100% for both malaria and syphilis.  Sensitivity of the assay was 100% 
effective for patients afflicted with Chagas disease, 88% for syphilis, and 90% and 47% respectively for 
malarial infections of P. vivax and P. falciparum.  In the thirty years following the initial introduction of the 
device format, several other indirect dipstick assays have been introduced for the detection of various 
conditions, ranging from bluetongue virus (BTV) in sheep, to leptospirosis and human immunodeficiency 
virus (HIV) infection in man (78–86).  
Arguably one of the most useful ELISA formats, however, is the immunometric ELISA, a.k.a. the sandwich 
or capture ELISA.  In this iteration, antibodies against the antigen of interest are immobilised to the surface 
of a plate.  Antigen in a sample is captured by these antibodies and detected in either a direct or indirect 




configuration by a second antibody recognising a different part of the molecule.  Sandwich ELISAs require 
multiple epitopes on an antigen to function.  A major advantage of the sandwich ELISA over the direct or 
indirect format is an increase in sensitivity and specificity, since two antibodies are involved in the capture 
and detection of the antigen.  One of the earliest dipstick dot-ELISAs using sandwich capturing was 
described by Savage et al. (87) in 1988.  This immunometric ELISA-based device enables the on-site 
identification of blood meal ingestion in mosquitoes; a valuable tool in the assessment of the Human Blood 
Meal Index (HBI), which is a crucial variable in epidemiological investigations of vector borne diseases 
such as malaria.  Since the HBI is a representation of the proportion of blood meals derived from humans 
by mosquito vectors, it is often used as a proxy measure of malaria transmission (88).  When estimated 
periodically, the HBI, in conjunction with other malariometrics such as sporozoite and parity indices, can 
provide valuable information regarding the efficacy of antivector interventions.  The simple, rapid assay 
could be completed in the field or in poorly equipped rural laboratories in less than two hours and, in 
contrast to conventional ELISA which were available at the time, provided a permanent record of the test 
results.  During an evaluation of the assay by a World Health Organisation (WHO) sponsored 
interlaboratory trail (89), the dipstick dot-ELISA positively identified human blood from mosquitoes at up 
to 32 hours post blood meal ingestion.  Furthermore, blood samples from cow, dog, pig, goat and chicken 
were all identified as nonhuman, whilst a 1:10 mixture of human and cow blood was correctly identified as 
containing human blood.  Sandwich ELISA-based methodologies are especially well suited for the 
detection of molecules containing antigenic determinants involved in blood borne disease aetiology; 
membrane-based assays have been developed for the detection of viral and bacterial, mitochondrial 
enzymes, and more (90–93).  However, the technique is also highly applicable in the determination of 
disease states via the analysis of other bodily fluids.  Human schistosomiasis is a major parasitic disease 
which is common to the tropics and Far East.  Depending on the site of infection, symptoms may include 
diarrhoea, dysentery, abdominal pain, lack of appetite, weight loss, hepatomegaly, splenomegaly, ascites 
and distal haematuria (94).  Measurement of Schistosoma infestation is mostly approached by quantitative 
parasitological examination of schistosome eggs in faeces.  However, due to fluctuation in egg output or 
low egg concentration, this parasitological method is often inadequate.  An effective alternative is the 
measurements of circulating anodic antigen (CAA) and circulating cathodic antigen (CCA) by ELISA.  
These genus-specific glyco-conjugates are associated with the gut of the adult worm and are detectable in 
serum and urine of infested hosts.  Resultantly, Van Etten et al. (95) adapted a plate-based ELISA method 
for the semi-quantitative detection of CCA, and subsequent diagnosis of Schistosoma mansoni infection, in 
urine samples by means of a sandwich dipstick dot-ELISA.  Nitrocellulose affixed to polyvinyl chloride 
was adsorbed with three 2 mm wide protein bands, consisting of purified mouse anti-CCA IgG3 mAbs and 
two dilutions (1:250 and 1:600) of rabbit anti-mouse IgG, to produce the dipstick.  The assay was 
conducted by incubating the NC in undiluted urine and subsequently in a solution containing biotinylated 
anti-CCA mouse IgM mAbs.  Next, the strip was transferred to streptavidin-conjugated HRP and the results 
were visualised with metal-enhanced DAB substrate solution.  By inclusion of two reference bands on the 
strip, standardised readings could be achieved.  These bands thus served as a positive control, as well as an 




indicator of cut-off values for semi-quantitative detection of the CCA antigen.  In many instances, 
quantitative assessment may be important since antigen levels likely indicate degree of infection.  However, 
with regards to in-field assessments or the implementation of control programs, the mere indication of 
parasite or pathogen presence may suffice.  The standard procedure for establishing an aetiological 
diagnosis for bacterial meningitis include direct examination of Gram stains and culture smears of 
cerebrospinal fluid (CSF).  Whilst Gram staining is an effective method to confirm meningeal infection 
with Streptococcus pneumoniae (96), the most common aetiological agent in pneumococcal meningitis, 
bacterial cultures containing more than 105 cells per millilitre are required; culturing of S. pneumoniae from 
CSF to this density takes between eighteen and twenty-four hours.  Pneumococcal meningitis presents as a 
medical emergency which require rapid diagnosis and treatment.  Thus, a sandwich dot-ELISA was 
developed by Rai et al. (97) for the direct detection of S. pneumoniae antigen in cerebrospinal fluid.  
Pneumococcal omni-serum (98) was utilised as capture antibody by application as distinct dots to NC 
combs, the teeth of which are spaced to fit into the wells of a 96-well microtitration plate for easy 
application of reagents.  The combs were dipped in 200 μL CSF samples added to the wells of a microtiter 
plate for the detection of S. pneumoniae.  Pneumococcal omni-serum, conjugated to HRP, was employed as 
the revealing antibody, with a mixture of DAB and 4CN as substrate.  The assay was shown to be highly 
specific; no cross reactions was observed with Neisseria meningitidis group A, Haemophilus influenzae 
type b, Escherichia coli, Klebsiella pneumoniae, Salmonella typhi, Proteus vulgaris or Bacillus subtilis.  
Furthermore, vis-à-vis a standard commercially available Wellcogen latex agglutination kit, the sandwich 
DIA exhibited better sensitivity, detecting 100% of samples positive for pneumococcal antigen presence, as 
compared to 86.6% identified by latex agglutination.  The assay could be conducted in under 90 minutes 
and was employed to detect S. pneumoniae directly in CSF without any sample pre-treatment.  Over and 
above the rapid evaluation of infection, the utilisation of a comb and plate technique also allows the 
simultaneous analysis of multiple samples.  Another sandwich-based DIA which utilises a comb as solid 
backing was produced to distinguish between snake venoms.  Due to the considerable amounts of 
snakebites which occur annually in India and high levels of mortality and morbidity associated with such 
injuries, Shaikh et al. (99) developed a direct sandwich dipstick dot-ELISA for the rapid and sensitive 
detection and identification of snake envenomation from four common medically important Indian snake 
species.  An NC membrane was affixed to the six teeth of an acrylic comb using a non-reactive acetone-
based adhesive.  Polyclonal venom-specific antibodies against the four snakes (generated by immunisation 
of individual rabbits with detoxified venom) were applied to four positions on the device.  The other two 
positions were impregnated with a polyvalent mixture of all venom specific antibodies.  The test was able 
to distinguish between all four different venoms when the membranes were treated with sera from 
experimentally envenomed mice, followed by polyvalent equine venom-specific antibodies conjugated to 
HRP and TMB as substrate.  No cross reactivities were observed.  Sandwich DIA have also been developed 
for the detection of several environmental contaminants.  Venkataramana et al. (100) recently prepared 
mAbs against ochratoxin A (OTA) to detect the mycotoxin in contaminated grain samples.  Consumption of 
mycotoxin contaminated foods can cause several acute and chronic diseases in humans and animals (101–




103).  Prior to conducting the assay, OTA had to be extracted from cereal samples by means of a 
chloroform-phosphoric acid extraction, followed by evaporation and reconstitution in acetonitrile-water-
acetic acid.  Following hexane removal of fats, the sample was filtered and applied directly to NC 
membranes which had been dotted with rabbit anti-OTA polyclonal antibody (pAb) containing serum.  
Once the sandwich was completed with mouse anti-OTA mAbs, HRP-conjugated rabbit anti-mouse IgG 
was used as reporter to catalyse deposition of DAB for colour development.  Mycotoxins were extracted 
from several Aspergillus and Penicillium isolates and subjected to the dot-ELISA for assay validation.  All 
strains previously reported to produce OTA yielded positive results, while none of the negative strains 
indicated the presence of OTA. 
Many other examples of dot-ELISAs and dipsticks based on the sandwich format exist.  Sandwich ELISAs 
are, however, limited in the types of molecules they can detect.  By their very nature, small molecules such 
as OTA rarely contain more than one antigenic region and therefore cannot be detected by capture assays.  
Unlike an immunometric assay which normally require multiple epitopes, a competitive ELISA is 
performed when only one epitope is available to antibody binding.  There are several versions of this type 
of assay.  One variation utilises pure antigen, mostly conjugated to carrier proteins such as bovine serum 
albumin (BSA), applied to the membrane.  Labelled antibodies against the antigen is combined with the 
sample being analysed and the mixture is incubated with the membrane.  Antigen in the sample binds to the 
antibody and inhibits its interaction with the surface immobilised antigen.  Thus, the formation of a 
measurable signal following substrate addition is inversely proportionate to the presence of antigen in the 
test sample.  Another means to conduct a competitive ELISA requires the conjugation of an enzyme 
reporter to pure antigen in lieu of an antibody.  Unlabelled antigen in the sample and labelled antigen are 
mixed and compete for binding to surface immobilised capture antibodies.  In some instances, to increase 
the sensitivity of the assay, the capture antibody is also added to the reaction mixture to be bound to the 
membrane surface by immobilised secondary antibodies.  As above, a diminishment in the signal following 
substrate addition indicate the presence of unlabelled antigen, as compared to assay spots which were 
incubated with labelled antigen alone. By utilising a competitive format, Cho et al. (104) devised a direct 
dipstick dot-ELISA for the detection of the organophosphorus insecticide fenthion.  As a competitive 
enzyme tracer, HRP was conjugated to fenthion following introduction of a succinimide ester to the 
pesticide.  The enzyme-conjugate would thus compete with fenthion, present in a methanolic extract, for 
binding to membrane-immobilised polyclonal anti-fenthion antibodies.  The assay was conducted with 
0.6 cm x 1.5 cm membrane sections affixed to polystyrene strips.  This size of the membrane allows 
spotting of two distinct dots on the strip; one to serve as the test and one permitting the integration of a 
negative control within each assay.  The control dot consisted of goat anti-HRP antibodies which bound the 
enzyme tracer during each test and allowed for a comparative visual response following incubation in 
substrate.  Furthermore, the inclusion of the control dot allowed for quantitative assessment of fenthion 
concentration by functioning as a normalisation reference point during analysis of the result with a 




reflectometer, enabling the conversion of the obtained values to a ratio (%B/B0).  The assay could be 
conducted in approximately 30 minutes with a limit of detection of 10 μg/L. 
A final format in which membrane-based ELISAs may be executed is known as the blocking dot-ELISA.  
In a way, the blocking ELISA is like a competitive ELISA in which antigen is immobilised to the surface of 
the membrane.  However, whilst competitive ELISAs are indicative of small molecular antigen presence in 
sample matrices, blocking ELISAs assess the presence of antibodies by a competitive mechanism.  
Antibodies in the sample are permitted to react with the surface-immobilise antigen.  These antibodies 
inhibit the interaction of primary detection antibodies which are introduced following removal of the test 
sample.  As with competitive ELISA formats, a reduction of the signal is indicative of the presence of 
antigen specific antibodies in the test sample.  Afshar et al. (105) utilised a blocking dipstick dot-ELISA to 
determine the presence of BTV antibodies in cattle sera.  Dots of BTV antigens were absorbed to NC test 
strips, which were subsequently blocked and incubated in test samples.  Next, the strips were exposed to 
mouse anti-BTV mAbs.  Bound mAbs were detected with peroxidase-conjugated anti-mouse IgG.  
Following substrate addition, coloured spots developed on test membranes treated with sera negative for 
anti-BTV antibodies.  In the presence of enough anti-BTV antibodies in sera, no precipitate formation was 
observed. 
The use of indirect detection methods in ELISA can greatly increase the sensitivity of antigen detection 
since multiple binding sites exist on primary antibodies for interaction with labelled secondary antibodies.  
Nevertheless, sensitivity can be increased even further by employment of a biotin/avidin system.  Biotin 
(Figure 2.9) is a vitamin that is critically important in various biochemical processes affecting central 
metabolism and cell growth.  In most cells, biotin occurs at relatively low concentration.  However, in 
certain plant and animal tissues, including brain, liver, nuts, whole grains and egg yolk, the molecule is 
present in abundance.  Avidin, a tetrameric glycoprotein found predominantly in the egg whites of 
oviparous animals, and a structurally related protein from the bacterium Streptomyces avidinii, streptavidin, 
exhibit exquisite affinity for biotin with dissociation constants of 10-15 M and 10-14 M, respectively (106, 
107). 
 
Figure 2.9 Biotin is a 244.3 Da that is a required coenzyme of carboxylase enzymes.  The molecule consists of an 
ureido ring joined to a tetrahydrothophen ring with a valeric acid side chain.  
Each mole of avidin or streptavidin can bind four equivalents of biotin and the strong attraction between the 
molecules have been exploited for various purposes in molecular biology.  The valeric acid side chain of 
biotin can be derivatised by a variety of methods to enable conjugation of the molecule to other compounds.  
Due to its small size, conjugation of biotin to proteins generally does not affect macro-molecular activity.  




Therefore, biotinylation of antibodies is a technique often employed in immunoassays such as ELISA to 
improve sensitivity by signal amplification.  Primary antibodies may be biotinylated to enable their 
detection by streptavidin- or avidin-conjugated reporter enzymes.  Alternatively, secondary antibodies can 
be biotinylated for use in indirect systems.  Both secondary antibodies and reporter molecule can be 
biotinylated, enabling crosslinking in the form of large avidin/streptavidin-biotin complexes (Figure 2.10), 
thus increasing sensitivity even further. 
 
Figure 2.10 Biotinylation of biomolecules allow for signal amplification due to cross-linkages between tetrameric 
avidin/streptavidin molecules and biotin which has been conjugated to detection and reporter molecules. 
Infectious bronchitis virus (IBV), a gamma coronavirus, is a highly contagious and economically important 
disease which affect chickens.  The virus affects the reproductive and upper respiratory tracts and may 
cause nephritis.  According to Cavenagh (108), the number of avian species in which coronaviruses have 
been detected has doubled in the past few years.  Furthermore, despite intensive vaccination programs, new 
variant strains are continually emerging which do not serologically cross-react.  Resultantly, an important 
measure in the control of IBV infection is the vaccination of chickens with the relevant disease-causing 
strains.  Typically, IBV is titrated in embryonated chicken eggs by clinical assessment of the embryos for 
evidence of viral propagation and correlating the results to the infectivity of the virus dilutions.  Clinical 
signs of infection often include dwarfism of the embryo which is utilised to quantify infectivity by means of 
an embryo to egg ratio.  Yuk et al. (109) compared the measurement of titres of IBV vaccines determined in 
this way to an indirect dot-ELISA of allantoic fluids from embryonated chicken eggs inoculated with 
serially diluted vaccines.  IBV in allantoic fluid was successfully detected with an immunocomplex 
consisting of anti-IBV mouse mAbs, biotinylated anti-mouse IgG and biotin/avidin-conjugated HRP.  In 
comparison, the dot-ELISA showed 9% higher sensitivity and 16% higher specificity than the clinical sign 
determination method.  Furthermore, the dot-ELISA was faster to perform and could reduce inter-observer 
differences.  As with the other examples of membrane-based ELISAs and dipsticks presented above, the 
IBV dot-ELISA is a relatively economical, rapid and sensitive method which is easily applicable in field 
environments where access to technically trained staff and sensitive equipment of analysis may be lacking. 




2.3 IMMUNO-CHROMATOGRAPHIC ASSAYS 
The use of the term ‘dipstick’ in immunological assays is a somewhat ambiguous concept.  As introduced 
in the preceding section, the original dot-ELISA assay (36) was simplified to a dipstick format which 
requires the sequential transfer of a membrane, affixed to a solid backing, from one reagent solution 
reservoir to the next to facilitate the development of an immunoblot.  However, many on-site test systems 
are frequently contained as easy-to-use, handheld membrane-based test strips which are often enclosed in a 
protective plastic enclosure.  These strip assays are extremely versatile devices which, once the sample is 
introduced, require no further manipulation from the user to generate a test result.  The technology is built 
on the principles of lateral capillary flow through a composite membranous matrix and are essentially 
immunoassays which have been adapted to operate along a single chromatographic axis to suit the test strip 
format.  Resultantly, these tests are called lateral flow immunochromatographic assays (LFIAs).  
Nevertheless, since sample introduction is most commonly achieved by dipping a section of the assay into a 
liquid to initiate the test, the term ‘dipstick’ is often incorrectly applied to such devices. 
Several threads of scientific inquiry, some dating back to the 1950s, converged to result in the development 
of the LFIA.  These include the latex agglutination assay of Plotz and Singer (110), the RIA developed by 
Berson and Yalow (111) and the extension thereof, the enzyme immunoassay.  Probably the most well-
known example of an LFIA, the home pregnancy test, was conceived as a modern consumer friendly device 
to monitor reproductive success.  The nanoparticle-based immunochromatographic devices originated 
following introduction of the sol particle immunoassay (SPIA) for the detection of human placental 
lactogen and human chorionic gonadotrophin (hCG) by Leuvering et al. (112, 113) at roughly the same 
time as the development of the dot-ELISA.  In 1985, Unipath launched the one-step lateral flow assay, a 
radical technological innovation for the rapid detection of hCG in a urine-based pregnancy test called 
Clearblue (114).  Specifically designed for single-use applications, LFIAs are increasingly important in 
diagnostics as POC devices and user-friendly over-the-counter (OTC) tests available to consumers for self-
assessment.  The technology has been widely exploited, with tests having been assembled for the indication 
of pregnancy, fertility, hormonal status, internal organ failure, drugs of abuse, pathogens and agents of 
biowarfare, toxic compounds and adulterants in food, feed and the environment, as well as DNA (115, 116, 
125–133, 117–124). 
LFIA devices consist of distinct types of membranes, each with a defined purpose, which have been 
assembled in a fixed order onto a backing card to expedite biorecognition reactions by exploiting the 
phenomenon of capillary flow.  The prefabricated strips contain dry reagents which are activated by the 
application of sample liquid.  Without the need for specialised equipment, LFIA test cassettes are mainly 
designed as qualitative assays to detect the presence or absence of a target analyte in a sample.  Yet, the 
simplicity of LFIA design cloaks the immense technological advancement that was needed for its function; 
not only to make a test possible, but also the complexity of the principles upon which it is based.  Thus, 
there are several key requirements which must be met to produce diagnostic systems which can be used in 




routine assessment and quality control.  The ASSURED (affordable, sensitive, specific, user-friendly, rapid 
and robust, equipment-free and deliverable to end users) criteria, outlined by the WHO (134), provide a 
good framework for evaluating any POC or on-site evaluation device for resource-limited environments.  
Tools that satisfy the ASSURED criteria primarily aim to provide same-day results to facilitate immediate 
decision-making and remediation strategies; most LFIAs enable visual reading of the result in under 
20 minutes.  The physical devices are generally economical to produce; the biggest cost being incurred 
during research and development.  The devices generally have long shelf lives and do not require 
refrigeration for storage.  As the visual result is usually clear and easily distinguished, no additional specific 
equipment is needed.  Resultantly, LFIAs are especially well adapted for use in developing countries or in 
rural settings. 
2.3.1 Principle of the test 
A typical LFIA is based on a series of capillary beds, such as pieces of porous paper or microstructure 
polymer membranes which have the capacity to transport fluids spontaneously (Figure 2.11).  The first 
element, the sample application pad, acts as a sponge and holds an excess of sample fluid.  Usually the 
sample application pad is impregnated with buffer salts, surfactants and proteins to control the migratory 
flow of liquid to the following areas of the device and to make the sample compatible with the rest of the 
test.  Moreover, the pores of the sample pad can act as a filter to inhibit access of unwanted particles 
contained within the sample, such as red blood cells, to the capillaries of the succeeding elements.  Once 
soaked, the fluid proceeds to the second element, the conjugate pad.  Here, a desiccated biological 
component, either antibodies or antigens conjugated to a reporter particle, has been stored in a salt-sugar 
matrix that contains everything needed to preserve the dried conjugate and guarantee an optimised chemical 
reaction between the target molecule in the sample, and its chemical partner.  Various particles can be 
conjugated to the biorecognition molecules to serve as reporters during the assay.  Typically, colloidal gold 
nanoparticles (AuNP) or coloured, fluorescent or paramagnetic monodisperse latex particles are used as 
reporter molecules.  While the sample fluid dissolves the salt-sugar matrix it also remobilises the conjugate 
and, in one combined transport action, the sample and conjugate mix whilst flowing through the porous 
structure.  In this way, the analyte binds to the particles while migrating further through a third capillary 
bed.  This section, the reaction matrix of the assay, is generally composed of NC membrane of a relatively 
defined pore size which impact upon the time required for the liquid to traverse and completely fill the 
membrane.  Importantly, this material has one or more areas where a second biological component has been 
immobilised.  These are typically proteins, either antibody or antigen, that have been applied as defined 
bands which serve to capture the analyte and conjugate as they migrate across the chromatographic axis.  
After a while, when more and more fluid has passed the capture line, analyte-conjugates accumulate, and 
the reporter areas are visualised by changes in colour.  In general, there are at least two of these reporter 
zones.  One, the test line, contains a specific capture molecule and only captures those particles containing 
the reporter-bound analyte.  The second line captures any excess reporter particle, leading to the appearance 
of a line every time the test is conducted.  This internal control thus demonstrates that the reaction 




conditions and technology functioned correctly.  The control line usually contains species-specific anti-
immunoglobulin antibodies, specific for the antibody in the conjugate.  After passing these reaction zones 
the fluid enters the final porous material, the wicking pad, that simply acts as a waste container, allowing 
larger sample volumes to be applied to the assay strip without resulting in saturation of the system prior to 
development of the result. 
 
Figure 2.11 The architecture of a typical lateral flow immunochromatographic assay strip.  Introduction of the sample 
to the sample pad initiates lateral capillary flow which dissolves the labelled detection conjugate stored in 
the conjugate pad.  Migration of the liquid to the test and control lines result in visualisation of the result as 
the labelled biomolecules accumulate via molecular interactions with the capture molecules.  Excess liquid 
and reagent are drawn into the absorptive wicking pad to continually drive the capillary flow.  Source: 
Merck (135). 
2.3.2 Assay formats 
As with other immunoassays, LFIA can function via several mechanisms.  In general, two formats of the 
LFIA can be distinguished (Figure 2.12): one-step two-site immunometric assays (also known as direct or 
sandwich LFIA) and competitive (or competitive inhibition) assays.  Mostly, LFIA are produced to perform 
as qualitative or semiquantitative testing systems, although in limited instances fully quantitative assays 
have been successfully fabricated. 
2.3.2.1 Immunometric assays 
Immunometric assays are reagent excess assays which utilise a surplus of labelled antibody to detect the 
antigen of interest.  Direct test formats are used to assay larger analytes which contain multiple antigenic 
sites, such as the p24 antigen used in human immunodeficiency virus (HIV) testing (115), hCG in 
pregnancy tests (116), troponins (117–120), fatty acid binding protein (121), creatinine kinase (122) and 
myoglobin (120) as cardiac markers and prostate-specific antigen (PSA) for prostate cancer screening 
(123).  In the direct test, labelled antibodies are temporarily adsorbed to the conjugate pad.  Once sample is 
introduced, the conjugate binds to the analyte and enters the liquid stream.  Capture antibodies against the 
target analyte subsequently binds the labelled complex, thus the development of the test line indicates a 
positive result.  Excess labelled antibody proceeds to the control zone where it is bound by species-specific 




anti-immunoglobulin antibodies, thus indicating functionality of the test.  The intensity observed at the test 
line corresponds to the amount of analyte present and may be inspected visually in qualitative assays.  
Depending on the sensitivity of the test, quantification by means of an optical strip reader may also be 
possible. 
 
Figure 2.12 Schematic representations of typical formats of immunometric (A) and competitive (B) assays.  Source: 
O’Farrell (136). 
Clinically, hCG is an accurate biomarker of pregnancy.  At approximately nine to ten days following 
conception, the urinary concentration of the oligosaccharide glycoprotein hormone rises rapidly and 
predictably (137–139).  Tests such as Clearblue utilises two mAbs specific for hCG; typically, one detects 
an antigenic region on the α-subunit whilst the other is specific for the β-subunit.  At the test zone of the 
reaction membrane, one of these mAbs is immobilised to serve as the analyte capturing agent.  The other 
antibody is conjugated to a detection particle and is stored in the conjugate pad.  When remobilised 
following application of urine to the sample application pad, the labelled conjugate binds to hCG in the 
liquid and is transported to the test zone where it is bound by the second anti-hCG mAb.  As more liquid 
passes this point a coloured line is produced indicating a positive result.  Since two antibodies bind the 
hormone in an immune-sandwich, this assay is an example of an immunometric assay.  In these types of 
assays, where the analyte concentration range is large, antigen excess may lead to false negative results 
(140).  As the concentration of hCG in the sample increases, a proportionate increase in the intensity of the 
test line is observed until a plateau is reached.  However, at very high levels of hCG exceeding the plateau 
concentration, direct assays may suffer from what is known as the high-dose hook effect (Figure 2.13).  
Above this point, the signal starts to decline at a rate which is also proportional to the sample analyte 
concentration.  It is caused when free analyte and analyte bound to labelled antibody compete for the 
limited number of capture antibody-binding sites at the test line.  This leads to a decrease, instead of an 
increase, in label bound to the solid phase with a concomitant decrease in the formation of a visual 
response.  The high-dose hook effect can be addressed either by dilution of the sample, or by reformulation 
of the assay to increase the antibody to antigen ratio, thus increasing the dynamic range of the test device. 





Figure 2.13 Diagrammatic representation explaining the high-dose hook effect, which is based on the saturation curve 
of antibody with antigen.  An excessive amount of the analyte overwhelms the capture antibody binding 
capacity resulting in an inappropriately low signal. 
2.3.2.2 Competitive assays 
In the case of small molecules with single antigenic determinants, which cannot bind to two antibodies 
simultaneously, competitive formats are typically used.  Competitive assays are reagent-limited in nature.  
In this type of test, the analyte blocks the binding sites on the antibodies on the test line, preventing their 
interactions.  Antibodies against a small molecule are labelled with a reporter particle and stored dry at the 
conjugation pad.  At the test zone of the reaction membrane, an analyte-protein conjugate is immobilised.  
When sample is applied to the sample application pad, antibodies stored at the conjugate pad is remobilised 
in the liquid stream where it interacts with the free analyte.  As the analyte-bound conjugate migrates past 
the test line it is inhibited from binding to the membrane-immobilised antigen.  A positive result is therefore 
indicated by the absence of a test line on the reaction matrix.  In another format with the same endpoint, a 
labelled antigen is dispensed to the conjugate pad while a primary antibody to the analyte is immobilised at 
the test line.  Following application of sample solution, competition occurs between analyte in the sample 
and the labelled analyte for interaction with the antibody at the test line.  Regardless of the result generated 
at the test line, however, a control line should still form.  Competitive LFIAs have been described for the 
detection of a variety of small molecular analytes including antibiotics (124, 141–144), naturally occurring 
toxins (129, 143, 145–148), pesticides and herbicides (143, 149), drugs (130), heavy metals (143), 
hormones (143), industrial chemicals (150) and more. 
Assays for which both POC and OTC tests exist use similar technology and function by the same 
methodology.  In general, the primary difference may be in the method of sample application.  An OTC test 
for the indication of pregnancy, for example, may be manufactured to contain a sampling wick which 
allows a consumer to urinate directly onto the wicking material, thus initiating the test.  The wicking 
material may be replaced by a sample pad in the same test manufactured as a POC device, allowing medical 
practitioners or technician to apply defined volumes of sample to the assay.  




2.3.2.3 Multiplex detection assays 
LFIA devices are mostly designed for the detection of single compounds per assay.  However, several 
formats have been developed which allow multiplexed analysis of several analytes at once.  In clinical 
diagnosis, detection formats that can be used for the simultaneous indication of several inter-dependent 
analytes, under the same conditions, is very useful in deciding about the stage of a disease or physiological 
state.  Ovulation, for example, follows approximately twelve to forty-eight hours following urinary peak 
detection of luteinising hormone surge (151, 152).  Therefore, OTC home ovulation tests such as the 
ClearPlan Easy Ovulation Test Pack and Clearblue Easy One Month Ovulation Test (Unipath Ltd., 
Bedfordshire, UK) are rapid one-step two-site immunometric assays for determination of the most fertile 
days during the menstrual cycle by measurement of urinary luteinising hormone (LH) levels.  The assay 
functions via the same principles as the test for hCG, with two antibodies detecting two different antigenic 
determinants on the LH molecule.  Positive development of a coloured line at the test zone equal to or 
stronger than the reference line is indicative that ovulation will occur within 24 – 36 hours.  However, 
fertility usually spans six days, starting approximately five days prior to ovulation and ending on the day of 
ovulation itself (137).  Thus, conception is most likely to occur when intercourse takes place during this 
window of opportunity.  Therefore, while effective in the prediction of ovulation, LH tests may lead to 
couples missing key fertile days before the LH surge if they use this measurement alone to time intercourse.  
Designation of this fertility window can, however, be achieved by monitoring the levels of LH in 
conjunction with a major urinary metabolite of oestrogen, oestrone-3-glucuronide (E1G).  Sustained 
increases in the concentration of this hormone in urine can be used to identify the onset of fertility while the 
surge in LH being indicative of impending ovulation and thus the end of the fertile period.  Unipath’s 
Clearblue Easy Fertility Monitor (Unipath Ltd., Bedfordshire, UK) is a handheld digital device which 
converts the coloured signals, generated on disposable sticks for both these hormones in a simultaneous 
LFIA format, into a personal indication of fertility which is displayed on the monitor as ‘Low’, ‘High’, or 
‘Peak’ (153).  On the same assay axis, LH is detected by a sandwich assay while E1G, being a small 
molecule, is monitored by a competitive assay.  Use of the OTC fertility test has been shown to increase the 
likelihood of conception in women during the first two cycles of use compared with its non-use (154). 
Multiplex lateral flow strips can be built in several ways.  By increasing the length of the reaction 
membrane, for example, multiple test lines may be applied on a conventional strip.  Peng et al. (144) 
developed a multiplexed competitive LFIA for the simultaneous screening of milk samples for the presence 
of five antibiotics.  The immunochromatographic strip was assembled by applying goat anti-mouse and the 
five different antigens to a 60 mm NC membrane, each 5 mm apart.  The sample application pad of the strip 
was submersed in a solution containing AuNP-labelled murine mAbs against the five antibiotics, mixed 
with the sample, to conduct the assay.  Utilisation of the same particles to label different biorecognition 
molecules may, however, complicate the interpretation of qualitative results produced by a multizone LFIA, 
especially if the test zones are spaced together closely.  A plausible solution to the problem is to increase 
the distance separating these zones.  Yet, additional spacing between detection zones ultimately increases 




the time required to conduct the assay and leads to increased consumption of membrane materials and 
sample volumes (148).  Taranova et al. (124) opted to utilise different fluorescent quantum dots (QD) to 
label antibodies against three different antibiotics to overcome these limitations.  The competitive assay 
monitored the formation of test lines with emission maxima at 525 nm, 585 nm and 625 nm.  Being in the 
visible spectrum, the quantitative detection of antibiotics was based on the decrease in line intensity as the 
concentration of the analytes increased.  By using this ‘traffic light’ detection approach, the limit of 
detection (LOD) for the antibiotics in milk was decreased by as much as 80 – 200-fold as compared to 
previously reported conventional ELISA. 
Multiple analytes can be effectively analysed in a traditional LFIA format; however, the test lines for each 
must be sufficiently spaced from one another.  Thus, another drawback to conducting multiplex assays on a 
single axis is the limit imposed by the dimensions of the strip itself since adding more test lines require 
lengthening of the test strip.  Combining the rapidity of LFIA with the high throughput obtainable by array 
techniques, Safenkova et al. (155) addressed this problem by developing a multiarray test strip for the 
detection of priority potato pathogens.  At the test zone of a LFIA strip, ordered rows of spots, 0.3 mm in 
diameter, containing antibodies specific for different potato pathogens were dotted.  Using this format, up 
to eight pathogens could simultaneously be detected in fifteen minutes on a LFIA strip of standard 
dimensions.  Another solution is to design alternative housing moulds in which other structures, such as 
parallel threads, stars or T-shapes, may be incorporated.  As an alternative approach to using successive 
zones containing reagents with different specificities, Hong et al. (156) developed a ten-channel up-
converting phosphor-based LFIA to profile antibodies against Yersinia pestis.  The test cartridge consisted 
of ten strip channels arranged symmetrically around a central sample addition port, which drains to the 
sample application pad of each strip.  Therefore, since sample liquid migrates along the axes of individual 
strips, increases in strip dimensions are not required for simultaneous analysis.  Furthermore, false positives 
due to binding of conjugates at incorrect test lines are completely excluded.  Zhao et al. (157) adapted this 
format to the multiplex detection of ten foodborne pathogens, which exhibited 100% specificity with no 
cross-reactivity between the channels. 
2.3.3 Components of the assay 
The most common difficulties in the manufacture of immunochromatographic devices are caused by the 
hidden complexity of the device.  For all their simplicity of design, LFIA devices conceal an elaborate 
depth of intricacy.  LFIA strips are composed of many elements.  As such, material incompatibility, poor 
material characteristics and flawed overlapping connections between adjacent elements can severely impact 
on the effective functioning of the test.  Yet, most research papers give scant information on the effects of 
varied materials on assay efficiency, if such optimisations were considered at all.  During the development 
of LFIA, attention is mostly focused on finding the most suitable detection method or choosing the best 
antibody.  Nonetheless, it is very important to pay attention to all elements of the test, including the basic 
components such as the backing card, adhesive strip and cover tape, to produce a consistent and high-




quality product.  The unique and remarkable properties of immunochromatographic flow assays have 
contributed to the detection of disease biomarkers and infectious agents in medicine, agriculture, food and 
environmental safety.  Although the principle of the method has remained unchanged for decades, there 
have been continuous improvements to the employed techniques, leading to increased sensitivity and 
reproducibility, and the simultaneous detection of several analytes.  Importantly, these assays can now be 
effectively performed outside the laboratory, providing great advantages for use in developing countries, 
whether in the field or in more traditional treatment facility settings. 
2.3.3.1 Adhesive card materials 
The membranous elements of LFIA devices are typically fragile and is thus laminated onto a suitable inert 
adhesive card for stabilisation.  The adhesive card consists of three components: the plastic backing, a 
pressure-sensitive adhesive coating, and the release liner.  Inclusion of a suitable backing is essential during 
manufacturing to arrange the multiple, delicate materials of the system into one unit that performs many 
functions.  The maintenance of precise, direct contact between assay components is therefore an absolute 
requirement for the preservation of even frontal flow through the capillaries of the test.  Furthermore, if the 
LFIA will be housed in a plastic enclosure, the thickness of the backing material must be uniform so that 
the porous materials are not subjected to variable degrees of compression.  The most common backing 
materials include polystyrene, polyvinyl chloride, polyester and other custom plastic materials available 
from specialist in vitro diagnostic suppliers (158).  Backing materials are produced in a variety of 
thicknesses and is normally supplied pre-coated with a diagnostic grade medium to hard tack adhesive to 
enable immediate positioning of the assay membranes.  Since the adhesive layer is in direct contact with the 
materials comprising the test strip, the type of coating can have a profound effect on the stability of the test.  
Flow of the adhesive into other components of the test, especially the sample application pad, conjugate pad 
and unbacked reaction membrane, can cause disruption of liquid flow characteristics by destabilisation of 
proteins and the generation of hydrophobic patches.  Medium tack adhesives, such as GL-187® (Lohman 
GmbH & Co.KG, Neuwied, Germany), a global standard for lateral flow devices, which do not leach 
chemicals, solvents or other additives is most often used for this reason (159).  Prior to assembly of the test 
components, the backing card is covered by a release liner which may be pre-slit for easier placement of the 
strip materials.  Many liners are coated with a silicone-based layer to promote release from the adhesive.  It 
is therefore important to avoid exposure of the membrane materials to the release layer since transferral of 
these compounds to the membrane may disrupt its surface chemistry, thus affecting the consistency of 
liquid absorption during capture reagent application. 
2.3.3.2 Sample application pad 
The proximal sample application pad is first element to which liquid is applied and, as such, is responsible 
for several important tasks.  The most critical of these is the even distribution of the sample and the 
initiation of even migration of the liquid to the next element.  The materials used for the sample application 
pad therefore depends not only on the requirements of the specific assay, but also on certain physical 




parameters such as filtration of particulates or separation of blood constituents, adsorption of unwanted 
immunoglobulins and other possible interfering compounds, as well as absorptive and liquid release 
characteristics.  Examples of common materials are cellulose, glass fibre, rayon and other filtration media 
such as cross-linked silica (160).  One of the major attractions of LFIAs in rapid diagnostics is the broad 
array of sample types that may be analysed in a single step.  The diversity of sample types is seemingly 
endless and may comprise of blood, urine, saliva or sputum, extractions of plant and animal materials, 
water and many more.  The composition of some of these sample mediums, especially urine and saliva, can 
vary significantly depending on a variety of biological factors.  Therefore, another key role fulfilled by the 
sample application pad is the appropriate adjustment of the sample to a composition which favours optimal 
reaction compatibility with the assay.  The impregnation of the material with buffer salts and molecules 
such as surfactants, blocking reagents, additives and proteins facilitate alteration to the pH and osmolarity 
of the sample when applied, blocks non-specific interactions and helps to maintain controlled release of the 
analyte from the pad with a suitable flow rate, all of which affects biomolecular interaction and stability of 
signal development.  Yet, the composition of the sample pad treatment buffer will ultimately depend on the 
type of sample which is to be analysed.  The viscosity of saliva, for instance, may inhibit its migration 
through LFIA membranes.  By raising surfactant and salt concentrations in the sample pad, proteins and 
mucins which increase viscosity may be broken down, thus improving flow rate.  However, if the sample 
comprises of whole blood, increased concentrations of these components may result in haemolysis of red 
blood cells, resulting in contamination of the assay with interfering compounds.  Pre-treatment of the 
sample application pad is achieved via immersion of the pad material in a solution or by spraying uniformly 
with an automated dispenser, followed by a controlled drying process to avoid the formation of buffer 
concentration gradients or edging effects. 
2.3.3.3 Conjugate pad 
The materials used for the conjugate pad in LFIA construction are synthetic non-absorbent polymer 
matrices that commonly consist of glass fibres, rayon or plastic polymers such as polyester, polypropylene 
or polyethylene (161).  In general, these polymers are hydrophobic in nature.  Therefore, materials used as 
conjugate pads are normally treated to increase their hydrophilicity, thus allowing rapid flow rates of 
aqueous samples through the matrix and facilitating defined rates of conjugate release.  Pad materials for 
these purposes are immersed in a solution containing proteins, polymers and surfactants, followed by high-
temperature drying prior to application of the conjugate.  As the temporary storage repository for labelled 
biorecognition molecules, it is imperative that the conjugate pad maintains the stability and reactivity of the 
conjugate over the entire shelf-life of the device.  Hence, in addition to the compounds impregnated to the 
pad on pre-treatment, the conjugate buffer used during the application and drying of the labelled molecule 
often contains carbohydrates such as sucrose or trehalose which serves as preservation and resolubilisation 
agents (162).  Upon removal of water during pad preparation, the sugar molecules form a stabilising layer 
which surrounds the labelled biomolecule, thus limiting molecular mobility via vitrification and the 
formation of hydrogen bonds during water replacement (163).  Once the liquid sample enters the conjugate 




pad, the sugar molecules are rapidly dissolved, and the particles are carried along the axis of the test in the 
direction of the capillary flow.  Consistent release of the particles from the pad is a principal factor that 
must be considered during the development of LFIA systems to ensure uniform and reproducible results.  
Therefore, other additives used during conjugate pad pre-treatment include buffers for pH stabilisation and 
proteins, polymers and detergents to aide in release of the conjugate into the liquid stream (161).  As with 
the sample application pad, pre-treatment of the conjugate pad may be approached either by immersion or 
spraying, with subsequent drying of the pad prior to application of the conjugate.  The particle-conjugated 
antibodies can also be applied to the prepared conjugate pad by immersion followed by drying.  However, 
quantitative non-contact air jet dispensers are often used since they allow for control over the conjugate 
volume which is critical for semi-quantitative or quantitative assays. 
2.3.3.4 Reaction membrane 
The most critical element in LFIA strips is probably the reaction membrane where the presence of the 
analyte is to be visualised.  Nitrocellulose is most commonly the primary choice in LFIA applications for 
several reasons (38).  Even though other materials such as nylon, polyethersulphone and polyvinylidene 
fluoride have been utilised to some extent (135), their use has been limited due to high cost, restricted 
utility, lack of consumer knowledge of processing requirements and of material chemistry, and resistance to 
change due to experience utilising NC (164).  Conversely, NC is economical, easy to handle and is 
available in direct cast or backed formats.  A variety of products are available; manufactured with various 
wicking rates and surfactant content.  Moreover, NC membranes exhibit well-defined characteristics of 
capillary flow and binds proteins with high affinity.  The binding capacities of membrane materials are 
determined by the available surface area, which is influenced by porosity, mean pore diameter, thickness 
and the surface chemistries unique to the polymer in question (165); all of which can be tailored depending 
upon the requirements of the assay.  NC membranes for LFIA applications are manufactured with pore 
sizes ranging nominally from 8 μm to 15 μm.  However, due to processes employed during the fabrication 
of NC, pore sizes are not uniform and are thus a poor indicator of liquid migration (135).  The distribution 
of pore sizes has dramatic effects on liquid migration rates through the capillary system which can greatly 
impact on the assay’s total performance.  Slow flow rates may result in an increase in background noise, 
thus causing a reduction in assay specificity, while flow rates which are too fast may cause a loss in 
sensitivity.  Accordingly, capillary rise time, which is defined by the time in seconds required for the liquid 
to traverse across a specified length, commonly 4 cm of the membrane, is a more accurate parameter in 
determining the most affective material for the application in question (135).  The capillary flow properties 
of a given membrane are influenced by the physical and chemical attributes of the membrane material.  In 
turn, these properties affect reagent deposition, assay sensitivity, assay specificity, and test line consistency 
(135).  Moreover, selection of appropriate membrane material should also consider the ability to effectively 
immobilise capture molecules and apply blocking reagents whilst retaining effective capillary forces to 
ensure the movement of liquid so that immunoreactions and analyte detection may occur.  The reaction 
membrane must be hydrophilic for liquid movement to occur.  Nitrocellulose is hydrophobic in nature and 




is made hydrophilic during manufacturing by the inclusion of various surfactants which serve as wetting 
agents (159).  Since certain surfactants can destabilise some proteins, it is important to optimise LFIA 
during the development phase by screening multiple membrane types.  Nevertheless, the type of membrane 
employed will also be affected by its ability to sequester reactants only at desired locations.  NC passively 
binds proteins primarily via strong initial electrostatic attractions between peptide bonds and nitrate esters, 
with long-term bonding being reinforced by a combination of hydrogen forces and hydrophobic interactions 
(159).  The consistent immobilisation of test and control reagents is a key factor in the reproducibility of 
LFIAs.  However, the non-specificity with which passive immobilisation of capture reagents occur is 
always concomitant with a degree of loss in immunological functionality.  It is therefore vital to consider 
the composition of buffers involved in reagent application, the humidity levels prior to and during coating, 
as well as the methods employed for dispensing and drying.  Deposition of test and control lines is 
performed with either contact or non-contact dispensing systems, with non-contact application providing 
the best measure of quantitative protein administering.  Once striping of the capturing reagents has been 
completed, the membrane is dried prior to immersion in a blocking solution which serve several functions.  
Primarily, blocking of the membrane inhibits the non-specific binding of the labelled conjugate to areas 
other than the test and control lines.  The inclusion of proteins, sugars, surfactants and polymers in the 
blocking solution, however, also serves to maintain hydration of the membrane pores during storage, thus 
keeping them from collapse.  Additionally, blocking agents improve flow by modification of wicking rates 
and help to stabilise the antibodies applied at the test and control lines during the duration of the LFIA 
shelf-life. 
2.3.3.5 Absorbent pad 
Lateral capillary flow of the sample liquid will continue within the test membranes until saturation is 
achieved; this limits the sample volume which may be processed by LFIAs.  Adsorbent pads are 
incorporated at the ends of test strips to wick the fluid through the membranes, thus overcoming this 
limitation.  Inclusion of absorbent pads, which typically consist of non-woven high-density cellulose filters, 
greatly increases the test sensitivity since larger sample volumes are drawn through the system once applied 
to the LFIA.  It is pivotal that the fluid not be released back into the assay once absorbed by the wicking 
material or false positives may occur. 
2.3.3.6 Laminate over tapes 
Many of the physical components from which LFIA are made are extremely delicate and must be protected 
from harm once the test has been assembled.  Cover tapes are generally made from thin, flexible film tapes 
which are used as a top laminate in many LFIA applications.  Like backing cards, cover tapes are coated 
with a pressure-sensitive adhesive on one side to facilitate adherence to the porous constituents of the 
device.  The same conditions regarding adhesive strength and migration into the assays membrane 
components therefore also applies to the cover tape.  In general, the purposes of the cover tape are to hold 
down the fragile components of the assay, to serve as a protective barrier, to prevent evaporation of 




reagents and to help limit back-flow.  Additionally, the clear or opaque white material can be printed with 
unique designs for test identification, to serve as orientation, or to delineate a stop line if the strip is to be 
immersed in sample liquid.  However, for obvious reasons the area over the test and control zones must 
remain clear.  
2.3.3.7 Antibodies as agents of detection and capture 
Optimisation of any LFIA test strip requires careful consideration of the physical components which make 
up the device.  The choice of materials used for each individual element, the buffers which impregnate 
them, and the techniques employed during construction can have profound effects on the functionality and 
reproducibility of the test.  Most importantly, however, at the core of the device are the antibodies that 
ultimately detect the analyte in question.  Optimisation of all other components of the system would 
ultimately mean nothing if care is not taken in the selection of antibodies based on their ability to recognise 
the target antigen.  Several parameters are essential to consider during antibody selection.  Among these, a 
consistent supply of antibodies with defined specificity and affinity is most pertinent.  Antibodies suitable 
for use in LFIA application are available from many commercial sources (166, 167).  Commercial 
antibodies can often be obtained in pairs to enable the development of sandwich assays against common or 
high-volume assays.  Similarly, antibodies required for competitive assays against prominent small 
molecules such as hormones and drugs are also readily available (168). 
One of the key questions to address during LFIA development is whether mAbs or pAbs are better suited 
for use.  Although pAbs have been utilised in several devices with success, a major concern is the continued 
availability of an antibody source.  It is hard to predict the lifetime volume of antibodies required at the 
inception of LFIA production and pAbs are subject to batch to batch and animal to animal variation.  
Resultantly, the use of mAbs in LFIA development is preferable for this and several other reasons (Table 
2.1).  Whatever the source of the antibody employed, its use is greatly dependent not only on the high 
affinity needed to detect sub-nanomolar concentrations of antigen, but primarily by a fast on-rate (kon).  This 
requirement is explicated in detail by Brown (168) in calculation of the potential time provided for binding 
at the test line (between one and six seconds) while considering typical flow rates in relation to the 
dimensions of a LFIA strip.  The situation may be slightly more favourable for the conjugate since its time 
of interaction with the antigen starts during remobilisation at the conjugate pad and ends at the test line; the 
effective binding reaction can therefore be extended to the order of ten to twenty seconds.  The sample 
could be used to rehydrate labelled antibodies stored in a test tube prior to transferring this solution to the 
sample pad of the assay, thereby increasing the time available for interaction between the conjugate and the 
analyte (169).  Antibodies used in LFIA must be sufficiently stable and pure to accomplish conjugation to 
nanoparticles (NP), immobilisation to membranes and to achieve the performance requirements of the test 
following prolonged desiccated storage.  Antibodies are applied to LFIA at relatively high concentrations.  
Thus, any contaminating proteins will compete for membrane binding sites and interaction with probes 
during conjugation procedures.  It is therefore important that the antibodies used be purified prior to 




attempting any such actions.  Multiple purification techniques are available to yield the antibodies suitable 
for LFIA application (170).  Salt fractionation, ion-exchange or affinity methods are most often used.  pAb 
preparations typically contain only 0.2 – 2% antigen-specific immunoglobulins (171).  Therefore, if pAb 
are to be used in LFIAs, affinity chromatography using specialised absorbents covalently modified with 
antigen can effectively separate specific antibodies from the majority, irrelevant immunoglobulins.  Most 
commonly, chemical immobilisation of protein and small molecular antigens onto solid matrices is 
performed on agarose resins activated with cyanogen bromide, carbonyl-diimidazole, succinimidyl esters, 
carbodiimides or epoxides which can be used to form stable bonds with hydroxyl and amino moieties (172–
175). 












• Production is relatively inexpensive 
• High affinity binding is possible 
• Robust detection via recognition of multiple 
epitopes 
• If protein antigen is prone to denaturation, 
polyclonal antibodies may be preferential 
• Higher tolerance for variations in antigen 
structure, such as glycosylation of proteins 
• Reagent can be well defined in terms of 
affinity, avidity and specificity 
• Constant and renewable source 
• Batches do not suffer variability 
• High homogeneity ensures reproducible 
results 
• Purification of pure antibody is easily 
achieved 













• Batch to batch variation between bleeds from 
the same animal and between animals 
• Non-specific antibodies increase background 
• Requires extensive purification since low 
percentage of antibodies are target specific 
• Multiple epitopes increase likelihood of 
cross-reactivity 
• Continual requirement for animal usage 
• Validation of alternate antibody pool is 
costly and may require re-optimisation of 
LFIA elements 
• Typically, more expensive than polyclonal 
antibodies 
• Labour intensive initial production 
requirements 
• May not provide highest affinities 
• High specificity reduces possibility of 
detecting analogous analytes from related 
species 
  




When coupling small molecules to solid supports, a spacer arm interposed between the ligand and matrix is 
often required to inhibit steric hindrance during antibody binding.  Once all reactive groups on the resin has 
been blocked, addition of partially purified sera to the affinity matrix will lead to sequestration of specific 
antibodies while non-specific ones can easily be washed away.  Thereafter, bound antibodies are easily 
recovered from the solid phase by a sharp decrease or increase of the pH, or by elution with ethylene glycol 
and chaotropic agents such as MgCl2 (176–179), all of which dissociate the antibody-antigen complex.  
However, the use of affinity matrices for pAb purification may be problematic since significant amounts of 
antigen is generally required for the fabrication of covalently modified adsorbent matrices (168).  Affinity 
chromatography is a somewhat ambiguous terminology when applied to purification of antibodies by 
means of ‘universal’ antibody binding proteins such as Protein A (Staphylococcus aureus) (180), Protein G 
(group G Streptococcus) (181), the recombinant fusion protein, Protein A/G (182), and the kappa light 
chain binding protein, Protein L (Peptostreptococcus magnus) (183).  These bacterially-derived proteins 
interact with immunoglobulins from varied species by non-immune binding mechanisms and therefore do 
not exhibit the specificity of interaction based on the affinity of an antibody for its target antigen.  
Regardless, when the source of antibodies contains a singular population of immunoglobulin, as is the case 
with mAbs, absorbents modified with these bacterial proteins may be the most efficient means of 
purification. 
2.3.3.8 Labels 
With respect to the conjugate system, the choice of labels and conjugation methods are crucial.  Ultimately, 
the indication of the presence or absence of the target analyte is achieved by concentration of coloured or 
fluorescent NP on the capture lines.  Visualisation of the interaction between the capture antibodies and the 
analyte therefore requires suitable labels which can be efficiently and reproducibly conjugated to detection 
antibodies in scalable conjugation chemistries which do not result in loss of chemical and biological 
functionality.  Moreover, labels must exhibit no to low non-specific binding characteristics, thus providing 
a high signal-to-noise ratio and should ideally be detectable over a large dynamic range.  The colloidal 
characteristics must remain stable under various chemical conditions and temperatures, in solution and 
upon drying, and should be commercially available at low cost (184, 185). 
The choice of NP used in the manufacture of a LFIA device will depend on several factors.  Due to its wide 
commercial availability, relatively low cost and intense optical properties, colloidal gold is the most widely 
used particle employed in commercial LFIA fabrication (186).  Furthermore, AuNP exhibit high stability 
when dried or suspended in liquids.  Colloidal gold has been used as a colourant during the production of 
textiles and glass for centuries.  The intense optical properties of AuNP are a result of the interaction of 
light with electrons on the particle surface and is explained by Mie theory (187).  The coherent delocalised 
electrons, referred to as surface plasmons, are collectively induced to oscillate at specific frequencies which 
result in a substantial extinction of light in the visual range (188).  AuNP can be manufactured to various 
diameters ranging between 1 nm and 100 nm and occur as quasi-spherical colloidal gold or irregular shaped 




gold nanorods, nanoshells, nanocages, or urchin shaped particles known as nanostars (189).  The 
aggregation state, size and shape of gold NP significantly impact upon the colour observed, which is 
directly correlated to the wavelength which induces surface plasmon resonance.  Spherical AuNP of 40 nm, 
for instance, exhibit a deep red colour, whilst nano-urchins of the same size appear blue.  The phenomenon 
is due to the anisotropic distribution of surface electron layers; spherical and irregular-shaped AuNP of the 
same average size exhibit differences in absorption properties, thus a visual difference in colour is 
observable (190).  Similarly, increases in the size of the particles also result in a red-shift of the absorption 
maximum.  The difference in extinction between different sized gold NP can conveniently be utilised for 
multiplexing.  Colloidal gold can be produced in the laboratory by various methods, all of which are based 
on the reduction of ionic gold to elemental gold in a controlled manner.  Among the reducing agents 
commonly employed, which include sodium borohydride, white phosphorus, ethyl alcohol, and ascorbic 
acid, the sodium citrate procedure introduced by Turkevich and optimised by Frens is most often employed 
(191–193).  Many producers of LFIA, nevertheless, prefer to source AuNP from specialist manufacturers to 
reduce batch to batch variability for consistent application in commercial assays.  Gold nanoparticles 
consist of an elemental gold core surrounded by an ionic double layer of negative charges (194).  The 
negative charges impose a charge energy barrier on the particles, inhibiting their interaction.  However, in 
the presence of high salt concentrations the charge barrier is neutralised, allowing the colloidal particles to 
interact and aggregate.  Visually, the aggregation can be observed as a change in colour from red to violet 
due to a phenomenon known as surface plasmon coupling (195).  Due to the negative charge of the native 
colloidal solution, proteins can be passively adsorbed to the particle surface via electrostatic interactions 
and other non-covalent forces, such as hydrogen bonding, Van der Waals interactions such as π-π stacking, 
as well as hydrophobic interactions (196).  Once surrounded by macromolecules, electrolyte-induced 
aggregation cannot occur and can therefore be used to determine the conjugation state of antibody coated 
AuNP.  A pH titration is required when using passive adsorption to determine the optimal pH for 
conjugation of antibodies to AuNP, which is followed by a salt stability test to ensure that the coupling 
reaction was successful.  The method of Horisberger et al. (197, 198) is an effective method to establish this 
value.  Small volumes of an aqueous solution of antibody is added to a series of colloidal suspensions of 
which the pH values differ incrementally by 0.5 units.  In some of solutions, aggregation of the gold will 
occur, thus the colour will shift towards violet.  The smallest pH value at which aggregation is not observed 
is the optimal pH for conjugation.  By adjusting the pH of the conjugation conditions to approximately 
0.5 pH units on the basic side of the pI of the antibody, the net charge of the protein is zero to slightly 
negative.  Consequently, the slight negativity prevents protein aggregation due to electrostatic attraction, 
while the prevailing hydrophobic interaction facilitates conjugation of the protein to the nanoparticle (199).  
Gold nanoparticles which have been surface-modified with proprietary coatings to introduce reactive 
moieties such as carboxylic acids, amines or thiols are, however, also commercially available.  These 
surface chemistries enable the covalent attachment of the particles to biorecognition molecules via 
crosslinking reagents, circumventing the need for pH titration and aggregation studies. 




A popular alternative to colloidal AuNP is monodisperse latex microspheres.  In fact, even though AuNP 
are most commonly used, dye-doped latex particles were the first to be used as labels in LFIA development 
and are available at relatively low cost, albeit more expensive than AuNPs, from many commercial sources.  
Latex particles are produced by the polymerisation of hydrocarbon monomers such as styrene with sodium 
dodecyl sulphate in the presence of potassium persulphate as reaction initiator.  During the process, 
hydrophobic polystyrene chains arrange as micelles to be shielded from the surrounding aqueous 
environment.  Due to the incorporation of sulphate moieties on the exterior terminal ends of the 
hydrocarbon chains, polystyrene microspheres are negative charge-stabilised colloidal particles (200–203).  
Resultantly, as with AuNP, latex particles can be conjugated to antibodies by simple passive adsorption 
procedures.  Functional treatments, such as amidation, amination, carboxylation and hydroxylation, enable 
the facile formation of covalent bonds between the NP and immunoglobulins (204).  Latex emulsions are 
intrinsically white, therefore no distinct change in colour would be observable upon aggregation at test and 
control zones in a LFIA if native particles were to be used.  However, latex NP can be efficiently coupled to 
a variety of detector reagents, such as coloured or fluorescent dyes and magnetic or paramagnetic 
compounds.  The multiple colours that can be incorporated into the micellular structure makes latex NP 
attractive for use in multiplex assays.  Nevertheless, due to their size latex NP generally suffer from low 
packing density because of steric hindrance at test and control lines.  The size of AuNP are typically in the 
range of 20 – 40 nm, whereas coloured latex NP are about 100 – 300 nm.  Furthermore, coloured latex has a 
lower colour intensity than AuNP; thus, AuNP exhibits a greater dynamic range of analyte concentration 
discrimination.  Consequently, latex is often less sensitive than gold as a visual label (136).  Even so, it is 
possible to produce darker coloured latex NP which can provide greater contrast against the white 
backgrounds of LFIA membranes.  Moreover, the ability to couple latex microspheres to paramagnetic or 
fluorescent compounds enable greater sensitivity of several orders of magnitude when assay results are 
evaluated with digital readers (205). 
Several other labelling options are available for use in LFIA; although, for the most part they have not been 
readily utilised in the development of commercial assays.  Colloidal carbon NP (CNP) are relatively 
inexpensive, non-monodisperse black NP that are a good substitute for traditional AuNP or latex 
microspheres.  Although mostly heterogenous in size distribution, CNP exhibit good stability, non-toxicity, 
can be easily conjugated by passive adsorption and requires no activation (206).  CNP is mostly obtained 
from soot.  However, several methods of CNP production have been proposed, including burning of toluene 
and preparation from graphene oxide (207), carbohydrates (208–210), cyclodextrins (211) or benzene 
(212).  These methods of production reportedly yield CNP with fluorescent, phosphorescent or luminescent 
properties (213–219).  Still, the complex procedures involved, high energy consumption, expensive starting 
materials and low yields associated with these methods excludes them from routine implementation (206).  
A process involving ultrasonic treatment of carbon with a hydroxide/peroxide solution has been reported as 
an economic method for large-scale homogenous CNP production, which results in hydrophilic particles 
with active functional groups for covalent attachment (218).  Due to their black colour, CNP exhibits higher 




contrast than AuNP and are thus easily detectable with high sensitivity and lower LOD.  Carbon 
nanoparticles have been incorporated in several sensitive immunometric and competitive LFIA (206).  
Linares et al. (220) compared several bioconjugates and found that CNP exhibited a 10-fold lower LOD in 
comparison to silver-coated AuNP, a 100-fold lower LOD than only AuNP and a 100,000-fold greater 
sensitivity than polystyrene beads.  Using CNP, a LFIA was designed that detected mosquito-borne Dengue 
virus, the vector responsible for potentially fatal Dengue haemorrhagic fever, at a limit of 57 ng/mL (220). 
Quantum dots (QDs) are inorganic semiconductor nanocrystal structures with dimensions of 1 – 10 nm.  
These small particles are composed of IIB-VIA groups such as CdSe, CdTe, CdS and ZnSe or IIIA-VA 
elements such as InP and InAc (221).  In general, QDs are spherical and exhibit extremely high 
photostability with very little susceptible to photobleaching.  Most intriguingly, QDs have unique size-
dependent optical properties which allow for a continuous absorption profile; the particles have broad 
excitation spectra and a size-tuneable emission spectra, i.e. by controlling the size of the particle, different 
emission wavelengths may be induced in different particles with a single excitation wavelength (222).  
Biomolecules can be immobilised to QDs by either covalent or non-covalent mechanisms.  Non-covalent 
coupling is primarily achieved by hydrophobic, electrostatic or hydrophobic interactions.  Several covalent 
conjugation chemistries have been employed to activate functional groups on QD surfaces, the most 
prominent being carbodiimide mediated conjugation as well as thiol-to-maleimide coupling (223).  These 
properties extends the utility of QDs over and above that of traditional fluorescent dyes such as Alexa 
Fluor, PromoFlor and DyLight Fluor; the stability of these dyes are limited, thus they suffer from restricted 
signal time which circumscribe their applicability for use in immunoassays (125).  The first LFIA in which 
QDs were used as detection label was designed by Li et al. (224) for the detection of nitrated ceruloplasmin, 
a main biomarker for cardiovascular disease.  The sensitive assay could detect the analyte in spiked human 
plasma at an LOD of 8 ng/L.  Several other groups have utilised QD technology in the development of 
immunoassays for the detection of toxins, pathogens or proteins.  Berlina et al. (225) used QDs to 
determine the presence of chloramphenicol in milk samples, the results of the assay could be visualised by 
ultraviolet (UV) light and seen by eye.  When registering the signal with a portable photometer, a LOD of 
0.2 ng/mL could be established, with a limit of quantification (LOQ) of 0.3 ng/mL.  Wang et al. (226) used 
QDs for neonicotinoid residue analysis in plant materials, while Qu et al. (227) analysed water and 
biological samples for the presence of the 8-C-glucoside of daidzein, puerarin.  Recently, a successful test 
for the early detection of acute myocardial infarction was developed by Savin et al. (228) based on the 
quantification of human heart fatty acid binding protein in serum within the range of 0 – 160 ng/mL, with a 
LOD of 221 pg/mL.  Clearly amenable to extremely sensitive analytical diagnostics, their narrow, sharply 
defined symmetrical emission spectra also makes QDs especially well-suited for use in multiplexing assays 
(124).  In search of rapid diagnostic techniques to discriminate acute from chronic bacterial infection as 
well as local from systematic bacterial infection, to differentiate bacterial infection from non-infective 
causes of inflammation and to determine appropriate antibiotic treatment regimens, Qi et al. (229) 
synthesised CdSe/ZnS QDs for use in a single LFIA to detect procalcitonin and C-reactive protein in blood.  




Procalcitonin was detected by an immunometric assay at a quantitative concentration ranging between 
0.3 – 200 ng/mL with a LOD of 0.1 ng/mL.  The competitive inhibition assay had an LOD of 1 ng/mL with 
a quantitation range of 50 – 250 ng/mL for C-reactive protein.  However, although the optical properties of 
QDs allow for the development of highly sensitive LFIA, particles made from cadmium are typically highly 
toxic, thus their practical application has been limited to some extent (230).  Addressing this problem by 
using cadmium-free indium phosphide QDs, Beloglazova et al. (231) designed a LFIA for the simultaneous 
detection of two mycotoxins.  Several advances in solution phase synthesis methods have resulted in the 
ability to produce next generation QDs from a variety of materials, including indium phosphide, copper 
indium sulphide, silver indium sulphide, silver sulphide, doped zinc chalcogenides, graphene and silicon 
(232). 
Up-converting particles (UCP) represents another group of NPs which exhibit excellent luminescent 
properties.  The particles are comprised of rare earth elements embedded in a crystalline lattice.  In contrast 
to fluorescence, which emit light at a longer wavelength than that used for excitation, up-conversion 
luminescence is based on the absorption of two or more low-energy photons by a nanocrystal, followed by 
the emission of a single higher-energy photon (233).  Since up-conversion occurs completely within the 
particles, the properties of UCP are unaffected by assay conditions or constituents and background emission 
is therefore minimal (234).  Up-conversion crystals and nanocrystals with sizes ranging from 5 nm to 
400 μm have been prepared and may be spherical, hexagonal, cubic, rod-shaped, diamond-shaped or 
amorphous.  By adjusting the morphology, size or other properties of UCP, the formation of materials with 
an infinite number of distinctive signatures can be achieved.  As with QD, multiple spectrally unique 
emissions can be obtained which are visible as a variety of colours.  These narrow emission bands can all 
be excited by the same source, typically a 980-nm diode laser (234).  The use of UCP in LFIA has led to the 
development of extremely sensitive assays.  Zhao et al. (235), for example, could detect aflatoxin B1 at 
0.03 ng/mL in standard solutions, with a LOD ranging from 0.1 – 5 ng/g in various crop samples.  Hua et 
al. (133) could detect the potential biowarfare zoonotic pathogen, Francisella tularensis, to a sensitivity of 
100 CFU/test within fifteen minutes and ten foodborne pathogens could be analysed in a single ten-channel 
LFIA by Zhao et al. (157), all at 10 CFU/0.6 mg in several food matrices. 
In most conventional LFIAs, the reaction zones of the device are analysed visually or integrated by an 
optical instrument that measures reflectance, contrast, colour, fluorescence or luminescence.  However, the 
reaction membranes used in these assays are typically several hundred microns thick.  Resultantly, most of 
the signal produced at test and control lines will not be observed, since optical readers or visual inspection 
do not penetrate through the entire depth of the membrane.  Magnetic and paramagnetic particles can, 
however, be detected by magnetic readers which determines the entire amount of label present, even if 
beneath the membrane surface and therefore not visible (184).  Several NP possess magnetic properties; 
such as hematite and maghemite, magnetite (Fe3O4) and crystalline modifications of Fe2O3, in addition to 
pure iron, cobalt, nickel, cadmium, technetium, and alloys thereof.  Many of these types of NP are, 




however, inherently unstable and are prone to rapid oxidation leading to spontaneous combustion in air 
(236).  Resultantly, they are encapsulated with various materials such as polystyrene, silica, zeolite or glass. 
Some important parameters that impact upon the choice of NP utilised in LFIA design include the stability 
of the colloid in solution when subjected to various conditions and temperatures, the ease, reproducibility, 
scalability and efficiency with which the particles can be conjugated to biorecognition molecules (without a 
concomitant loss of biological and chemical integrity and activity), cost and commercial availability, 
dynamic detection range and high signal-to-noise ratios due to the absence of or very low non-specific 
binding characteristics.  Labels in LFIA are, however, not limited to NP; even enzymes have been used as 
primary detection conjugates.  An innovative method for the quantitative electrochemical detection of 
testosterone (T) was designed by Inoue et al. (237).  The competitive assay is based on the amperometric 
measurement of an oxidation product formed by HRP-mediated catalysis.  A solution containing T, which 
competed with HRP-labelled T for binding to anti-T antibodies at the test line, was applied to the LFIA 
device to perform the assay.  Once immunocomplex formation was complete, the membrane was 
transferred to an assay chamber containing citric acid buffer containing ferrocene methanol and hydrogen 
peroxide.  In the presence of H2O2, HRP catalyses the oxidation of FcOH to Fc+OH.  Subsequently, this 
catalytic product is reduced back to FcOH by an electrode chip consisting of three gold-plated electrodes.  
The resulting reduction current is monitored by cyclic voltammetry as an indicator of HRP quantity and 
thus, by extension, the amount of T in the sample.  The inverse proportionality could quantitate T 
concentrations between 1 and 625 ng/mL. 
2.3.4 Reader systems 
Membrane-based rapid diagnostic tests which use coloured labels such as AuNP, CNP or latex NP can be 
inspected visually to determine a result.  Originally, LFIA were used solely as qualitative assays; however, 
low analyte concentrations often resulted in inherent ambiguity due to differences in interpretation of 
results, human error or poor contrast of test and control lines against the reaction membrane background.  
The development of labels for LFIA has gone hand in hand with technological advances in detection 
methodology and instrumentation.  One of the first low-cost test strip readers were proposed by Kim and 
Park (238) and consisted of the linear movement mechanism of a standard compact disc read-only memory 
deck and a home-made optical head constructed with a green light-emitting diode mounted in an anodized 
aluminium block and a large area silicon diode for detecting reflected light.  With the introduction of 
electronic components, the subjective bias of the human eye could be mediated by measuring light 
reflectance or transmission, converting the optical density (OD) and intensity of colour to readable values, 
testing the validity of the result against pre-programmed software and providing a clear indication to the 
user of the outcome.  Nevertheless, there are many factors which may influence the OD of test and control 
lines, including ambient temperatures, the materials used for strip construction, the time permitted for 
immunoreactions to occur and the concentration of target compounds present in the sample (239).  These 
parameters may severely impact upon the reliability of digital detection.  However, by correcting for the 




ratio of the OD measured at the test lines to that of the control line, the effect of these factors can be 
compensated for (240, 241).  Currently, there are several reader types employed in LFIA applications.  
Visual detection is performed primarily with the use of charged coupled device cameras, reflectance-based 
measurement systems or complementary metal oxide semiconductor-based cameras.  Fluorescence is 
monitored by light emitting diode excitation via confocal or other optical sensors and magnetic assay 
readers are employed if the particles are magnetic or paramagnetic (125).  It is essential that several 
performance requirements, including wavelength, sensitivity, dynamic range, stability, time resolution, and 
costs are considered, for LFIA labels and their corresponding detectors.  Reader-based assays are often 
much more sensitive than visually assessed tests.  Furthermore, by using fluorescent or paramagnetic 
particles instead of visual labels such as latex or AuNP, it is often possible to generate signals of several 
orders of magnitude greater which may be quantitatively assessed.  The technology required to produce 
specialist readers for commercial applications are, however, often expensive and thus reduces their 
applicability in the developing world.  Nevertheless, due to their ubiquitous distribution and international 
connectivity, several biosensors have been developed by the integration of smartphones for signal detection, 
image acquisition and data handling (160, 242–245). 
2.3.5 Signal enhancement strategies 
Colloidal gold probes deposited at the sites of immune reactions gradually develop a reddish colour that can 
be seen with the naked eye.  Although AuNP are readily detectable on standard immuno-chromatographic 
assay strips, they can be difficult to visualise if the analyte of interest occurs at low concentrations.  One 
course of action may be to use larger AuNP which are more readily observed.  However, aggregation of 
AuNP larger than 60 – 70 nm are known to occur after only several days’ storage at 4°C (246).  
Furthermore, larger concentrations of antibodies are required during conjugation reactions, thus increasing 
costs, and bigger particles may cause steric hindrance, thus negatively impacting upon antigen-antibody 
binding interactions at the test line of the device. 
Thus, some strategies of signal enhancement have been developed to overcome low sensitivity in LFIA.  
Owing to the large surface area of AuNP, numerous macromolecules can be coupled to their solid support, 
allowing several forms of surface chemistries to be carried out.  Parolo et al. (247) prepared AuNP which 
was further modified with HRP-conjugated anti-human IgG γ chain-specific antibodies.  They used the 
labelled enzyme-conjugated antibodies in a LFIA to detect human IgG and compared the response obtained 
with only AuNP to that generated following enzymatic deposition of coloured precipitates after substrate 
conversion.  Multiple concentrations of sample solution were dispensed to individual LFIA strips to 
conduct the test.  Liquid migration proceeded for fifteen minutes until the flow stopped, following which 
phosphate buffered saline was added to the sample application pad to wash away excess detection particles.  
The results were recorded with a strip reader to produce a calibration curve.  After the first reading step, the 
LFIA strips were dipped into one of three HRP substrate solutions: TMB, 3-amino-9-ethylcarbazole (AEC) 
or DAB with metal enhancement.  Five minutes later, the strips were washed and again analysed with the 




reader.  The red colour of the AuNPs on their own could detect human IgG to approximately 50 ng/mL by 
visual inspection.  The LOD of the reader, calculated as three times the standard deviation (SD), was 
determined to be 2 ng/mL.  The highest sensitivity was obtained by using TMB as a substrate, with a LOD 
for the reader of 0.2 ng/mL.  The reader LOD for AEC and DAB were 0.31 ng/mL and 1.6 ng/mL, 
respectively.  Therefore, by utilising an enzymatic enhancement step coupled to a digital reading device, the 
sensitivity of the LFIA could be increased by approximately one order of magnitude. 
To increase the sensitivity of pathogen detection LFIA, Cho et al. (248) devised a similar system in which 
the conjugation of biotin-avidin constructs to AuNP allowed for the immobilisation of various enzymes to 
NP, in conjunction with analyte-recognition antibodies.  The test reagents consisted of anti-E. coli 0157:H7 
antibodies as capture agent and two conjugates, a biotinylated AuNP-antibody and streptavidin-HRP, 
respectively stored at the sample application pad and conjugate pad.  Once the sample was introduced, 
fifteen minutes was permitted for lateral flow to proceed and, following completion of immunocomplex 
formation, the strip was connected to two absorption pads on either side and washed with deionised water 
via horizontal flow (Figure 2.14).  Next, TMB was added to the horizontal absorption pad to induce the 
enzymatic reaction.  The insoluble product was deposited onto the membrane, thus deepening the visual 
responses observed, and the signals were captured by scanning to obtain OD values.  By following this 
approach, as little as 100 CFU/mL E. coli could be detected, yielding a decrease in LOD of approximately 
1,000-fold. 
 
Figure 2.14 Schematic representation of a LFIA with enzymatic signal enhancement.  First, the assay is conducted via 
lateral flow along the test strip axis (blue arrow).  Following completion of sample migration, the test strip 
is transferred to secondary reagent pads on the horizontal axis (red arrow).  Addition of substrate solutions 
to the substrate pad results in capillary flow across the membrane and subsequent enzymatic reaction 
catalysis leading to signal amplification.  Adapted from Cho et al. (248). 
  




A drawback to the use of enzymes for signal enhancement is the need for an extra step, which complicates 
the procedure.  In addition, the added biological component may negatively impact on the shelf life of the 
device.  Alternatively, AuNP may be auto metallographically enhanced; increasing the particle size by the 
reductive addition of elemental metal from a metal salt, resulting in the particles becoming larger in size 
and thus easier to see.  In the presence of a suitable reducing agent, AuNP can act as catalysts for the 
reduction of copper, silver and gold ions into their respective metals (249).  During metal signal 
intensification, colloidal gold particles serves as a nucleation site for the deposition of the elemental metal, 
resulting in remarkable signal amplification at the test and control lines of immunoassays.  The enhancing 
solutions are physical developers that contain both metal ions and a reducing agent, such as hydroquinone 
(250, 251) or n-propyl gallate (252), buffered to a specific pH.  Silver intensification has been used to better 
visualise gold labelling, especially when using small gold particles (147, 253–255) during 
immunohistochemistry. 
Chiao et al. (256) developed a LFIA in which AuNP-labelled pAb was used to detect botulinum neurotoxin 
type B in cooked meat matrices.  With visual inspection of the results, an LOD of 50 ng/mL was achieved 
with no cross-reactivity to type A and type E neurotoxins.  Following silver deposition using a commercial 
silver enhancer kit available from Sigma, however, the toxin could be detected down to 50 pg/mL.  
Similarly, the detection of OTA in grape must was significantly improved with AgNO3/hydroquinone-
mediated silver deposition by Anfossi et al. (147) in the production of a fully quantitative LFIA.  Recently, 
Panferov et al. (255) compared different methods of silver intensification and found dispensing silver 
lactate and hydroquinone directly onto the membrane resulted in high background with poor contrast, 
hindering even visual detection.  Placing silver lactate- and hydroquinone-soaked pads on top of the test 
zone after immunocomplex completion, followed by dispensing a drop of silver lactate onto the pads 
yielded the best results with a LOD for Ralstonia solanacearum in potato tubers of 200 CFU/mL, a tenfold 
enhancement over the AuNP-assay without enhancement. 
An alternative method to increase the amount of elemental metal available for visualisation was introduced 
by Choi et al. (118) to enhance the detection of troponin I.  By introducing a second conjugate pad to the 
LFIA device, an assay was design containing two AuNP-conjugates spatially separated at sequential 
locations in the device.  As the first conjugate, 10 nm AuNP were passively coated with anti-troponin I 
antibodies and subsequently blocked with BSA.  The second conjugate consisted of larger 40 nm AuNP to 
which anti-BSA antibodies had been passively adsorbed.  Introduction of the sample to the LFIA 
remobilised the two conjugates and permitted interaction of the different components within the liquid 
stream prior to capture at the test and control lines.  Resultantly, at the test line a complex was formed 
consisting of membrane-bound capture antibody/antigen/anti-troponin I-AuNP-BSA conjugate/anti-BSA-
AuNP conjugate.  When compared to a conventional LFIA, a 100-fold increase in sensitivity was observed 
with a LOD of 0.01 ng/mL troponin I detected in ten minutes. 
Rodríguez et al. (123) produced a similar system for signal enhancement for the detection of PSA by 
producing a second conjugate via the adsorption of neutravidin to 20 nm AuNP.  The first conjugate was 




anti-PSA antibodies adsorbed to AuNP, which were subsequently blocked with biotin-conjugated BSA.  In 
contrast to Choi et al. (118), Rodríguez et al. (123) opted not to incorporate the second conjugate in a 
separate pad in the device.  Instead, the LFIA was conducted as a standard immunometric assay and, after 
completion of the first immunocomplex formation, was transferred to a tube containing a solution of the 
second conjugate.  After allowing ten minutes for the second conjugate to migrate to the test line, the 
intensities of the signals were recorded with a digital scanner.  The results were compared to signal 
amplification produced by three different methods of silver intensification.  In the first instance, a 
traditional silver intensification protocol with ten-minute immersion of the LFIA in a silver 
nitrate/hydroquinone mixture following run completion was used.  In the second instance, two additional 
glass fibre pads were produced: one impregnated with silver nitrate and one saturated with hydroquinone.  
Following completion of the LFIA sample migration, the dried pads were placed on the test zone of the NC 
membrane, first the silver pad, followed by the hydroquinone pad on top.  Water was added to the pads to 
rehydrate the reagents and initiate silver intensification of the result which was recorded after ten minutes.  
Finally, in the third instance, a silver salt impregnated pad was assimilated into the LFIA device itself in the 
place of the sample application pad.  After the completion of lateral flow, the bottom of the strip was dipped 
in a solution of hydroquinone, run for ten minutes and scanned to record the line intensities.  The LOD for 
binding of the first conjugate at the test line was determined to be 0.5 ng/mL.  Immersion of the test strip in 
the developer solution yielded the most sensitive signal amplification of all the enhancement protocols 
employed, with a LOD of 0.1 ng/mL upon visual inspection. 
Technologies have, however, also been developed to deposit elemental gold onto AuNP (257–259).  Gold 
has several advantageous over silver, including higher sensitivity and lower background generation.  
Importantly, gold deposition is better compatible with physiological buffers and is less sensitive to shifts in 
pH.  Silver precipitates in the presence of chloride ions, which is generally included in physiological buffers 
as a stabilizing ion (260) and suffers from re-oxidation which may reverse the silver staining process (149).  
Conversely, gold reduction can be performed at near neutral pH, increasing the structural preservation of 
biological samples.  By incorporating an additional gold intensification step utilising HAuCl4 as metal salt 
and NH2OH·HCl as reducing agent, Wang et al. (261) could increase the sensitivity of a E. coli 0157:H7 
LFIA by 8-fold, from 4 x 104 CFU/mL to 5 x 103 CFU/mL.  Similarly, Kaur et al. (149) increased the 
sensitivity of a competitive atrazine detection assay, which could detect less than one part per billion 
without additional enhancement, by a further four-fold following a two-minute immersion in a gold 
chloride/hydroxylamine solution. 
When needed, additional chemically-based signal enhancement steps contribute an extra level of 
complexity to the device since pre-concentration of the AuNP to the detection zone is required prior to a 
chemically mediated process being initiated.  Enhancement systems based on lateral flow therefore 
normally comprise two-step procedures consisting of sample flow and immunocomplex formation, 
followed by the addition of developmental reagents or substrate solutions.  This process requires the 
sequential transfer of the strip from a position where the sample can migrate along a longitudinal axis 




(immunocomplex formation) to a position where horizontal flow can deliver the developing reagent to the 
test and control windows (enhancement).  Apart from altering the basic design to incorporate additional 
elements such as conjugate or reagent pads, microfluidic devices may enable the sequential delivery of 
samples and enhancing reagents to the system by means of a one-step format.  Han et al. (262) recently 
addressed the problem by designing a three-dimensional paper-based microfluidic system that is housed in 
a device which contain a movable slip used for sample application.  The analytical fluidic system is 
constructed out of wax patterned papers which, when layered on top of one another, provides different 
paths for liquids to migrate through to gain access to the reaction membrane of a traditional LFIA.  The 
device contains two ports to which sample and enhancement buffer is respectively loaded.  The 
enhancement channel had been impregnated with gold intensification reagents (Nanoprobes Inc., Yaphank, 
NY, USA).  Once the liquids are added to these ports, the assay is initiated by closure of the slip.  At that 
time, sample enters a fluidic channel which is shorter than the path needed to be followed by the 
enhancement reagents.  In this manner, the sample interacts with the conjugate and enters the reaction 
membrane faster than the secondary solution, which upon reaching the test and control lines deposits 
elemental gold onto the AuNP.  Using this system, the release and mixing of the enhancement reagent 
greatly improved the sensitivity and LOD (3 x SD) of the assay to 9.5 x 104 GII.4 norovirus copies per 
millilitre as compared to approximately 106 – 107 copies per millilitre for a conventional LFIA.  The limit 
of quantification (10 x SD) was determined to be 6.3 x 105 viral copies per millilitre.  The highly sensitive 
assay is especially useful in resource-limited environments and can be utilised by unskilled users without 
any need for extra manipulation for signal amplification.  Another device well suited to multi-step reactions 
on LFIA membranes which can be conducted with minimal technical skill was designed by Shin and Park 
(263).  By altering the housing of the test to consist of two portions that can rotate incrementally with 
respect to one another, multiple reagents can sequentially be delivered to a test strip.  The top piece of the 
device can be oriented so that each end of the test strip, located on the bottom half, can contact the sample 
application pads and absorbent pads of the individual reagents.  Reagent is loaded into the sample pad, 
flows through the NC strip, and is then absorbed by the wicking pad.  The device is rotated to the next 
position and the next reagent is dispensed.  As a proof of the concept, the device was used to detect E. coli 
O157:H7 in a four-step ELISA-process involving sample introduction and immunocomplex formation the 
test line, labelling of the immunocomplex with a secondary HRP-conjugate, washing with buffer to remove 
excess reagent and signal generation by means of DAB addition.  The multi-step reaction could be 
conducted within 22 minutes and exhibited a LOD of 5 x 104 CFU/mL. 
2.4 CONCLUSION 
Within developing countries, the burden of communicable diseases such as HIV/AIDS, tuberculosis, 
malaria, diarrheal disease and acute respiratory infections are leading causes of high mortality.  Several 
reasons, including socio-economic, geographic and demographic factors, as well as poor medical 
infrastructure, make low-income countries especially vulnerable to neglected diseases such as lymphatic 




filariasis, leishmaniasis, schistosomiasis, cholera, cysticercosis, dracunculiasis, foodborne trematode 
infections, hydatidosis, helminthiasis, trachoma, sleeping sickness, onchocerciasis, Chagas disease, Dengue 
fever and many more (264).  Despite this, relatively few diagnostic tools have been designed to address the 
specific needs and challenges of the developing world.  With the introduction of membrane-based 
technologies, however, the problems faced by resource-limited environments and rural areas of developing 
countries, especially pertaining to the rapid identification of disease and the establishment of surveillance 
programs to monitor individual, population and environmental health, can be effectively addressed.  
Moreover, with further advancements in nanotechnology, microfluidics, and device fabrication, LFIA are 
becoming increasingly sensitive and adaptable to specialised applications.  Their intrinsic advantages 
(Table 2.2), such as portability, ease of use by unskilled personnel, low production cost, long shelf life 
when not refrigerated and rapid result generation make LFIAs ideal POC diagnostic platforms for use in 
rural settings or other resource-limited environments. 
2.4.1 LFIAs in EDC detection 
However, even though LFIA development within the clinical and veterinary sectors have been highly 
stimulated, with a combined market share of 98% at the end of the last decade, environmental monitoring 
and water utilities account for merely 0.4% (205).  In less than a century, global production of synthetic 
anthropogenic chemicals has risen from approximately one million tons per year during 1930, to more than 
an estimated 400 million tons in 2000 (265).  As one of the world’s largest economic sectors, chemical 
industrial enterprises exert considerable influence over many other industries.  In 2016, the global value of 
output in chemical compounds were worth an estimated 5.2 trillion U.S. dollars.  A forecasted 
US$16.4 billion of this, equating to eight million metric tons, was ascribed to the volume consumption of 
bisphenol A (BPA) alone (266).  Compounds such as BPA, a known EDC, any many other hazardous 
chemicals are released into the environment due to industrial, agricultural, medical and municipal practices, 
poor waste management, and lacking infrastructure (267).  Increasingly, the presence of compounds that 
were not traditionally viewed as environmental contaminants are being detected in soils, sediments, 
groundwater and ecosystems far removed from their original sites of production or use (268).  Commonly 
known as emerging pollutants (EPs), these contaminants encompass a wide array of natural and man-made 
chemicals, including medical and veterinary pharmaceuticals, hormones, pesticides, cosmetics, personal 
and household care products, industrial compounds and others.  Moreover, several of these compounds 
have been shown to elicit physiological responses at low doses via endocrine mechanisms relating to the 
disruption of the normal cellular and physiological processes governed by natural endogenous hormones 
(269).  LFIAs technology has been applied to the specific detection of a multitude of EDCs and other EPs, 
with some multiplexed units designed to detect more than one related or dissimilar analyte at once.  
However, due to the chemical heterogeneity of compounds which can elicit similar molecular processes, its 
application to the broad-based detection of specific classes of EDCs has been limited.  One attempt to 
construct a LFIA for the broad-based detection of oestrogenic environmental EDCs was described by 
Maltais and Roy (270).  By determining the plasma and surface mucus vitellogenin (VTG) levels of fish, a 




measure of xenobiotic activation or repression of the sex steroid hormone receptors, the cognate nuclear 
transcription factors to oestrogens and androgens, could be estimated.  The expression of VTG is a primary 
example of how certain EDCs can impact upon physiological homeostasis by interfering with nuclear 
receptor-ligand interactions.  Yet, assessment of biologically derived materials such as VTG for 
environmental monitoring is only feasible when a suitable model animal is available, whether collected 
from a natural source or bred for use in testing.  Since steroid receptors govern gene expression principally 
by acting as signal transducers to cognate ligands, the assembly of an alternative, truly in vitro membrane-
based device can be envisioned which exploits the molecular events that follow ligand-binding.  Such a 
device, whether assembled as a dot-ELISA or LFIA, would require a continual source of the receptors 
involved in ligand-binding and a qualitative or semi-quantitative means to indicate the protein-analyte 
interaction.  Therefore, the next chapters discuss the production, purification and ligand-binding capacity of 
recombinant human oestrogen receptor ligand-binding proteins and immunological methods to indicate 
ligand-binding events to these proteins. 
Table 2.2 The advantages and limitations of lateral flow immunochromatic assays. 
Advantages Limitation 
• Technology has been well defined 
• Ease of device production 
• Low development costs 
• Long shelf life 
• Environmental stability 
• Simplicity of usage with a low skills 
requirement 
• In general, minimal sample volumes are 
required 
• Samples of multiple types can mostly be 
analysed without pre-treatment 
• Short analysis times 
• Versatility of formats, labels, biorecognition 
molecules and detection systems 
• Easily integrated with electronics 
• No or little energy consumption 
• Sensitivity and specificity are comparable or 
better than other well-established methods of 
analysis 
• Wide range of applications 
• High commercialisation potential  
• Market presence and acceptance – users and 
regulators require minimal education 
• Cross reactivity of analytes may occur 
• Low biomolecule affinity towards analytes 
may occur 
• Pre-treatment may be required for certain 
samples, increasing analysis time 
• Nature of the sample may impact upon analysis 
time 
• Reproducibility may vary between lots 
• Capillary action cannot be increased or 
decreased following sample application 
• Mostly qualitative or semi-quantitative 
• Patent situation may be unclear 






The recombinant human ERα LBD: 
Binding characteristics of selected natural and synthetic ligands  
3.1 INTRODUCTION 
The endocrine system is responsible for the regulation of life-sustaining processes within the human body.  
These processes include growth and development, homeostasis, cell differentiation, osmoregulation, 
reproductive function, neurological function and metabolism.  The endocrine system is vast.  A multitude of 
ligands (including hormones) and their interactions with respective cognate receptors (both extra and 
intracellularly) regulate processes from the level of individual cells up to the level of a whole organism.  
With rising degrees of global industrialisation ever increasing the usage of chemicals in industry, commerce 
and agriculture, global research into the fate of these chemicals has revealed a growing body of evidence as 
to their effect on biological systems (10, 271–273).  Consequently, a specific class of naturally occurring 
and synthetic xenobiotic compounds, which exhibit disruptive effects on endocrine function, has come to 
light. 
The deleterious effects imposed on the endocrine system by many xenobiotics is known to converge on 
genetic expression due to alterations to the regulatory actions of a group of transcription factors known as 
the nuclear receptors (10).  These proteins exert control over transcription by acting as transducers of 
extracellular signals brought about by small lipophilic molecules.  Structurally, nuclear receptors share a 
modular organisation which delineate the proteins into six distinct domains.  Each of these regions, 
domains A – F, are involved in specific spatial or molecular events pertaining to the functioning of the 
receptor.  Region C, the DBD, and region E, the LBD, is evolutionarily conserved amongst species with the 
biggest variations occurring between fish and other vertebrates (274).  Thus, ligands which can interact with 
the LBD of a nuclear receptor can elicit similar cellular responses in different animals by trans-repression 
or transactivation of genes via the DBD.  The alpha isoform of the human oestrogen receptor (hERα) is a 
member of the nuclear receptor superfamily.  Steroid hormone receptors, such as the hERα, are distinct 
from other nuclear receptors due to their ability to bind to a multitude of structurally diverse ligands, their 
association with multiple heat shock proteins (Hsps) in the absence of ligand and their ability to 
homodimerise when interacting with regulatory DNA elements (275–278).  Due to its role in embryology, 
development and reproduction, numerous studies into the phenomenon of transcriptional dysregulation by 
xenobiotics have focused on hERα (279).  As such, the ERα has become an important focal target to 
identify compounds with potential endocrine disruptive capabilities. 




Therefore, the first step in the development of a novel portable biologically-based endocrine disruptor 
testing method, specifically for the indication of compounds with oestrogenic activity, is the production of 
proteins capable of binding such molecules.  In previous studies, the expression of two soluble constructs of 
the hERα LBD was described (15).  The receptor domains were heterologously produced in insect cells as 
hexahistidine fusion proteins following infection with recombinant baculovirus DNA.  Once expressed, the 
receptor proteins were purified from cell lysates using immobilised metal affinity chromatography (IMAC) 
followed by gel permeation chromatography, rendering pure (more than 95%) and homogenous protein in 
high yields of between 3.75 mg/L and 5.10 mg/L culture.  In this chapter, assessment of the ligand-binding 
capabilities of the recombinant hERα-derived receptors are described and the binding parameters, KD and 
Bmax, were elucidated for each protein.  Furthermore, competitive binding assays were performed using 
multiple compounds known to be disruptors of the endocrine system.  From the results of these assays, 
inhibitory binding constants in relation to a radiolabelled high affinity ligand of the hERα LBD proteins, 
could be established for each compound.  Finally, it is shown that the LBD proteins can be immobilised in a 
facile manner to a novel metal affinity membrane for the selective sequestration of natural and synthetic 
compounds exhibiting hERα-binding capabilities. 
3.2 MATERIALS AND METHODS 
3.2.1 Expression and purification of hERαLBD and hERαLBD-f 
3.2.1.1 Preparation of recombinant baculoviruses 
Spodoptera frugiperda Sf9 (Sf9) and Trichoplusia ni BTI-Tn-5B1-4 (T. ni) cells were resuscitated from 
cryogenic storage and plated to 75 cm2 tissue culture flasks in complete TNM-FH medium consisting of 
Grace’s insect cell culture medium supplemented with yeastolate (3.33 g/L), lactalbumin hydrolysate 
(3.30 g/L), sodium bicarbonate (0.35 g/L) and 10% foetal bovine serum (FBS).  Cells were passaged to 
4 x 104 cells/cm2 until regular division and viability of over 97% was observed.  At such time, cells were 
transferred to suspension cultures and maintained in 250 mL Erlenmeyer flasks at working volumes of 
50 mL.  T. ni was adapted to suspension by the inclusion of 10 U heparin per millilitre culture until cell 
clumping was reduced to less than ten cells per aggregate.  Suspension cultures were incubated at 28°C in 
an Innova 2100 platform shaker set at 120 rpm.  Cells were counted by means of a haemocytometer to 
assess cell density and viability was assessed by the Trypan Blue dye exclusion method (280). 
Recombinant baculoviruses expressing recombinant forms of the hERα LBDs were prepared as previously 
described (15).  Briefly, two DNA fragments, respectively encoding amino acid residues 302 – 553 
(hERαLBD) and 302 – 595 (hERαLBD-f) were amplified from the mammalian expression vector 
pSGhERα66 (281).  Polymerase chain reaction (PCR) primer pairs were designed according to 
complementary DNA (cDNA) sequence accession NM_000125.3, available from the National Centre for 
Biotechnology Information (NCBI), to obtain the open-reading frames for the truncated genes.  The 




5’-primer for both amplifications was 5’-TCTACCCGGGAAGAAGAACAGCCTGGCCTTGTC-3’.  This 
primer incorporates additional bases for recognition site for the restriction enzyme Cfr9I (indicated in grey) 
to the leading strand.  The 3’-primers were 5’-AAGAATTCTCATAGGCGGTGGGCGTCCAG-3’ and 
5’-AAGAATTCGAGCTCTCAGACCGTGGCAGG-3’, respectively for the hERαLBD and hERαLBD-f 
constructs.  Both lagging strand primers introduced EcoRI recognition sites to the amplicons.  The obtained 
amplicon fragments were purified, digested with EcoRI and Cfr9I and cloned into the baculovirus transfer 
plasmid pAB-6xHis, which encodes a hexahistidine tag to the 5’ of the inserted gene.  The resulting 
pAB-6xHis/hERαLBD and pAB-6xHis/hERαLBD-f vectors were co-transfected with linearised 
ProFold®-C1 baculovirus DNA into Sf9 cells to produce recombinant baculoviral particles. 
Recombinant baculoviruses were propagated by infection of Sf9 suspension cultures at low multiplicity of 
infection (MOI) until titres of more than 4 x 107 plaque forming units per millilitre (pfu/mL) were obtained.  
Viral titration was performed by terminal green dilution against a titrated baculovirus reference stock, 
Green Control (108 pfu/mL), and validated by quantitative PCR (qPCR) with a LightCycler® 96 System 
(Roche Diagnostics GmbH, Mannheim, Germany) thermal cycler following extraction of viral DNA from 
culture media with the BacPAK™ qPCR Titration Kit according to the manufacturer’s directions. 
3.2.1.2 Infection of T. ni and purification of recombinant receptor ligand-binding domains 
When expressing the N-terminal histidine-tagged recombinant proteins for purification, cells from T. ni 
suspension cultures, exhibiting viabilities above 97%, were collected by centrifugation at 200 xg for five 
minutes and resuspended in fresh TNM-FH at densities of 106 cells/mL.  Cells were infected with 
recombinant virions at MOIs greater than ten.  Infected cells were maintained at 28°C with agitation of 
120 rpm and harvested 62 hours post infection (hpi).  The cultures were cooled in an ice bath for ten 
minutes and collected at 4°C by centrifugation at 750 xg for 15 minutes.  Following decantation of the 
growth media, the cells were suspended in 25 mL ice cold TNNI+ lysis buffer (50 mM Tris-HCl (pH 8.0), 
150 mM NaCl, 5 mM sodium metabisulphite, 10 mM imidazole, 25 mM sucrose, 0.5% Nonidet-P40, 
5% glycerol, 5 mM β-mercaptoethanol, 100 mM phenylmethanesulphonyl fluoride, 0.6 μg/mL pepstatin A, 
6.5 μg/mL aprotinin, 6.5 μg/mL leupeptin and 6.5 μg/mL antipain) per 100 mL starter culture.  The 
suspension was snap frozen in liquid nitrogen allowing storage at -80°C if immediate processing had to be 
deferred.  The frozen lysate was rapidly thawed in a circulating water bath at room temperature and 
immediately transferred to a Power Sonic 405 sonication bath (Hwashin Technology Co., Seoul, South 
Korea) and sonicated in an ice slurry for ten minutes at the lowest setting.  The lysate was subsequently 
centrifuged at 15,000 xg for 20 minutes, 4°C, and further clarified by filtration through a 0.45 μm pore size 
filter.  Affinity purification of the recombinant proteins was performed on an Äkta Prime protein 
purification system in a cooled environment (maximum temperature 18°C).  Clarified lysates were injected 
onto 1 mL HiTrap Chelating columns charged with nickel ions and equilibrated with C-IMAC+ buffer 
(50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 20 mM imidazole, 5 mM sodium metabisulphite, 0.15% 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate, 25 mM sucrose).  Following application 




of protein lysates, columns were washed with C-IMAC buffer after which the imidazole concentration was 
increased to 92 mM to remove contaminating metal chelating proteins.  Elution of the histidine-tagged 
proteins from the affinity columns were facilitated by a rapid increase of the imidazole concentration to 
500 mM.  Protein containing fractions were immediately pooled, subjected to a buffer exchange step on 
5 mL HiTrap Desalting columns equilibrated with CD+ buffer (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 
5 mM sodium metabisulphite, 0.15% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate 
hydrate, 25 mM sucrose, 3.75 mM dithiothreitol (DTT)), aliquoted into 500-μL thin-wall PCR tubes, 
instantly frozen in liquid nitrogen and transferred to -80°C for storage until required for use. 
3.2.1.3 Protein characterisation 
Protein concentrations in the eluents were determined by the Bradford microtiter assay against a standard 
curve generated with BSA in CD+ buffer.  Hand-cast 12% SDS-PAGE gels were used to determine protein 
purity.  Protein samples were diluted 1:1 in 2x SDS-PAGE sample buffer according to Laemmli (125 mM 
Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 10% β-mercaptoethanol, 0.001% Bromophenol Blue) (282).  
Electrophoresis was performed using a Bio-Rad Mini-PROTEAN system (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA) at 4°C, 200 V.  After electrophoresis, proteins were visualised by gel staining with 
Coomassie Brilliant Blue R-250, prior to fixing and destaining with glacial acetic acid and methanol. 
For identification of resolved bands, proteins were transferred to Amersham™ Protran™ 0.45 μm NC 
nitrocellulose blotting membrane at a constant amperage of 400 mA for 90 minutes.  The membranes were 
blocked overnight in casein buffer (10 mM Tris (pH 7.6), 0.15 M NaCl, 0.5% casein) at 4°C with gentle 
shaking.  Detection of ERα analogues was achieved by incubation of membranes at 37°C in working 
solutions of rat anti-ERα IgG (1:1,000) followed by HRP-conjugated goat anti-rat IgG (1:10,000) in casein 
buffer.  Co-eluting proteins were identified by incubation of membranes with mouse anti-Hsc70 IgM 
(1:1,000) and rabbit anti-HDJ2 IgG (1:10,000), followed by HRP-conjugated goat anti-mouse IgG 
(1:50,000) or HRP-conjugated goat anti-rabbit IgG (1:20,000).  Chemiluminescent signals were generated 
by addition of Clarity ECL substrate solution which were detected and photographed with a myECL digital 
transilluminator imager (Thermo Scientific, Waltham, MA, USA). 
3.2.2 Establishment of hERα LBD activity 
The radiolabelled steroid utilised in all radioligand-binding assays was [2,4,6,7-3H(N)]-oestradiol (3HE2). 
3.2.2.1 Binding assays 
All receptor radioligand-binding assays were conducted in pyrolysed 350 µL glass conical tubes contained 
in polypropylene 96-deepwell plates.  The binding buffer (TEENDB) consisted of 10 mM Tris-HCl 
(pH 7.4), 1 mM ethylenediaminetetraacetic acid disodium dihydrate (EDTA), 1 mM ethylenebis-
(oxyethylenenitrilo)-tetraacetic acid (EGTA), 1 mM NaVO3, 10% glycerol, 1 mM DTT and 10 mg/mL 
BSA to equalise the protein concentrations.  The assay volume was 100 μL, consisting of 50 μL TEENDB, 
10 μL radiolabelled 3HE2, 10 μL 20% dimethyl sulphoxide (DMSO) containing TEENDB (for total binding 




determination) or 10 μL competitor in 20% DMSO containing TEENDB (for non-specific binding and 
competitive binding determinations) and 30 μL protein in TEENDB.  All constituents of the binding assays 
were assembled in room temperature buffers prior to protein aliquots being thawed on ice.  Dilutions of 
active protein were made in ice cold TEENDB.  Once protein solutions were added, binding experiments 
were performed for two hours at room temperature with constant shaking.  At the end of the assays period, 
100 μL of a 0.4% dextran-coated charcoal (DCC) suspension was mixed with the contents of each tube to 
separate bound from free radioligand.  The plates were incubated with shaking on ice for 15 minutes and 
centrifuged at 3,750 xg for 15 minutes, 4°C, to pellet the DCC.  Suspensions of DCC were prepared 
16 hours prior to execution of binding assays by gentle mixing of 200 mg activated charcoal and 20 mg 
70 kDa dextran from Leuconostoc spp. with 50 mL TEENDB at 4°C on a tube roller. 
Determination of the radioactivity contained in the assay supernatants was performed on a Tri-Carb® 2810 
TR Liquid Scintillation Analyzer (Perkin Elmer, Boston, MA, USA) under the control of the 
QuantaSmart™ Instrument and Data Reduction Software package for Windows® XP.  One hundred 
microliters of each DCC treated sample was transferred to 1 mL FlowScint III liquid scintillation cocktail 
(LSC) in labelled 6 mL disposable LSC vials.  All measurements were taken as radioactive counts per 
minute (cpm) in duplicate, for two minutes each.  Following background subtraction, total decay per minute 
(dpm) of bound radioligand in each assay was calculated by multiplying cpm with two and correcting for 
the counting efficiency of the counter for tritium (61.17%). 
3.2.2.1.1 Determination of nominal protein concentration for use in saturation and binding assays 
Prior to the execution of saturation and competitive binding studies, nominal concentrations of active 
receptor LBDs in the purified preparations had to be determined.  Tritiated E2 (0.5 nM) was incubated with 
or without 1 μM unlabelled E2 in the presence of various dilutions of hERαLBD or hERαLBD-f to optimise 
the amount of receptor required in each assay.  Assays were performed with nominal protein concentrations 
in pre-assay dilutions ranging between 600 nM and 0.313 nM.  Total radioactivity in the assay was 
determined by counting 10 µL of the added 5 nM radioligand solution with 90 μL TEENDB containing 2% 
DMSO in 1 mL LSC.  All subsequent characterisations of binding activity by saturation and competitive 
assays were performed with the same batches of hERαLBD and hERαLBD-f for which nominal activity 
had been established. 
3.2.2.1.2 Determination of KD and Bmax for E2 binding to recombinant hERαLBD/-f proteins  
Sixty nanomolar 3HE2 was prepared by diluting stock solution with room temperature TEENDB containing 
20% DMSO which was used to prepare a serial dilution range of 3HE2 solutions.  Saturation binding assays 
for the two recombinant receptors were performed in TEENDB containing 2% DMSO with a radioligand 
range of 0.0625 nM – 6 nM 3HE2 and a nominal protein concentration of 1.8 nM in a final volume of 
100 μL.  Non-specific binding was accounted for by diluting 120 μM E2 in TEENDB containing 20% 
DMSO to allow 2,000-fold excesses of unlabelled competitor in the control wells.  Six biological replicates, 
each consisting of three technical repeats, were conducted for each of the two heterologous proteins.  




Calculation of the amount of radioligand bound by per unit of protein in each assay, in relation to the 
observed scintillation, was achieved by applying equation 3.1.  The amount of active receptor in each assay 
was 180 picomoles, thus 5.49 ng hERαLBD or 6.34 ng hERαLBD-f. 
Equation 3.1 Conversion of dpm to femtomole radioligand bound per milligram protein during saturation binding 
assay; where cpm equals the observed radioactive decays per minute, εI is a correction factor for 
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Saturation binding curves were fitted to the data with GraphPad Prism for Windows, Version 6.01.  
Specific ligand-binding curves were generated by subtraction of the non-specific binding data from total 
3HE2 binding observed.  The binding parameters Bmax and KD were calculated by applying a robust one-site 
total and nonspecific binding non-linear regression model thus directly analysing the data without Scatchard 
transformation.  Detector background was subtracted prior to data analysis and background was therefore 
constrained to zero.  The model used to fit the data is outlined in equation 3.2 and equation 3.3. 
Equation 3.2 Specific binding (SB) for any given coordinate is calculated from the maximal binding (Bmax) that can 
occur for any given concentration or radioligand X (in nM) to a receptor exhibiting a defined affinity 
for the ligand (KD).  
𝑆𝐵 =
𝐵𝑚𝑎𝑥 × 𝑋
(𝑋 +  𝐾𝐷)
 
Equation 3.3 The non-specific binding (NSB) interaction of ligands, including the radioligand, within the assay 
system is linearly correlated to its concentration and NS defines the relationship between the amount 
of non-specific binding which will occur in relation to the added concentration of a measurable ligand 
X. 
𝑁𝑆𝐵 = 𝑁𝑆 × 𝑋 + 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 
3.2.2.1.3 Determination of binding parameters for selected EDCs by competitive binding 
In order to determine inhibition constants (KI) for several hormones and xenobiotic compounds as well as 
their relative binding affinities (RBA) for the hERαLBD and hERαLBD-f proteins, 180 pmol of the 
recombinant LBDs were incubated with 0.5 nM 3HE2 together with increasing concentrations of 
competitors in a final volume of 100 μL TEENDB containing 2% DMSO.  Three biological replicates 
consisting of three technical repeats were performed for all hormones and xenobiotics as described above.  
All compounds, except E2 and zearalenone (ZEA), were dissolved in DMSO as 100 mM stock solutions.  
E2 and ZEA were made up to a final concentration of 10 mM in the same solvent.  Competitor compounds 
were added to the assays in concentration ranges as per table 3.1.  Triplicate wells containing 0.5 nM 3HE2 
and 10 μM (20,000-fold excess) unlabelled E2 were included in all analyses to calculate non-specific 
binding while maximal binding was assessed in the absence of competitor. 





Table 3.1 Competitor compounds used in the analysis of recombinant hERαLBD and hERαLBD-f relative binding affinity determinations. 
Competitor 
   Chemical grouping Density Mr Assay range 
CAS number Supplier Code  g/cm3 g/mol log10M 
17β-Oestradiol E2 50-28-2 Sigma E8875 Hormone  272.38 10-6 - 10-10 
Oestrone E1 53-16-7 Sigma E9750 Hormone  270.37 10-6 - 10-10 
Oestriol E3 50-27-1 Sigma E1253 Hormone  288.38 10-6 - 10-10 
17α-Ethynyloestradiol EE2 57-63-6 Sigma E4876 Synthetic hormone  296.04 10-6 - 10-10 
Diethylstilboestrol DES 56-53-1 Fluka 32500 Synthetic hormone  268.35 10-6 - 10-10 
Genistein GEN 446-72-0 Sigma G6649 Flavonoid  270.24 10-3 - 10-10 
Zearalenone ZEA 17924-92-4 Fluka 34126 Mycotoxin  318.37 10-3 - 10-10 
Bisphenol A BPA 80-05-7 Sigma 239658 Plasticiser  228.29 10-2 - 10-9 
Bisphenol S BPS 80-09-1 Sigma 43034 Plasticiser  250.27 10-2 - 10-9 
4-Nonylphenol 4NP 104-40-5 Fluka 46405 Detergent 0,953 220.35 10-3 - 10-10 
4-tert-Octylphenol TOP 140-66-9 Sigma 290823 Detergent  206.32 10-3 - 10-10 
Di-n-butyl phthalate DBP 84-74-2 Sigma 524980 Industrial chemical 1,05 278.34 5-4 - 10-10 
Carbamazepine CMZ 298-46-4 Sigma C4024 Anti-convulsant  236.27 10-3 - 10-10 
Propylparaben PB 94-13-3 USP 1577008 Cosmetic preservative  273.24 10-3 - 10-10 
Atrazine AT 1912-24-9 Sigma 45330 Insecticide 1,19 215.68 10-3 - 10-10 
α-Cypermethrin ACM 67375-30-8 Sigma 45806 Insecticide  416.30 10-3 - 10-10 
Endosulfan END 115-29-7 Sigma 32015 Herbicide 1,74 406.90 10-3 - 10-10 
p,p'-Dichlorodiphenyl-trichloroethane DDT 789-02-6 Sigma 31041 Insecticide  354.49 10-3 - 10-10 
p,p’-Dichlorodiphenyl-dichloroethylene DDE 72-55-9 Sigma 35487 Insecticide  318.02 10-3 - 10-10 
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Generation of binding curves and isotherms were executed with GraphPad Prism.  Competitive binding 
curves were generated for every biological replicate by fitting a one-site non-linear competitive regression 
model with automatic outlier exclusion to the specific dpm measurements to determine the presence of 
possible outlier measurements.  Next, the percentage specific binding for each technical replicate was 
calculated by normalisation of the data against the mean of the replicate measurements with constraint 
definitions of 0% binding as Y equalling zero and 100% binding as the largest value in each data set.  The 
means of these normalisations were used to construct binding curves for each compound. 
Many publications report competitor binding affinity to the ER as RBA based on the concentration of 
inhibitor which causes 50% inhibition (IC50) of radioligand binding.  The IC50 for each competitor was 
therefore determined by fitting robust one-site binding isotherm to the biological replicate data 
(Equation 3.4).  The IC50 for active compounds was determined three times, once for each biological repeat. 
Equation 3.4 Calculation of the concentration of unlabelled ligand required to inhibit 50% binding of radiolabelled 
ligand to a single receptor binding site.  Top and Bottom are the plateaus of the curve in units of Y 
(283). 




An IC50 value is not a direct measure of a ligand’s affinity for the receptor.  Rather, such values can only be 
viewed as a comparative means to relate the binding of a ligand to a receptor to that of a known high-
affinity ligand.  Therefore, the RBA of each compound for the respective receptor proteins was calculated 
by determining the ratio of the IC50 of the test compound to the IC50 of the unlabelled E2 competitor.  RBA 
was expressed as percentage in relation to E2, thus the RBA of E2 was arbitrarily set at one hundred. 
In determining the binding inhibitory constants, KI, of each competitor compound, the means of the 
normalised technical replicate measurements in each biological replicate were fitted to a robust non-linear 
one-site regression model for competitive binding to directly calculate the KI (Equation 3.5).  Since there is 
a relationship between the KI and the IC50 the model uses the values determined by applying equation 3.4 to 
the determination of the logKI, and by extension the KI. 
Equation 3.5 Non-linear regression model for the calculation of KI, the equilibrium dissociation constant of the 
unlabelled competitor compounds.  The logKI is the logarithm of the equilibrium dissociation 
constant of the unlabelled ligand, [R] represents the concentration of radioligand used when 
conducting the assay and RKD refers to the dissociation constant of the radiolabelled compound as 
calculated by saturation binding analysis (284). 
𝑙𝑜𝑔𝐼𝐶50 = 𝑙𝑜𝑔 (10




For each biological replicate, the logKI was determined using GraphPad Prism and from these values the 
KIs for active compounds were calculated. 
  




3.2.2.2 Testing of EDC sequestration to affinity membrane by competitive radio ligand assays 
The hERαLBD was used to bio-functionalise a novel poly(styrene-maleic anhydride) polyvinylpyrrolidone 
co-polymeric membrane (PVP-PSMI) (Figure 3.1), synthesised at the Department of Polymer Science, 
Stellenbosch University (285), to investigate whether heterologously expressed receptors could be 
immobilised to a solid support and still retain ligand-binding activity in an aqueous matrix. 
 
Figure 3.1 Co-polymeric PVP-PMSI affinity membrane and its interaction with recombinant polyhistidine tagged 
proteins.  The PSMA scaffold serves as the base of the membrane.  PVP spacer arms are coupled to a 
chelating ligand capable of metal ion complex formation.  The divalent metal ion, Ni2+ in the figure, can 
interact with the imidazole rings of the histidine moieties of the tagged fusion protein, thus forming stable 
dative covalent bonds. 
The PVP-PMSI nanofibrous membrane has been functionalised with a chelating moiety and can thus serve 
as a metal affinity membrane.  PVP-PSMI was cut into 1 cm2 squares, each of which was placed in an 
individual 2.0 mL crimp top autosampler vial.  The membrane squares were functionalised with Ni2+-ions 
by immersion in 1.5 mL 100 mM NiSO4.  Following a 30-minute incubation at ambient temperatures, 
20 rpm, the NiSO4 solution was aspirated and the membranes washed twice with 2 mL deionised water.  
Two millilitre phosphate buffered saline (PBS; pH 7.4) containing affinity purified hERαLBD (in CD+ 
buffer without DTT) at a concentration of either 20 μg/mL or 50 μg/mL was added to duplicate vials.  The 
vials were sealed and incubated at 4°C overnight, at 20 rpm.  The membranes were subsequently washed 
three times with PBS containing 0.2% Tween-20 (PBST) after which 1.5 mL PBS containing 50 pM 3HE2 
was added to each vial to assess the ability of the immobilised protein to bind its cognate ligand.  
Furthermore, experiments were conducted with the addition of competitor compounds to determine whether 




3HE2 could be displaced from the hERαLBD protein via competitive binding.  Three duplicate sets of vials, 
containing 1.5 mL 20 μg/mL hERαLBD with either 50 nM unlabelled E2, 200 nM DES or 200 nM BPA, 
were prepared.  The vials were incubated at 4°C for 8 hours, 20 rpm.  The 3HE2 solution, referred to as the 
eluent, was subsequently removed and stored.  The hERαLBD-functionalised PVP-PSMI membranes were 
washed three times, each for ten minutes with 2 mL cold PBST, and the three wash volumes for each 
sample were pooled and stored.  Each membrane was subsequently transferred to 6-mL polyethylene LSC 
vials containing 4 mL LSC fluid and 1 mL PBS.  One millilitre of the eluents and wash solutions was also 
added to individual vials containing 4 mL LSC fluid.  Radioactivity measurements of the membranes, 
washing liquid and eluents were collected as cpm with a Tri-Carb® 2810 TR Liquid Scintillation Analyzer 
over five-minute periods.  Data was analysed with GraphPad Prism by ordinary two-way ANOVA 
implementing Tukey’s multiple comparisons test.  The family wise significance and confidence level was 
set to 99.9% (α = 0.001). 
3.3 RESULTS AND DISCUSSION 
3.3.1 Receptor purification 
With the aim of identifying novel methods to rapidly detect oestrogenic EDCs in environmental samples, 
the genes encoding two variants of the hERα LBD were cloned into the genome of a recombinant 
baculovirus.  These proteins were isolated in active forms from the baculovirus expression vector system 
(BEVS) recombinant protein production platform by careful optimisation of lysis and chromatographic 
conditions.  Both the 30.5 kDa hERαLBD and 35.2 kDa hERαLBD-f eluted from IMAC and desalting gel 
permeation columns as single peaks.  Analysis of the purified receptor preparations by SDS-PAGE 
(Figure 3.2) revealed the presence of higher molecular weight proteins bands at approximately 46 kDa and 
72 kDa.  The co-eluted proteins were identified by western blot as human heat shock protein Hsc70 and its 
co-chaperone partner Hsp40.  ProFold-C1™, the recombinant baculovirus genome to which the genes for 
the receptor LBDs had been cloned, had been engineered to express two human chaperone proteins to assist 
with the correct folding of heterologous proteins within the insect cell cytosol.  Hsc70 is a constitutively 
expressed chaperone with weak intrinsic ATPase activity and a high affinity for extended hydrophobic 
peptides (286).  As peptide chains emerge from ribosomes during translation, Hsc70 associates with its 
hydrophobic peptide substrates, thus shielding them from the polar cytosolic environment and preventing 
their aggregation.  Once bound to a substrate, its ATP hydrolytic activity is increased, resulting in 
dephosphorylation of ATP to ADP which induces a conformational change in the chaperone and further 
stabilisation of the substrate interaction.  Return to an ATP-bound state releases the hydrophobic substrate, 
which consequently allows its folding within the incipient peptide chain or its transfer to the following 
chaperone complex (287).  This process is regulated by Hsp40 co-chaperone proteins which stimulate and 
enhance Hsc70’s ATPase activity while also recruiting the chaperones to various subcellular locations or 
protein complexes which require stabilisation by the protein. 





Figure 3.2 Representative chromatogram (A) of the one-step IMAC purification of recombinant human oestrogen 
receptor ligand-binding domains from baculovirus infected T. ni culture lysates and images of (B) proteins, 
7.5 μg, electrophoresed on a 12% SDS-PAGE and visualised with Coomassie Blue staining and (C) a 
composite chemiluminescence western blot positively identifying the proteins as human heat shock protein 
Hsc70 (72.0 kDa), its co-chaperone partner Hsp40 (46.0 kDa) and the two hERα analogues, hERαLBD 
(30.5 kDa) and hERαLBD-f (35.2 kDa). 
Insect cells can synthesise these molecular helper proteins - indeed Hsp70, the stress-induced connate of 
Hsc70, is up-regulated during baculovirus infection (288, 289).  Autographa californica multicapsid 
nucleopolyhedrovirus (AcMNPV, the parental genome of ProFold™-C1) replication is assisted by heat-
shock proteins during infection of Sf9 cells (290, 291).  It has been reported that Hsc70 and Hsp70 associate 
with the VP1, VP2 and VP3 capsid proteins of polyomaviruses in the cytosol with consequent nuclear 
translocation, thus assisting in viral assembly (292).  Upon expression of VP1 and VP2 in Sf9 cells with 
baculovirus vectors, co-immunoprecipitation with Hsp70-like proteins has also been observed (292).  Such 
results suggest that molecular chaperones are involved in the prevention of premature cytosolic capsid 
assembly and/or the transport of unassembled capsid proteins to the nucleus.  Nobiron et al. (293) 
demonstrated by a differential display approach that Sf9 host mRNA encoded by Hsc70 was transiently up-
regulated during AcMNPV infection, with expression reaching a peak at 6 hpi and complete down-
regulation occurring at 24 hpi.  Down-regulation of the expression of these proteins from 12 hpi onwards 
implies that recombinant eukaryotic constructs, expressed during the late stages of infection under the 
control of the polyhedrin or p10 promoters, do not have access to these molecular chaperones.  
Heterologous proteins which require the assistance of heat-shock chaperones are thus often misfolded, 
which may lead to aggregation in structures reminiscent of bacterial inclusion bodies. 
The presence of these chaperones in association with the recombinant hERα LBDs are therefore not all that 
surprising, since Hsp70 has been shown to copurify with the progesterone receptor (PR) from oviduct 
cytosolic extracts in a stoichiometric ratio (294).  Furthermore, association with Hsps have been positively 
associated with increased solubility and activity of nuclear receptors in other studies by interaction with the 
LBDs.  Alnemri and Litwack (295), for example, reported on poor solubility and aggregate formation when 
full-length glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) were overexpressed in the 
BEVS.  Expression of soluble truncated receptors could be achieved by deletion of the LBD.  Yet, in vitro 




incubation of partially purified full-length MR and GR aggregates with reticulocyte lysate containing Hsps 
led to reconstituted oligomeric forms of the receptor in a soluble state which regained steroid binding 
abilities.  Current data therefore suggest that Hsps associate with the LBD, thus inhibiting the aggregation 
of the receptor by shielding these hydrophobic regions from the solvent environment.  Interestingly there 
nevertheless seems to be a slightly greater association of the chaperones with the larger hERαLBD-f 
protein, which contains the additional F-domain of the ERα encompassing residues 553 – 595, in 
comparison to ERαLBD at the same concentration (Figure 3.2).  hERαLBD-f is slightly less hydrophobic 
than hERαLBD with a grand average hydropathy (GRAVY) (296) score of 0.0071 versus 0.097. 
3.3.2 Establishment of hERα LBD activity 
3.3.2.1 Binding assays 
3.3.2.1.1 Determination of nominal protein concentration for use in saturation and binding assays 
Whether or not the additional 42 residues present at the C-terminal of hERαLBD-f provides potential 
molecular interaction sites for chaperones, the differential co-elution of stabilising proteins presents a 
problem.  When attempting to relate the specific binding of one recombinant hERα LBD to another, the 
presence of unwanted proteins confounds estimates of protein concentration which is not reflective protein 
ability to bind ligand.  Moreover, while dye-binding assays are the most prominent means to quantify 
proteins routinely in a laboratory setting, it is well known that differences in protein primary structure, 
amino acid composition and size can have a significant impact on the accuracy of concentration estimates 
relative to a reference protein.  Although most applications commonly use BSA as a reference standard for 
protein quantitation, the difference in size between the two hERα LBD proteins and BSA means that the use 
of this protein to determine recombinant protein quantity is inherently inaccurate.  Different proteins 
produce different absorbances when assayed be colourimetric methods (297).  The use of BSA as reference 
standard during protein quantitation of purified IgG, for example, results in underestimation of 
immunoglobulin quantity.  Bovine gamma globulin (BGG) is a better standard to use in such an instance, 
since BGG produces a colour response that is similar so that of IgG.  Nonetheless, BSA may still be 
employed as a standard to determine a reference concentration to each batch of recombinant protein, from 
which a nominal concentration can be assigned which correspond to the ligand-binding capability of the 
receptor in that preparation.  Under conditions corresponding to competitive binding, i.e. 0.5 nM 3HE2 (18), 
specific binding is plotted against protein concentration.  The concentration of receptor that specifically 
binds 40% of added radiolabel (acceptable range 30 – 50%) is thus related to the corresponding nominal 
receptor concentration.  Prolonged storage of purified hERαLBD-f at -20°C, for example, resulted in a 
pronounced loss of ligand-binding activity (Figure 3.3).  The nominal concentration of hERαLBD-f stored 
at -20°C required to specifically bind 0.2 nM 3HE2 was 136 nM, in comparison to 6 nM needed when a 
preparation stored at -80°C was used. 





Figure 3.3 Effect of long-term storage on the ligand-binding activity of hERαLBD-f.  Marked differences in activity 
could be observed between receptors that were isolated and immediately stored at -80°C (blue) versus 
preparations that were stored at -20°C for six months (green).  With nominal concentrations of 6 nM and 
136 nM, respectively, inadequate storage conditions accounted for an approximated 40-fold loss in binding 
activity. 
In order to standardise the amount of receptor to be used in the determination of binding parameters for 
both hERα LBD proteins, nominal concentrations of hERαLBD and hERαLBD-f were determined that 
satisfy the benchmark of 40% specific binding of available radioligand.  During nominal concentration 
determinations, 9,628 dpm of the 10,826 dpm added to the assay system was available to be bound 
specifically by the receptors.  At 0.5 nM 3HE2, 10% of the available ligand was non-specifically bound in 
the assay system, resulting in ± 0.45 nM 3HE2 available for specific binding by the receptor molecules 
(Figure 3.4) which was used to normalise the response following background subtraction (Figure 3.5).  At 
nominal receptor concentrations of < 10 nM receptor, the amount of radioactivity bound by the hERαLBD 
and hERαLBD-f was comparable.  Thus, dilution of the receptor LBDs to nominal concentrations of 6 nM 
resulted in final assay conditions containing 180 picomole available receptor in each assay.  This quantity 
was used for all subsequent analyses since both LBD constructs bound the same amount of radioligand 
under these conditions.  Interestingly, at increased LBD concentrations a marked difference in radioligand 
binding was observed between the two proteins. 
 
Figure 3.4 Total 3HE2 measured following incubation with nominal concentrations of hERαLBD (red) and 
hERαLBD-f (blue).  Non-specific binding (grey) observed for both receptors similar.  





Figure 3.5 Nominal receptor concentration determination for use in saturation and competitive radioligand binding 
assays.  At smaller dilutions both the hERαLBD and the hERαLBD-f specifically bound 3HE2 at 
approximately the same quantity per amount of receptor present.  Consequently, a nominal concentration of 
6 nM was assigned to both receptor preparations.  Results are expressed as the mean ± the standard 
deviation from the mean of three technical replicates. 
3.3.2.1.2 Saturation binding 
Hormone receptor radioligand assays consist of two parts, saturation binding and competitive binding.  The 
saturation binding assay is designed to characterise the isolated receptor proteins regarding their affinity for 
ligand (KD) and maximal binding activity (Bmax) in preparation for competitive binding experiments.  
Functional characterisation of the two purified proteins was therefore approached by measuring 3HE2 
binding ability.  In this experiment, 3HE2 was incubated at multiple concentrations with the same quantity 
of hERαLBD or hERαLBD-f, in the presence or absence of a 2,000-fold excess of competitor.  The total 
amount of radioligand binding occurring in the assay system was subsequently observed together with the 
non-specific binding (Figure 3.6).  From this data, saturation binding curves indicating the specific binding 
of radioligand to the receptors were generated. 
Figure 3.6 Saturation binding curves obtained following incubation of 180 picomoles of hERαLBD (left panel) or 
hERαLBD-f (right panel) with varying concentrations of 3HE2 in the presence or absence of 2,000-fold 
excess unlabelled E2.  Data was collected by performing six biological replicates, each consisting of three 
technical replicates measured in duplicate.  Error bars indicate the distribution of technical repeats within 
each of the biological repeats.  




The binding parameters, Bmax and KD, was calculated for both hERα LBD proteins by fitting a global model 
to the total and non-specific binding curves.  The calculated Bmax for the F-domain-containing hERαLBD-f 
was 3,312 fmol/mg protein while ligand was bound to the receptor protein with high affinity – the KD for 
the interaction was 0.9688 nM.  Conversely, the hERαLBD protein, which lacks the C-terminal F-domain, 
exhibited a greater binding capacity for the radioligand with a Bmax of 4,945 fmol/mg protein.  However, 
with a KD of 1.525 nM, the affinity of the hERαLBD for the ligand was marginally lower than that of the 
F-domain containing protein.  A visual representation of the binding isotherms is presented in figure 3.7. 
 
Figure 3.7 Curves depicting the specific binding of 3HE2 to the recombinant hERαLBD and hERαLBD-f proteins.  
Specific binding was calculated directly from the globally fitted non-linear regression model. 
In the absence of ligand, H12 of the hERα LBD is distended from the main protein body.  This 
conformation allows access of the ligand to the binding cavity of the protein.  However, in the E2-bound 
state, H12 takes part in a protein conformational change, allowing the formation of the coactivator 
interaction site of the receptor, AF-2.  The F-domain, which is present in only certain members of the large 
nuclear receptor superfamily, is located at the extreme carboxyl-terminus of the receptor distal to the larger 
LBD.  The flexible domain differs from the main LBD body of the hERα due to its lack of sequence 
conservation between ER proteins and subtypes of different vertebrate species (298) although it seems to be 
conserved in length (299).  The translocation of H12 following ligand binding also results in repositioning 
of the F-domain which inhibits activation of the receptor by antagonists, a phenomenon that can be partially 
relieved by deletion of the domain (299).  Even though the F-domain is not required for transcriptional 
activation of the hERα by E2, it seems to modulate the magnitude of ligand-dependent gene transcription in 
different cells by maintaining receptor conformation following ligand binding (298). 
The F-domain is not required for high affinity binding of hormones (300).  However, in contrast to 
observations made during previous studies (298, 300), here the absence of the last C-terminal domain led to 
a slight increase in the KD of the receptor for E2.  This may confirm the hypothesis that once bound to a 
ligand, translocation of H12 is stabilised by intra-protein molecular interactions imposed on the LBD by the 
F-domain, which in turn stabilises the ligand-bound conformation thus inhibiting release of the ligand 




molecule (301).  Regarding the saturation binding curves for the hERαLBD and hERαLBD-f, a stark 
difference in the maximal ligand binding achievable by the same quantity of the two proteins at equal 3HE2 
concentrations was observed (Figure 3.7).  However, when considering the ratio of receptor density to the 
constant of radioligand dissociation at equilibrium (Bmax/KD), similar binding potentials are exhibited by the 
hERαLBD and hERαLBD-f proteins; respectively 3,243 fmol/mg/nM and 3,357 fmol/mg/nM. 
3.3.2.1.3 Competitive binding 
One of the key components of radioligand-binding assays is the measurement of the degree of displacement 
of a radiolabelled high affinity ligand, 3HE2 in this case, from a receptor in the presence of increasing 
concentrations of unlabelled test compounds.  Test chemicals that possess a high affinity for the hERα can 
successfully compete with the radioligand at a lower concentration than compounds with lower affinities.  
The competitive binding of such compounds can be measured by decreasing amounts of radioactivity as 
competitor concentration increases.  The obtained values, once graphically represented and fitted with non-
linear one-site regression models for competitive binding, enable the determination of the amount of 
competitor required to reduce radioligand binding by 50% (Equation 3.4) and to directly extract a 
descriptive inhibitory constant from the plotted data (Equation 3.5).  The mean KIs, IC50s and RBA values 
for the 19 compounds tested in competitive radioligand-binding assays with two recombinant hERα LBD 
proteins are presented in table 3.2.  Thirteen of the 19 compounds tested were binders, two were equivocal 
(very weak binder which may interact under specific conditions) and four did not interact with either of the 
hERα LBDs.  Six of the active compounds were strong binders to both proteins (log RBA > 0), three were 
moderate binders (log RBA between 0 and -2) and three bound the proteins only weakly (log RBA between 
-2 and -3).  The two equivocal compounds respectively bound the LBDs weakly and very weakly, while the 
other bound very weakly or not at all.  Finally, one compound exhibited strong binding to one LBD and 
moderated binding to the other. 
The competitive binding curves generated for the natural ligand to the hERα, E2 (Figure 3.8), was nearly 
identical for the hERαLBD and hERαLBD-f proteins.  Deletion of the F-domain resulted in an increase in 
the IC50 of only 0.63 nM.  In the presence of the C-terminal domain, the absolute KI decreased nearly two-
fold from 1.28 x 10-9 nM to 6.98 x 10-10 nM. 





Figure 3.8 Competitive binding curves of indicating the displacement of 3HE2 from the hERαLBD (red) end 
hERαLBD-f (blue) by the natural ligand to the ERα, E2.  Data was collected by performing three biological 
replicates, each consisting of three technical repeats. 
The competitive binding curves for the eighteen compounds tested for interaction with the hERα LBDs, in 
addition to E2, are presented in figures 3.9 – 3.11.  As expected, all the steroidal and non-steroidal synthetic 
hormones exhibited strong binding affinity for both hERα receptor proteins.  The synthetic oestrogens DES 
and EE2 exhibited greater affinity for the hERα LBD compared to E2 – increases in the IC50’s for these 
compounds were observed which was also reflected in a fold-change in the affinity of these compounds 
favouring the hERαLBD-f.  In this category, E3 exhibited the largest fold-change in KI at 7.85. 
Genistein (GEN) was classified as a moderated binder to the hERαLBD.  However, incubation of the 
natural flavonoid with the hERαLBD-f resulted in a 11.2-fold increase in affinity for the receptor containing 
the additional F-domain.  Resultantly, the compound was viewed as a strong binder with a logRBA of 0.60 
for the hERαLBD-f in comparison to -0.36 when assayed with the hERαLBD.  Another naturally occurring 
xenobiotic, ZEA, bound to both forms of the recombinant LBDs with high affinity, with a nearly 8-fold 
increase in affinity when competing with 3HE2 for binding to the hERαLBD-f, as compared to the 
hERαLBD. 
The plasticisers, BPA and BPS exhibited moderate to weak binding to the hERα LBDs.  BPA bound both 
receptors with higher affinity than its sulphonylated analogue.  However, while BPS exhibited slightly 
increased affinity for hERαLBD-f, the affinity of BPA did not change with regards to the presence or 
absence of the F-domain.  In the detergent-class, TOP had moderate affinity for both forms of the 
recombinant receptors, albeit 22.8-fold more so for the hERαLBD-f.  The affinity of 4NP was also 
marginally higher for hERαLBD-f than for hERαLBD (1.44-fold) yet bound both receptors only weakly. 
 





Figure 3.9 Competitive binding curves indicating the dosage-dependent displacement of 3HE2 by the endogenous 
oestrogens, E1 and E3, the synthetic hormones, EE1 and DES, and the natural phyto- and myco-oestrogens, 
GEN and ZEA, from the hERαLBD (red) and hERαLBD-f (blue).  In all graphs the competitive curves for 
3HE2 displacement from the hERαLBD (red dotted line) and hERαLBD-f (blue dotted line) by E2 has been 
added as reference.  The Y-axis represents the percentage 3HE2 specifically bound by the receptor LBDs 
and the X-axis is the concentration of competitor in log10M.  All measurements reported as the standard 
error of the mean of three biological replicates. 





Figure 3.10 Competitive binding curves indicating the dosage-dependent displacement of 3HE2 by the plasticisers, 
BPA and PBS, the industrial detergents, 4NP, TOP and DBP, and the pharmaceutical, CMZ.  In all graphs 
the competitive curves for 3HE2 displacement from the hERαLBD (red dotted line) and hERαLBD-f (blue 
dotted line) by E2 has been added as reference.  The Y-axis represents the percentage 3HE2 specifically 
bound by the receptor LBDs and the X-axis is the concentration of competitor in log10M.  All 
measurements reported as the standard error of the mean of three biological replicates. 





Figure 3.11 Competitive binding curves indicating the dosage-dependent displacement of 3HE2 by the personal care 
product, PP, and the pesticides, AT, ACM, END, DDT and DDE.  In all graphs the competitive curves for 
3HE2 displacement from the hERαLBD (red dotted line) and hERαLBD-f (blue dotted line) by E2 has been 
added as reference.  The Y-axis represents the percentage 3HE2 specifically bound by the receptor LBDs 
and the X-axis is the concentration of competitor in log10M.  All measurements reported as the standard 
error of the mean of three biological replicates. 




Table 3.2 Determined KIs, IC50s and RBAs for selected EDCs in relation to recombinant hERα LBD interaction.  Competitive binding was conducted with 0.5 nM 
3HE2 and 









E F KI IC50 RBA logRBA KI IC50 RBA logRBA logRBA 
17β-Oestradiol E2 SB SB 1.28 x 10-9 1.70 x 10-9 100 2.00 6.98 x 10-10 1.07 x 10-9 100 2.00 1.83 2.00 
























Zearalenone ZEA SB SB 1.90 x 10-8 2.52 x 10-8 6.74 0.83 2.38 x 10-9 3.44 x 10-9 31 1.49 7.98 1.45c 1.64d 





Bisphenol S BPS WB WB 1.88 x 10-5 2.50 x 10-5 0.0068 -2.17 5.83 x 10-6 1.26 x 10-5 0.0085 -2.07 3.22   
4-Nonylphenol 4NP WB WB 7.95 x 10-5 1.06 x 10-4 0.0016 -2.80 2.44 x 10-5 5.51 x 10-5 0.0019 -2.72 1.44 -1.58a, b 0.18c 
4-tert-Octylphenol TOP MB MB 1.46 x 10-5 1.46 x 10-5 0.012 -1.92 6.41 x 10-7 1.17 x 10-6 0.091 -1.04 22.8 0.015a -0.71d 
Di-n-butyl phthalate DBP - - > 5.00 x 10-5 > 5.00 x 10-5 - - > 5.00 x 10-5 > 5.00 x 10-5 - - - -a -2.59d 
Carbamazepine CMZ - -f > 1.00 x 10-4 > 1.00 x 10-4 - - > 1.00 x 10-4 > 1.00 x 10-4 - - -   
Propylparaben PB MB MB 1.13 x 10-5 1.50 x 10-5 0.011 -1.96 1.86 x 10-6 3.04 x 10-6 0.035 -1.46 6.08   
Atrazine AT - - > 1.00 x 10-4 > 1.00 x 10-4 - - > 1.00 x 10-4 > 1.00 x 10-4 - - - -a -d 
α-Cypermethrin ACM - - > 1.00 x 10-4 > 1.00 x 10-4 - - > 1.00 x 10-4 > 1.00 x 10-4 - - -   
Endosulfan END VWB WB > 2.00 x 10-4  > 2.00 x 10-4  < 0.00085 < -3.07 2.22 x 10-5  3.21 x 10-5  0.0033 -2.48 > 9.01 -a -3.36d 
p,p'-DDT DDT WB WB 3.98 x 10-5 5.28 x 10-5 0.0032 -2.49 1.04 x 10-5 1.62 x 10-5 0.0066 -2.18 3.83 -a -d 
p,p'-DDE DDE - VWB 1.47 x 10-1 1.95 x 10-1 8.71 x 10-7 -6.06 1.78 x 10-4 2.43 x 10-4 0.00044 -3.36 >> -a -d 
 Binding activity according to logRBA: SB: Strong binder (logRBA > 0); MB: Moderate binder (logRBA between 0 and -2); WB: Weak binder (logRBA between -2 and -3); VWB: Very weak binder (logRBA < -3); -: Non-binder 
 KI_e/KI_f is the ratio of the KI of the truncated LBD to that of the F-domain containing protein. 
a Blair et al. (302) Uteri from ovariectomised Sprague-Dawley rats. b Average 
c Ohno et al. (303) Human recombinant hERα (PanVera Corporation) assayed by fluorescence polarisation 
d Waller et al. (304) Competitive ER binding assays using mouse uterine cytosol. 
e Kuiper et al. (305) Radioligand binding assays with ER expressed in vitro with TnT-coupled reticulocyte lysate system. 
f Compound exhibited a U-shaped curve 
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The cosmetic preservative, PB, bound to both hERα LBD proteins with moderate affinity.  Yet again, the 
presence of the F-domain increased affinity by 6.08-fold.  The other compound in the PPCP-class of EDCs 
tested, CMZ, did not bind to either of the receptors at the concentration ranges tested, nor did the pesticides 
AT or ACM.  The organopesticide, DDT, was shown to be a weak binder and had increased affinity for the 
hERαLBD-f, compared to hERαLBD.  The metabolic breakdown product of DDT, DDE did not bind to the 
receptor protein in the absence of the F-domain, yet exhibited very weak binding affinity towards the 
hERαLBD-f.  Endosulfan exhibited weak binding affinities for the both ligand-binding domain proteins, 
which was marginally increased in the presence of the F-domain. 
Nichols et el. (299) produced several recombinant ERα mutants in yeast to study the effects of the 
F-domain on agonist and antagonist activity.  During their study they performed radioligand-binding assays 
using E2, 4-hydroxytamoxifen (4OHT), raloxifene (RAL) and ICI 182,780 (ICI) as competitors.  None of 
the mutants or deletions showed significant effects on the IC50 for these compounds.  In this study, 
however, deletion of the F-domain from the receptor evidently decreased the RBA of all compounds tested 
(Figure 3.12), with the exception of BPA for which a slight increase in RBA was observed.  As a matter of 
fact, when considering the ratio of change in KI, no change for BPA affinity was recorded.  Moreover, for 
all other active compounds affinity for the competitor increased markedly in the presence of the F-domain 
with KI_e/KI_f of between two- and 8-fold for most compounds.  
 
Figure 3.12 Chemical structures of compounds analysed for binding to recombinant hERα LBD proteins. 
  




Over and above the observed shift in binding affinity in the absence of the F-domain, its deletion have been 
implicated in a reduction of transcriptionally activity (301), with a distinct effect on dimerisation ability 
(306).  The observed increases in affinity may therefore support a hypothesis that the F-domain can stabilise 
the ligand-bound conformation of the LBD, resulting in a slower release of ligand from the ligand binding 
pocket.  Yet, to truly determine whether the additional C-terminal domain affects rates of association and 
dissociation of ligand, kinetic studies will need to be performed to enable the calculation of Kon and Koff 
parameters. 
3.3.2.2 Testing of EDC sequestration to affinity membrane by competitive radio ligand assays 
A means to directionally immobilise histidine-tagged proteins in a facile manner was developed following 
the synthesis of a novel chelation membrane.  Once charged with divalent Ni2+-ions, the PVP-PSMI 
membrane successfully sequestered the histidine-tagged hERαLBD protein.  The binding of radioactive 
labelled steroid to the bio-functionalised membrane is apparent when compared to the radioactive counts of 
the pristine PVP-PSMI membrane (Figure 3.13).  In the absence of receptor protein, 6% of the total 
radioactivity added remained on the pristine PVP-PSMI, whilst 94% of the 50 pM 3HE2 was distributed 
between in the eluent and the wash buffer following removal of the eluent and subsequent washing steps. 
In contrast, 26% of the observed counts were retrieved from the membrane following prior incubation with 
20 μg/mL hERαLBD, approximately four times more steroid than in the absence of protein.  Increasing the 
bio-functionality of the membrane by incubation with 50 μg/mL hERαLBD led to a nine-fold increase of 
steroid sequestration over that of the control.  The increase in binding of 26% to 44% of the total added 
counts observed on the membranes incubated in 50 μg/mL solution of hERαLBD, when compared to that of 
the membranes incubated in 20 μg/mL hERαLBD, would suggest that steroid binding to the membrane is 
occurring in a manner that is dependent on the amount of immobilised hERαLBD.  In comparison to the 
760 dpm retained on the pristine membrane, the 20 μg/mL treated membrane bound 3,200 dpm of the 
available radioactivity which was increased significantly (P < .0001) to 4,400 dpm when the membrane was 
treated with 50 μg/mL protein.  Moreover, a statistical difference (P < .001) was observed between the 
radioactivity contained in the eluent of the 20 μg/mL (2,600 dpm) treated membrane compared to the 
50 μg/mL treated membrane (1,800 dpm), a reduction which can be attributed to increased binding of 
radioligand by the immobilised receptors.  Similarly, the amount of radioactivity removed from the 
membrane during washing decreased from 6,300 dpm to 3,750 dpm for these treatments (P < .0001).  
Interestingly, the reduction in eluent radioactivity in the 20 μg/mL treated group was transferred not only to 
the increased specific binding to the immobilised receptors, but there seems to be a slightly higher degree of 
non-specific adherence to the protein coated membrane prior to removal of these ligands during the 
washing steps.  This effect was not as evident in the 50 μg/mL treated membrane group, possibly due to 
more binding of ligand by the greater biofunctionalised membrane. 




The addition of competitor compounds during incubation of the radioligand resulted in significant reduction 
in the amount of radioactivity retained on the membrane.  With the complete excess of competitor added, 
all specific binding of the labelled steroid could be inhibited. 
 
 
Figure 3.13 Binding of 3HE2 to the biofunctionalised PVP-PSMI membrane.  All measurments were taken in duplicate 
(SD: n = 2). Data was analysed by ordinary two-way ANOVA implementing Tukey’s multiple 
comparisons test.  The family wise significance and confidence level was set to 99.9% (α = 0.001); 
**** P < .0001. 
The tritiated ligand was specifically bound by receptors immobilised to PVP-PSMI membranes treated with 
20 and 50 μg/mL hERαLBD at 11.6 and 17.4 fmol/cm2, respectively.  A negligible degree of non-specific 
binding did occur on the pristine PVP-PSMI membrane as there is a measure of radioactivity indicating the 
presence of 3HE2 in the absence of receptor.  However, the more than four-fold increase in radioactive 
counts retained by the 20 μg/mL treated membrane over the control membrane, strongly indicate that 
steroid binding to the membrane is dependent on the immobilisation of truncated receptor to the polymeric 
surface.  Furthermore, retention of 3HE2 to the bio-functionalised membrane is diminished in the presence 
of a competitive ligand.  Excesses of E2, BPA, and DES clearly inhibit binding of 3HE2 to the bio-
functionalised membrane.  The high dpm values of the eluent and low counts detected on the membrane 
following the competitive binding assays indicate that less 3HE2 bound to the membrane than was bound in 
the absence of a competitive ligand.  Though steroid has bound to membrane for the competitive binding 
assays, this is most probably due to non-specific binding of the steroid to the membrane, as the levels of 
radioactivity for all three competitive assays are comparable to the percentage dpm retained to the pristine 
membrane. 





Historically, in vitro ER binding assays have proven to be valuable and relatively simple tools for rapidly 
identifying chemicals that can compete with endogenous oestrogen for ER binding.  In this chapter, 
experiments are described in which two heterologously expressed variants of the hERα were tested for their 
ability to bind to a multitude of natural hormones and xenobiotics.  It was established that the receptor 
LBDs bind the natural ligand for the hERα, E2, with high affinity.  KD values for the two proteins were 
calculated by saturation binding analysis and corroborate dissociation constants reported in literature for the 
endogenous receptor (307), as well as for other recombinantly produced constructs (17, 305, 306, 308).  
hERαLBD-f exhibited greater affinity for the natural ligand, E2, than the hERαLBD counterpart protein.  
Furthermore, up to 8-fold difference in the affinity for model compounds displaying strong binding was 
observed when protein-ligand interactions were analysed via competitive radioligand assays – KIs for these 
chemicals being lower for the F-domain containing hERαLBD-f than for the hERαLBD protein.  However, 
these values were not significantly different to enable drawing of conclusions regarding the role that the F-
domain may play during ligand-binding.  The difference in Bmax observed between the two constructs when 
incubated with radioligand at the same molar concentration suggest greater availability of binding sites 
when comparing the hERαLBD to the hERαLBD-f.  Conversely, the similar binding potentials observed for 
the two protein variants indicate that the additional F-domain does not impact significantly upon ligand-
binding. 
In many cases, hormonal or endocrine disruptive activity is initiated by the binding of an endogenous ligand 
or xenobiotic to a specific receptor, thus signalling the start of a cascade of molecular events which 
ultimately culminates in a physiological response.  Nuclear receptors, such as the ER, are intricately 
involved in the regulation of these events.  Several historically relevant examples of exogenous compounds 
which impose a severe negative affect on human and animal welfare, including DES, chlordecone and 
DDT, are well described in literature, with several EPs such as bisphenol-derived compounds, parabens and 
other PPCP being of current concern.  Consequently, the Endocrine Disruptor Screening and Testing 
Advisory Committee (EDSTAC) was established in October 1996 by the United States Environmental 
Protection Agency (US-EPA) under the Food Quality Protection Act and the amended Safe Drinking Water 
Act (309).  The mandate of the EDSTAC was to provide information on how to “develop a screening 
program, using appropriate validated test systems and other scientifically relevant information, to 
determine whether certain substances may have an effect in humans that is similar to an effect produced by 
a naturally occurring oestrogen, or other such endocrine effect as the Administrator may designate” (309).  
While the EDSTAC focused on the activities of androgen, oestrogen and thyroid hormones, the science 
regarding disruption of the endocrine system by environmental small molecules is rapidly expanding to 
include other steroid and neuroendocrine hormones. 
Several in vivo and in vitro methodologies have consequently been proposed and now form part of the 
OECD framework for the Testing and Assessment of Endocrine Disrupting Chemicals and the US-EPA 




Endocrine Disruptor Screening Program (EDSP) for the classification of EDCs.  Within these frameworks, 
in vitro assays based on equilibrium dialysis, fluorescence anisotropy, surface plasmon resonance and 
reporter gene assays, as well as the radioligand binding assays used during this study are very effective at 
identifying whether compounds can interact with nuclear receptor LBDs.  However, these methodologies 
are limited to the laboratory setting and therefore cannot be readily applied to rapid environmental 
monitoring programs in rural or resource-limited scenarios.  Accordingly, several immunoassays, including 
ELISA (310–314) and LFIA (150, 270, 315) have been developed for the detection of specific chemical 
compounds capable of endocrine disruption.  Although these assays are extremely sensitive and may enable 
the amelioration of a variety of problems caused by chemical residue exposure, they are only capable of 
detecting the particular compounds for which they were designed.  As a result, many other environmental 
EDCs of which the identities are unknown and thus are not being screened for will go undetected.  As such, 
there is a need for the development of a sensitive, rapid and broad-spectrum detection method which should 
detect EDCs by their biological mode of action, not by their individual chemical identities or structural 
elements.  The first step towards the design of such a system would be to devise a means to selectively 
concentrate compounds with analogous biological effects.  The receptor LBDs produced during this study 
has been shown capable of the specific binding of a broad range of molecules originating from various 
chemical classes.  Furthermore, the concentration dependent sequestration of E2, DES and BPA to affinity 
matrix-immobilised hERαLBD suggests the potential of developing a membrane-based EDC detection 
method to determine oestrogenic load in a semi-quantitative, or perhaps even quantitative means.  
Investigation carried out in this laboratory utilised radiolabelled E2 as a reporter to indicate binding of 
hormone to hERα LBD, or displacement thereof from the proteins by competitor compounds.  The use of 
radioactive substances as tracers in field adapted assays is precluded for obvious reasons.  However, with 
advances in molecular labelling, fluorescent hormones such as EstradiolGlow™ (Jena Bioscience GmbH, 
Jena, Germany) (316, 317) have become commercially available and could possibly serve as an alternative 
reporter molecule in a portable membrane-based competitive assay coupled with an electronic reader 
device.  The feasibility of developing such an assay will remain the subject of inquiry.  On the other hand, 
mAbs are extremely discriminatory regarding the epitopes to which they bind and can distinguish between 
differences in amino acid structures as small as a single residue change or phosphorylation event.  An 
alternative in vitro methodology for the detection of a broad range of structurally dissimilar EDCs, capable 
of binding to a nuclear receptor such as the ERα, may function by selectively concentrating such 
compounds to membrane-immobilised receptor LBDs.  Further characterisation of the protein binding 
capabilities of the IMAM and the ligand-biding capabilities of immobilised receptor should still be done.  
However, in the current assessment, membranes bio-functionalised with hERαLBD were able to retain 
tritiated ligand at between 11.6 and 17.4 fmol/cm2.  If all binding was specific and assuming stoichiometric 
binding of one molecule 3HE2 by one molecule hERαLBD with a molecular mass of 30,200 g/mole, 350 –
 525 ng protein was immobilised to the IMAM per square centimetre.  Yet, depending on antibody 




sensitivity and substrate formulation, AP and HRP mediated chromogenic detection can detect protein 
quantities in the low picogram range. 
Monoclonal antibodies that can distinguish between the ligand-bound and apo conformational states of 
receptor of ligand-induced protein conformation change may thus be hypothetically possible by standard 
colorimetric techniques using secondary, enzyme-coupled antibodies.  Consequently, the following chapter 
will focus on the production and isolation of hybridoma cell strains which secrete mAbs raised against 
specific proteins or peptides relating to the hERα.  





The production of monoclonal antibodies and the search for a 
novel membrane-based EDC detection method 
4.1 INTRODUCTION 
Nuclear receptors, the class of protein to which the hERα have been assigned, belong to a family of highly 
conserved transcription factors which regulate genetic expression in response to small lipophilic 
compounds.  The three-dimensional crystal structures of most of the 48 recognised NR LBDs, including the 
already adopted orphan receptors have been resolved (318).  Most of these structures were obtained by 
crystallisation of LBDs in the liganded state.  When crystallised, LBD polypeptides are typically 
destabilised in the absence of ligand.  Still, several apo-structures have been characterised (319), enabling 
the development of models describing a conformational switch which regulate nuclear receptor 
transcriptional activity (Figure 4.1).  In general, nuclear receptor LBDs consist of twelve highly structured 
α-helices arranged in a three layered anti-parallel sandwich (320).  Eleven of these helices are actively 
involved in the formation of a hydrophobic cavity constituting the LBP at the narrower end of the structure.  
Yet even though the overall architectures of different NR LBDs are extraordinarily alike, their LBPs are 
sufficiently different in size and characteristics to ensure specificity for endogenous lipophilic ligands.  The 
LBP of nuclear receptors are predominantly formed by a diverse arrangement of non-polar amino acid 
residues, with one or more polar residues allowing effective hydrogen bonding with hydrophilic groups 
which may be present on lipophilic small molecules. 
 
Figure 4.1 The structure of the hERαLBD in complex with different ligands.  The backbone structure of the apo LBD 
is shown in pink, with holo hERαLBD complexed with E2 in green and antagonist hERαLBD complexed 
with tamoxifen in blue.  The differences in the position of H12 (highlighted in yellow in the traces) 
determine co-factor binding properties of the transcription factor.  The approximate position of AF-2 is 
shown on the holo conformation image in red.  The relevant helices are labelled.  Figure adapted from 
(321). 




The most C-terminal helix, H12, is not involved in formation or maintenance of the three-dimensional 
molecular organisation of the LBD; instead it is mobile and unstructured (322).  However, H12, which 
contains the regulative sequence which defines AF-2, is a key component in the modulation of nuclear 
receptor transcriptional activity.  Following the initial structure determination of the thyroid receptor (TR) 
and retinoic acid receptor (RAR), respectively by Wagner et al. (323) and Renaud et al. (324), comparisons 
made to the non-liganded retinoid X receptor (325) suggested that H12 is distended away from the main 
LBD body in the apo-state, while folding over the LBP to encapsulate the ligand during receptor activation 
in what is referred to as the “mouse trap model” (326).  Further biochemical and biophysical studies have 
revealed that H12 is not fixed in a single position in the absence of ligand, but rather in constant movement 
along other portions of the LBD.  This has led to the preposition of an alternative view on the apo-state, the 
“dynamic stabilisation model” (23).  Although the exact orientation of H12 in the apo-state requires further 
investigation, it is known that binding of ligand to the LBP results in a global stabilisation of the LBD fold 
by lowering conformational dynamics, fixing H12 in a stable position and enabling the recruitment of 
coregulatory elements required for signal transduction (327).  Moreover, research performed in the 
laboratories of Hubbard, Carlquist and Gustafsson (328) revealed that the nature of the ligand determines 
whether molecular restructuring of the LBD will result in activation or repression of transcriptional activity 
(321).  Upon agonist binding to the LBP, H11 is shifted to a position which allows H12 to translocate to a 
position below H4, facilitating the formation of AF-2.  This shallow surface accessible hydrophobic groove 
is defined by the surfaces of H3, H4, H5 and H12 (328–332) and provides a recognition site with which 
nuclear receptor coactivators of the p160 protein family, comprising the members SRC1, GRIP1 and AIB1, 
can interact (332–335).  Recognition of the binding site occurs due to the presence of a nuclear box within 
coactivator proteins; a LxxLL-motif present in short amphipathic α-helices on the co-activator surface.  
Conversely, receptor antagonists cannot be wholly accommodated within the LBP due to the presence of 
extended side chains from the molecule which exits between H3 and H11.  Thus, binding of an antagonist 
to the LBP results in slight unwinding of H11, thereby inhibiting the translocation of H12 to the position 
required for coactivator recruitment.  Instead, H12 rotates approximately 120° clockwise toward the N-
terminus of the LBD, obstructing the formation of the coactivator recruitment site.  This molecular 
configuration is stabilised by a degenerated LxxLL motif within H12.  Consequently, the receptor itself 
inhibits the binding of coactivators to the activation domain by competition for binding to AF-2 (328, 330, 
336).  Furthermore, repression of receptor transcriptional activity is compounded by the recruitment of a 
second class of coregulators, the corepressors which include NCOR1 and SMRT to other molecular 
interaction surfaces (335, 337).  As highlighted by Brzozowski et al. (328), the change in receptor LBD 
conformation is dependent on the class of ligand bound to the LBP.  EDCs able to bind directly to the 
flexible hydrophobic LBP of the oestrogen receptor LBD have been proposed to induce similar molecular 
configurations on the polypeptide as the endogenous ligands by several methods, including analysis of 
crystal structures (338) and structure-based virtual screening approaches utilising quantitative structure-
activity relationship (QSAR) (302, 339–342). 




In section 3.3.2.2, the ability to immobilise the recombinant receptor LBDs produced during this study to a 
novel affinity membrane was shown.  Moreover, evidence was provided that once immobilised, these 
proteins retained their ligand-binding capabilities and could successfully sequester and concentrate model 
oestrogenic compounds from solution.  Countless tests have been assembled to assess the presence or 
absence of specific proteins within a sample, enabling diagnosis of altered physiological or disease states, 
food safety and environmental monitoring.  The use of antibodies as molecular probes in diagnostic tests 
has been developed and refined over the past six decades.  Many of these assays utilise monoclonal 
antibodies because they are extremely specific regarding their interaction with cognate antigens.  Moreover, 
a steady supply of antibodies obtained from culture is economical, reproducible and ultimately reduces the 
need for animal utilisation in research, in line with the principles of replacement, reduction and refinement.  
Accordingly, several advances in the field of mammalian cell culture have resulted in rapid expansion of 
the global manufacturing capacity of mAbs.  Many commercial culture-derived antibodies are cultivated in 
bioreactors of up to 20,000 litres, enabling large scale production of immunological assays for use in 
mainly clinical and veterinarian settings (205).  The power to elicit immune responses that target specific 
proteins and small molecules, combined with the great specificity exhibited by the resulting 
immunoglobulins towards their intended molecular partners, make mAbs well-suited for candidacy as 
molecular probes to indicate a binding event.  Therefore, we propose that high affinity steroid receptor 
LBDs immobilised to inert polymeric surfaces may allow for the assembly of a novel membrane-based 
method for the in vitro detection of endocrine active compounds (Figure 4.2). 
 
Figure 4.2 Proposed immunochemical EDC detection system, based on conformational changes to the nuclear 
receptor LBD tertiary structure following ligand binding.  Monoclonal antibodies, selected for specificity to 
ligand-bound conformations, are visualised by an enzyme-conjugated secondary antibody that produces a 
coloured product in the presence of a suitable substrate.  In this way, the formation of colour is proportional 
to the amount of secondary antibody, which is proportional to the amount of primary, anti-LBD antibody, 
which is indicative of changes in the protein structure due to interaction with ligand. 




Napier and Venis (343) utilised two mAbs (MAC 256 and 259) prepared against auxin-binding protein to 
study ligand-binding using a sensitive sandwich ELISA.  These mAbs could only bind to auxin-binding 
protein in the absence of auxin.  Similarly, during preparation of mAbs against a synthetic peptide 
containing the fourteen C-terminal residues of the PR, Wiegel et al. (344) fortuitously isolated a hybridoma 
clone that produces a conformation-dependent mAb (C-262).  When in the apo-state or bound to an 
antagonist an epitope on the PR surface could be bound by C-262.  However, in the presence of agonists, 
the mAb was incapable of binding to the receptor.  Presuming that the specific binding of EDCs induces 
similar molecular alterations to the hERα LBD structure, and whether a conformation-dependent mAb can 
be isolated for this receptor, indication of three-dimensional structure could be used to designate the 
presence of oestrogenic compounds.  Once bound to the LBD, the antibody-receptor interaction could be 
visualised by standard immunochemical methods such as the enzyme-mediated deposition of a suitable 
coloured precipitate on the membrane. 
The side-chain theory of receptor pathogen binding was first proposed by Paul Ehrlich in 1897 (345).  The 
model suggests that branched antibodies on the surfaces of cells contain multiple sites for binding to foreign 
antigens.  In 1940, Pauling introduced a theory where the antigen acted as a template for the reconfiguration 
of the antibody structure (346).  However, the description of plasma B cell antibody generation by Fagraeus 
(347) led to the development of the clonal selection theory by Jerne (348), and Burnet and Talmage (349) 
which stated that a lymphocyte makes a single specific antibody molecule that is determined prior to it 
encountering an antigen.  It is now recognised that these Y-shaped (350, 351) glycoprotein molecules are 
derived from naïve B cells which have undergone a process of genetic shuffling prior to interaction with 
antigen.  Structurally, antibodies are composed of two identical heavy chains and two identical light chains 
which are held together by disulphide bridges.  Variations in the amino-terminal regions of the heavy and 
light chains form the antigen binding sites.  Conversely, the carboxy-terminal constant regions of the heavy 
chains are responsible for the functional interaction of immunoglobulins with other molecules in the 
immune system.  The diversity of antigen receptors is produced by alternate use of V, D, and J gene 
segments in different lymphocyte clones.  Additionally, even more changes are introduced in the nucleotide 
sequences at the junctions of these segments.  This process is random and therefore not biased towards 
antigens of an exogenous nature.  However, through processes of positive selection, B cells which express 
antigen-recognising immunoglobulins can mature, whereas immature B cells which exhibit ‘self-
recognition’ are disposed of by means of apoptosis owing to negative selection. 
Historically, serum was the first source of antibodies.  Typically, to obtain immunoglobulin containing 
serum, an immunogen is mixed with an adjuvant and injected into an animal.  Adjuvants are selected to 
increase the strength of the immune response as many antigens may be poorly immunogenic in isolation.  
Following the initial immunisation, a primary immune response is elicited which produces antiserum of a 
relatively low titre.  After a brief waiting period, immunisation is repeated, thereby producing a secondary 
response of which the titre is, generally, much greater (Figure 4.3). 





Figure 4.3 Diagram depicting the concentration of antibody produce as a function of time following two antigen 
exposure events.  Following initial exposure, the primary response is low since immature immune cells are 
under development.  Repeat exposures, however, stimulate memory cells which result in rapid expansion of 
lymphocytes expressing high affinity antibodies to the foreign object. 
Serum is produced by withdrawing blood from an immunised animal and allowing it to clot, thus removing 
erythrocytes, leukocytes and some serum proteins.  The remaining fluid contains a heterogeneous mixture 
of proteins, including the antibodies of interest.  This procedure can be repeated many times.  However, 
with each subsequent immunisation the repertoire of antibodies raised in the animal is slightly different.  In 
1975 Georges Köhler and Cézar Milstein (352) pioneered a method to select for a single B cell which 
produces a singular antibody of interest, and to expand that cell into a population that produces large 
amounts of the antibody in question. 
The antibodies found in serum are polyclonal in nature, being derived from a large library of B cells, each 
producing antibodies which recognise a defined epitope.  Following immunisation, B cells can be isolated 
from the spleen, where such cells are stored in high concentrations.  These cells are, however, short-lived 
by nature and therefore not amenable to cloning and expansion.  Köhler and Milstein addressed this 
problem by creating hybridoma cells from isolated B cells by fusion with an immortalised B cell line.  It is 
essential for the procedure that the chosen immortal fusion partner does not produce antibodies itself.  
Furthermore, suitable immortal cells must contain a selectable marker so that parental cells may be 
removed following successful fusion, resulting in the survival of only hybrid cells.  The next, and 
experimentally most challenging, part of the procedure was to design a method of selecting an individual 
cell that produces the antibody of interest.  This is most commonly approached by the limiting dilution 
approach and will be employed in the description of the experiments to follow.  The initial culture is 
divided into a multitude of individual smaller cultures.  Following a period of cellular growth, the 
supernatant of each culture is assayed for the antibody of interest.  This is ordinarily achieved by indirect 
ELISA of the supernatant against the antigen used for immunisation.  Cultures identified by the assay to 
contain the antibody of interest are subsequently isolated and divided to lower dilutions, with the goal of 
producing a homogenous population of cells originating from a singular cell which had been selected due to 
its ability to manufacture the correct antibody.  Once established, a hybrid cell line in culture can produce 
mAbs in essentially unlimited quantities.  




By their very nature, mAbs are specifically adept at identifying protein surfaces which are only available 
under certain conditions.  Thus, this chapter discusses the development of antibodies against recombinant 
hERα LBD and selected synthetic peptides, which are analogous to a region of the LBD, or have been 
reported to interact with the receptor in ligand-bound conformations (25, 353).  The conditions under which 
laboratory mice were maintained for generating antigen-specific B lymphocytes are outlined and the 
procedures for the propagation of hybrid cell lines and the selection of suitable clones are described. 
4.2 MATERIALS AND METHODS 
4.2.1 Growth and maintenance of Sp2/0-Ag14 murine myeloma cells 
SP2/0-Ag14 cells (CVCL_2199) (354), obtained from Prof. Edmund Pool at the University of the Western 
Cape, were maintained using culturing protocols set forth by the American Type Culture Collection 
(ATCC® CRL­1581™).  In brief, upon culture initiation, cells were rapidly thawed from cryogenic storage 
by gentle agitation in a 37°C water bath, keeping the vial o-ring and cap out of the water.  The vial was 
decontaminated with 70% ethanol and transferred to sterile conditions in a laminar flow hood, where all 
procedures were carried out under strict aseptic conditions.  The vial contents were transferred to a 
centrifuge tube containing 9.0 mL complete medium (full medium (RPMI-1640, pH 7.2, 10% heat 
inactivated FBS, 1X GlutaMAX™, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL 
amphotericin B, 50 μg/mL gentamicin) supplemented with 10% conditioned medium and centrifuged at 
200 xg for five minutes.  After aspiration of the supernatant, the cell pellet was suspended in complete 
medium and dispensed to 25-cm2 or 75-cm2 culture flasks at seeding densities of 4 x 104 cells/cm2.  Cells 
were cultured at 37°C in a 5% CO2 regulated incubator set to 98% relative humidity and maintained in 
culture at 104 – 105 cells/cm2.  Conditioned medium was prepared by mixing whole blood from a male 
donor with full medium (1:9) supplemented with 100 ng/mL lipopolysaccharides from Salmonella enterica, 
serotype enteritidis.  The medium was incubated overnight at 37°C, clarified by centrifugation at 3,000 xg 
for 15 minutes and stored at -20°C until required.  Full culture medium was supplemented with 5% (v/v) 
DMSO and cells were dispensed to cryo-vials at 3 x 106 cells/mL for cryopreservation and frozen 
at -1°C/min in a -80°C chest freezer, prior to transferral to liquid nitrogen storage. 
4.2.2 Animal husbandry 
Ethical clearance for this project was obtained from the Stellenbosch University REC: ACU, under the 
application number SU-ACUD15-00036.  No adverse effects were observed in any animals involved in the 
current study. 
BALB/c mice were maintained at the Stellenbosch University animal housing facility in accordance with 
SANS 10386:2008 (355) and EU-directive 2010/63/EU (356).  Female mice were housed together, 
permitting social interaction, in Ehret type 2L polyetherimide IVC cages (365 mm x 205 mm x 140 mm) 




which were maintained at temperatures of between 20°C and 22°C, with a 12:12 hour light-dark cycle.  
Individual mice were either identified by ear clipping or semi-permanent tail marking.  Groups of mice 
were continually monitored to ensure social stability and to detect behavioural and physiological 
abnormalities.  During this study, no aggression between cage mates was detected, thus the need to separate 
animals from one another did not manifest.  The living area for the mice allowed them to satisfy all their 
basic physiological and behavioural needs.  Food and tap water were provided ad libitum.  All mice were 
allowed two weeks to acclimatise to the animal house and handling by the investigator prior to 
commencement of blood collection and immunisation protocols.  At no time were such protocols, which 
may cause distress to the animals, preceded or followed by routine husbandry procedures such as cleaning 
of cages, change of water and feed and conducting visual or manual inspections. 
4.2.3 Synthetic peptide immunogens 
Small molecules such as peptides do not readily illicit immune challenges in animals.  Therefore, to 
generate antibodies against small haptens, a strategy is needed to facilitate their presentation to cells of the 
immune system.  By conjugating the small molecule to a structure that is large enough to interact with 
immune cells, a suitable response can be elicited.  Commonly, proteins that are evolutionary removed from 
the animal to be immunised are used for this purpose due to its biologically foreign nature and the 
accessibility of surface moieties such as amines, carboxylic acids or thiols that can readily be reacted with 
by a variety of chemistries to facilitate conjugation. 
4.2.3.1 Helix 12 of the hERαLBD 
Some interactions between co-activator proteins and the hERα LBD is mediated by the defined protein-
protein binding surface, AF-2.  H12 of the hERα LBD (CKNVVPLYDLLLEMLDAHR), comprising the 
activating domain of AF-2 is integral to activation of the transcription factor following ligand-binding.  In 
the apo-state, H12 is normally extended away from the ligand binding domain (320).  Following binding of 
an agonist, H12 is translocated to a position across the surface of the LBD, which leads to the formation of 
a shallow surface accessible hydrophobic groove.  The hydrophobic groove allows for interaction with co-
activator elements containing a helical nuclear receptor LxxLL motif called a nuclear box.  Conversely, if 
an antagonist is present in the ligand binding pocket of the receptor, translocation of H12 occurs in such a 
manner that the formation of AF-2 is obscured by the helix itself, a conformation that is stabilised by a 
degenerated LxxLL motif within H12 (320).  Therefore, to investigate the possibility that a mAb directed 
against this helix may be able to distinguish between different conformational states, a synthetic peptide 
(ERh12; CKNDVPLYDLLLEMLDAKR) encompassing H12 was designed with rational alterations to the 
primary sequence. 
ERh12 differs from the native hERα LBD H12 at only two positions.  Valine and histidine occurring at 
positions 4 and 18 in H12 were respectively altered to aspartic acid and lysine in ERh12 to increase 
solubility of the peptide.  These alterations increased the ratio of hydrophilic amino acids to total amino 




acids from 32% to 42%, thus shifting the calculated hydrophilicity of the synthetic peptide from -0.1 to 0.3 
(296) and decreasing the pI of ERh12 from 5.3 to 4.5.  Helix 12 occurs at the very C-terminal end of the E-
domain of hERα.  The cysteine residue in the first position of the ERh12 peptide enables conjugation of the 
hapten at its N-terminal to carrier proteins which had been modified with a heterobifunctional N-hydroxy 
succinimide/maleimide crosslinker.  The passive reaction is performed at neutral pH and introduces a 
thioether bond between the maleimide moiety of the crosslinker and the β-thiol of the cysteine side chain of 
the peptide.  At this pH, the introduced aspartic acid residue is deprotonated and therefore negative.  Since 
aspartic acid is, however, not much larger than valine, the molecular radius surrounding the residue at that 
position will not be significantly impacted.  This alteration, and that of His18 to lysine, flanks an 
immunogenic region, as determined by the method of Kolaskar and Tongaonkar (357), allowing selection 
for mAbs which bind at the centre of the peptide, while retaining polar residues. 
The ERh12 peptide was coupled to maleimide activated mariculture keyhole limpet haemocyanin (mcKLH) 
by the formation of thioether bonds between the sulphhydryl-containing hapten and the carrier protein.  
Two-hundred microliters ultra-purified water was added to lyophilised mcKLH to make a 10 mg/mL 
solution.  The ERh12 peptide exhibited limited solubility in the manufacturer proposed conjugation buffer 
(100 mM sodium phosphate, 150 mM NaCl, pH 7.2), therefore 2 mg of the hapten was dissolved in 500 μL 
20% (v/v) DMSO and added to the reconstituted carrier.  The peptide and activated mcKLH was reacted at 
ambient temperature for two hours with rotation at 20 rpm.  The conjugate was subsequently purified by gel 
filtration using 2-mL 7K MWCO Zeba™ desalting columns equilibrated with PBS containing 20% (v/v) 
DMSO.  Conjugation of the hapten to maleimide activated BSA (mBSA) and subsequent purification of the 
conjugate was performed as described above for utilisation in ELISAs to positively identify clones 
expressing antibodies against ERh12. 
4.2.3.2 The αII peptide 
Norris et al. (24) identified a synthetic peptide (αII) via phage display experiments which reportedly 
interacts with the hERα LBD at a unique site located distal from the AF-2 coregulatory binding site.  This 
peptide (SGSGLTSRDFGSWYA) was coupled to mcKLH by 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDAC)-mediated crosslinking.  One vial of the carrier protein was reconstituted to 
10 mg/mL following the addition of 200 μL ultrapure water.  Two milligrams of the peptide, in 500 μL 
EDAC conjugation buffer (100 mM 2-(N-morpholino) ethanesulphonic acid (MES), 900 mM NaCl, 
pH 4.7), was added to this suspension.  Next, 50 μL EDAC at 10 mg/mL was added and reacted at ambient 
temperature for two hours to facilitate conjugation.  Following coupling of the hapten to the carrier, the 
conjugate was purified by gel filtration using 2-mL 7K Zeba™ desalting columns equilibrated with PBS.  
Two milligrams of the hapten was conjugated to 2 mg BSA for use as immobilised antigen in ELISA and 
desalted by means of the same protocol. 
  





In an attempt to produce antibodies capable of polyhistidine tag recognition, Poly-L-histidine was 
conjugated to the same carrier proteins described above.  The histidine polymer, however, proved to be 
insoluble in EDAC conjugation buffer.  Consequently, the coupling procedure was performed in ultrapure 
water.  Still, following conjugation to mcKLH, a precipitate was observed.  This precipitate was collected 
by centrifugation and the supernatant was desalted as above.  The column eluent was subsequently 
combined with the precipitate and used for immunisation.  The PolyHis-BSA conjugate was fully soluble in 
PBS. 
4.2.3 In vivo induction of antibody-producing lymphoid cells by immunisation of 
BALB/c mice 
For the preparation of immunogens, equal volumes of TiterMax Gold® adjuvant were mixed with antigen as 
per the manufacturer’s instructions.  Mice to be immunised were randomly allocated to experimental groups 
consisting of no more than two animals per antigen.  Six-to-eight-week-old female BALB/c mice received 
aseptic injections of affinity purified recombinant hERαLBD or carrier protein linked synthetic peptides 
with 23-G 12 mm hypodermic needles.  Female mice were preferred over male mice due to the elevated 
levels of endogenous oestrogens capable of stabilising the recombinant receptor LBD in a ligand-bound 
conformation.  In all cases the antigen mixture was administered s.c. at the regio inguinalis and regio 
interscapularis or intraperitoneally (i.p.) for the initial injection (day 0) and subsequent booster injections.  
A total volume of 200 μL, containing 400 μg antigen, was injected at three sites.  Following screening of 
serum antibody titres by ELISA, booster injections occurred by either s.c. or i.p. administration of antigen 
in adjuvant at fortnightly intervals.  No adverse reactions to the initial injections were observed, therefore 
booster injections were given in the vicinity of the previous immunisation sites to take advantage of 
memory cells established in the draining lymph nodes (358), yet sufficiently separated from the initial sites 
to prohibit coalescing of inflammatory lesions.  All mice received a final booster injection of 400 μL 
antigen (800 µg) without adjuvant by i.p. administration four days prior to euthanasia.  Immediately 
following all injections, the animals were monitored closely for any anaphylactic reactions and daily for 
signs of clinical or behavioural changes.  Examinations for specific side effects pertaining to severe 
pathology was performed at least three times per week by palpation of the sites of injection. 
4.2.3.1 Blood collection 
One day prior to initial immunisation, and seven days after each subsequent booster injection, 50 μL of 
blood was obtained from the tail veil following aseptic preparation and warming of the tail.  During the 
procedure, mice were restrained in a tubular device which allowed access to the tail whilst inhibiting 
movement of the animal, thus minimising the possibility of injury to either animal or handler.  After the 
collected blood had clot, 450 μL PBS was added followed by centrifugation at 16,000 xg for ten minutes at 




4°C.  The supernatant was subsequently transferred to a clean vial containing an equal volume of glycerol.  
The collected serum was stored at -20°C until further analysis was required. 
4.2.3.2 Titre determination and screening for antigen-specific immunoglobulins by means of 
ELISA 
Antisera and hybridoma supernatants were assayed for the presence of antigen specific antibodies by means 
of indirect ELISA.  In brief, the wells of Nunc-Immuno™ Maxisorp™ 96-well microtiter plates were 
coated with 50 μL protein or BSA-conjugated peptide in ELISA coating buffer (28.6 mM Na2CO3, 
71.4 mM NaHCO3, pH 9.6) at 5 μg/mL.  The plates were sealed and stored at 4°C for one week or less 
before use.  When needed, the coated plates were rinsed three times with deionised water after which 
200 μL casein buffer was added to each well.  Next, plates were incubated at 37°C for one to two hours, 
with gentle agitation, rinsed three times with PBST and patted dry by sharp face-down flicking onto several 
paper towels laid on the bench top. 
To assess the immune responses generated in antigen challenged mice, serum was serially diluted 1:1 in 
casein buffer in duplicate from row A to G of the 96-well ELISA plate, at dilutions of 200-fold to 25,600-
fold.  Pre-immunisation serum, diluted in the same manner, was included as negative control. 
Next, the plates were rinsed with PBST and dried as before, after which 50 μL of a 1:50,000 solution of the 
secondary antibody, horseradish peroxidase-conjugated goat anti-mouse IgG, Fab specific (RRID: 
AB_258476) was added.  Incubation of the plates were maintained at 37°C, for a minimum of one hour 
and, following rinsing as before, 50 μL TMB was added per well.  The plates were incubated in the dark 
until colour development was adequate before termination of the enzymatic reaction by the addition of 
50 μL 1 N H2SO4 to each well.  Colour development was assessed quantitatively at 450 nm using a BioTek 
PowerWave 340 variable wavelength plate reader spectrophotometer under the control of Gen5 data 
analysis software version 1.07 (BioTek Instruments, Inc., Winooski, VT, USA). 
4.2.3.3 Euthanasia of mice and preparation of myeloma and spleen cells 
Immediately prior to sacrifice of a mouse, 107 Sp2/0-Ag14 cells were transferred to a sterile 50-mL 
centrifuge tube.  The percentage viable cells was determined using the Trypan Blue dye exclusion method 
(359).  All mice were euthanised by cervical dislocation, after collection of a final blood sample of 50 μL 
from a blood vessel of the tail.  Following euthanasia, the animal was placed in a beaker containing 70% 
ethanol and transferred from the animal housing facility to a sterile work area.  The animal was laid out on a 
dissection board and, using sterile forceps and scissors, ventral longitudinal and proximal transverse 
incisions were made to expose the abdomen, lower thoracic area and left side of the rib cage (Figure 4.4). 
Following disinfection with alcohol swabs and removal of the peritoneum, the spleen was separated from 
the surrounding mesenchymal tissue and placed in a petri dish containing 3 mL serum-free medium (full 
medium lacking serum).  The surface adipose tissue and other adhering tissues were carefully removed 
using a sterile forceps and scissors.  The spleen was subsequently transferred to a sterile 40 μm cell strainer 




in a petri dish containing 10 mL serum-free medium.  Using a 26-G needle attached to a 3-cc syringe, the 
spleen was filled with 2 mL serum-free medium by injections at several sites.  Next, the organ was cut into 
pieces with sterile scissors and, using circular movements, pressed against the screen of the strainer with the 
plunger of the 3-cc syringe until only fibrous tissue remained on top of the strainer screen.   
 
Figure 4.4 In situ view of the abdominal visceral organs of the mouse indicating the position of the spleen behind the 
stomach and pancreas (inset).  Figure adapted from (360). 
The screen was rinsed with 2 mL serum-free medium and the splenocyte-containing suspension was 
transferred to a 15-mL centrifuge tube.  Any clumps which may have formed were dispersed by drawing 
and expelling the suspension up several times with a 10-mL serological pipette.  The suspension was left to 
stand for three minutes at room temperature before transferring the top 95% of the cell suspension to a 
15-mL centrifuge tube.  At that point, the viability of the recovered splenocytes was determined with 
Trypan Blue, whilst ignoring the smaller red blood cells.  The 107 Sp2/0-Ag14 cells were washed twice 
with serum-free medium by centrifugation at 200 xg, each for five minutes, followed by resuspension in 
5 mL serum-free medium and addition of 108 viable spleen cells.  The 50-mL centrifuge tube was filled 
with serum-free medium and the mixed cell suspension was centrifuged at 200 xg for five minutes.  The 
media was aspirated, and the cell pellet was again suspended in 50 mL serum-free medium.  Centrifugation 
was repeated and the medium decanted.  Removal of FBS was important at that time, since serum inhibits 
the hybridisation of cells during fusion protocols.  The cell pellet was warmed briefly for two minutes in a 
200-mL Erlenmeyer flask containing 100 mL sterile water at 37°C.  Next, the pellet was loosened by gentle 
tapping of the tube on the work surface.  




4.2.4 Hybridoma generation 
4.2.4.1 Immortalisation of antibody-producing cells via fusion with a murine myeloma cell 
line 
The tube containing the cell suspension was placed back in the flask containing water at 37°C for the fusion 
procedure.  Over a period of 90 seconds, 1 mL polyethylene glycol solution (P-7306; Sigma-Aldrich) was 
added drop by drop, while gently rotating the tube to avoid shocking the cells.  The fusing cells were 
incubated at 37°C for one minute after which 2 mL serum-free medium was added at approximately 
100 μL/10 seconds.  Thereafter, 2 mL serum-free medium was added at approximately 200 μL/10 seconds 
after which 2 mL serum-free medium was added at approximately 500 μL/10 seconds.  The tube was filled 
to the 50-mL mark with serum-free medium and centrifuged at 100 xg for ten minutes.  The serum-free 
medium was aspirated from the cells and 50 mL full HAT medium (complete medium containing 100 μM 
hypoxanthine, 0.4 μM aminopterin, 16 μM thymidine, 0.0001% β-mercaptoethanol and 0.25 mM sodium 
pyruvate), which selects for hybrid cells (Figure 4.9), was slowly added while gently rotating the tube to 
suspend the cells.  The cell suspension was subsequently incubated for 30 minutes at 37°C in a 5% CO2 
regulated incubator, set to 98% relative humidity.  Following incubation, the cells were plated to five 
96-well culture plates at 100 μL/well.  These plates were transferred to a closed container and incubation 
was continued for 48 hours during which the cells were not disturbed.  After 48 hours, the membrane 
integrity and cell size of the hybridomas were assessed microscopically and 50 μL full HAT medium was 
added to all wells.  The plates were incubated for a further 72 hours, following which the growth medium 
was aspirated and replaced with 100 μL full HAT medium.  Incubation was continued until the cell growth 
necessary for screening of antibodies and cloning of hybridomas were observed.  At that time, the media 
was removed and replaced with 100 μL full HT medium (complete medium containing 100 μM 
hypoxanthine, 16 μM thymidine, 0.0001% β-mercaptoethanol and 0.25 mM sodium pyruvate).  The 
original media removed from all wells were subsequently assessed for antibody production by means of 
ELISA.  All cells contained in positive wells were transferred to 48-well culture plates containing 250 μL 
full HT medium and incubation was continued. 
4.2.4.2 Selection and clonal expansion of antibody-producing hybridomas 
For screening of hybridoma growth media following fusion and cloning, 50 μL of the growth medium from 
each well was transferred to ELISA plates pre-coated with 5 μg/mL antigen and incubated at 37°C for a 
minimum of one hour, with shaking.  As negative and positive controls, 50 μL 200-fold dilutions of mouse 
pre-immunisation and polyclonal antibody-containing pre-euthanasia sera were respectively added to two 
wells of the ELISA plates.  ELISAs for clonal selection were performed in the same manner as for serum 
immune response determination.  Screening of growth media was performed against hERαLBD 
immobilised to ELISA plates in the presence or absence of 10 μM E2 or 10 μM ICI to select for anti-
hERαLBD hybridoma populations.  Also, to ensure recognition of the recombinant hERα LBD proteins by 




antibodies generated against ERh12, screening of anti-ERh12 hybrid cell populations contained in 48-well 
plates during every round of selection was screened against hERαLBD in addition to ERh12-BSA. 
After performing ELISAs, cells in the ten wells of the 48-well plates exhibiting the highest absorbances 
were cloned to select for antibody-producing hybridomas.  Following a count of the cells contained in each 
of these wells with Trypan Blue exclusion, approximately 100 viable cells from each was transferred to 
5 mL fresh HT medium and dispensed to an individual 96-well microtiter plate at 50 μL per well.  The 
remainder of the cells from the ten original wells were transferred to 6-well plates, with the addition of 
3 mL full medium with HT supplement to serve as clonal backups.  When cell populations were 
macroscopically visible on the bottom surface of the new wells, the growth medium of the ten plates were 
again assessed by means of ELISA.  The ninety-six wells exhibiting the highest responses were transferred 
to individual wells of four 48-well plates.  The transferral of cells from 96-wells to 48-wells to 96-wells 
were considered one round of selection.  Cloning in this fashion was carried out for five successive rounds, 
following which cells from each of the ten most responsive wells were transferred to individual 25-cm2 cell 
culture flasks in 5 mL full medium with HT media supplement.  Cell cultures were monitored daily and, 
when the culture flask reached confluency, cells were transferred to larger 75-cm2 flasks in 20 mL full 
medium.  Once these cultures reached confluency, aliquots were cryogenically frozen for long-term storage 
at 3 x 106 cells/mL. 
4.2.5 Inhibitory binding studies utilising the αII peptide and its cognate mAbs 
To conduct inhibitory binding studies regarding the binding of anti-αII antibodies to αII-BSA in the 
presence of the hERαLBD, two modalities were utilised.  First (Figure 4.5, panel A), the wells of a NUNC 
Maxisorp™ plate were coated with 50 μL of a 5 μg/mL αII-BSA solution in ELISA coating buffer, as 
described before.  Following rinsing with PBST, the wells were incubated at 37°C, for two hours, with 
50 μL of a 10 μg/mL solution of hERαLBD in PBS, in the presence or absence 15 μM E2 or 15 μM ICI.  
Next, following rinsing with PBST, 50 μL anti-αII culture supernatant (clone 2H5) was added to each well 
and incubated at 37°C for 90 minutes.  The wells were subsequently washed three times with PBST, 
following which 50 μL HRP-conjugated goat anti-mouse IgG (1:50,000) was added to each well.  
Incubation of the plates was maintained at 37°C for 90 minutes.  After washing as before, 50 μL TMB was 
added per well.  Colour development in the dark was carried out for 30 minutes followed by the addition of 
50 μL 1 N H2SO4 to each well.  The colour intensity of each well was assessed spectrophotometrically 
450 nm as previously described. 
Alternatively (Figure 4.5, panel B), the wells of a NUNC Maxisorp™ plate were coated with 50 μL of a 
5 μg/mL hERαLBD solution in ELISA coating buffer, in the presence or absence of 15 μM E2 or 15 μM 
ICI.  Following rinsing with PBST, the wells were incubated at 37°C for two hours with 50 μL of a 
10 μg/mL solution of αII-BSA in PBS.  All subsequent steps were performed as described above. 





Figure 4.5 Binding study for the detection of compounds capable of ERα interaction using αII-BSA, anti-αII mAbs 
and recombinant hERα LBD.  In panel A, a colourimetric signal is generated in the absence of ligand since 
no interaction between the apo LBD and αII occurs.  As a result, anti-αII mAbs can bind to the surface 
immobilised peptide conjugate, which is subsequently visualised by an enzymatic reaction facilitated by 
labelled secondary antibodies.  In the presence of ligand, hERα LBD undergoes a conformation change, 
interacts with the αII-conjugate and inhibits binding of anti-αII mAbs.  In panel B, the opposite format is 
presented.  hERα LBD is immobilised to the assay surface.  In the absence of ligand, the receptor does not 
bind the αII-BSA conjugate and therefore a colourimetric signal cannot be produced following incubation 
with anti-αII mAbs.  In the presence of ligand, however, the conformation change in the receptor allows 
interaction with the peptide conjugate, thus permitting binding of anti-αII mAbs with the resultant enzyme-
mediated visualisation of the interaction by the formation of a coloured product. 
4.2.6 Titration of antibodies in hybridoma growth medium against recombinant 
hERα LBDs 
Following several rounds of selection, clonal populations of anti-ERh12 hybridomas were expanded to 
75-cm2 monolayer cultures for further characterisation.  All eleven of the selected cell lineages exhibited 
elevated absorbances during the final selection screening in relation to the positive control.  ELISA of the 
growth media was performed to establish the functional titre of secreted antibodies.  Nunc Maxisorp™ 
ELISA plates were prepared to this end by coating the surfaces with 5 μg/mL solutions of ERh12-BSA, 
hERαLBD or hERαLBD-f.  Following blocking and washing steps, 50 μL of each of the eleven anti-ERh12 
culture media, serially diluted in casein buffer starting at 1 in 200, was pipetted to duplicate wells.  The 
plates were incubated, washed and developed as previously described.  Based on the results of these assays, 
the cell lineages were assigned to groups depending on their ability to recognise the recombinant proteins.  
Cultures which exhibited the highest affinity for the hERα LBDs were reanalysed in the same fashion at 
dilutions between 5-fold and 5,120-fold.  Gaussian distribution of the data was confirmed by the 
D’Agostino-Pearson test for normality for these analyses.  Differences in recognition of hERαLBD and 
hERαLBD-f by mAb populations were analysed by paired parametric t tests with 95% confidence levels.  
Titre of the antibody following ELISA was established as the last dilution to yield a signal above three 
times the limit of determination.  Limits of detection and determination was calculated according to the 
parameters set out by Riedel (361–363) and is described by equation 4.1 and equation 4.2, respectively. 




Equation 4.1 Calculation of the limit of detection, YL, where B is the value of the blank and SB is the standard 
deviation of the blank sample. 
𝑌𝐿 = 𝐵 + 4.65 ∙ 𝑆𝐵 
Equation 4.2 Calculation of the limit of determination, YD, where B is the value of the blank and SB is the standard 
deviation of the blank sample. 
𝑌𝐷 = 𝐵 + 14.1 ∙ 𝑆𝐵 
4.2.7 Isotyping of antibodies 
To qualitatively determine the isotypes of anti-ERh12 mAbs in hybridoma growth media, capture ELISAs 
were performed with ISO-2 mouse monoclonal antibody isotyping reagents.  Isotype specific goat-anti 
mouse antibodies were diluted in ELISA coating buffer (1:1,000).  One hundred microliters of this solution 
were added to each well of 96-well Nunc MaxiSorb™ ELISA plates and incubated for six hours at 4°C.  
The coating solution was aspirated, the plates were rinsed once with PBST, 200 μL casein buffer was added 
to each well and the plates were left at 4°C overnight.  The blocking buffer was removed, and the wells 
were washed with PBST.  To the wells of duplicate columns, 100 μL undiluted culture media from anti-
ERh12 hybridoma cells were added.  The plates were incubated for one hour at room temperature and 
washed as before.  A 1:10,000 dilution of Fab specific HRP-labelled goat anti-mouse IgG antibody in 
casein buffer was added to each well.  The plate was incubated for one hour at room temperature and 
washed as before.  Next, 75 μL TMB was added to each well.  Following incubation in the dark for 
ten minutes, 75 μL 1 N H2SO4 was added.  The wells were inspected visually to ascertain the isotype 
identities of the mAbs. 
4.2.8 Conformation studies with anti-ERh12 monoclonal antibodies 
Investigating whether anti-ERh12 antibodies can distinguish between the apo, holo and antagonist 
conformations of the hERαLBD and hERαLBD-f proteins were approached by indirect ELISA and 
chemiluminescent development of dot blots of untreated and activated receptors. 
4.2.8.1 ELISA of anti-ERh12 against apo, holo and antagonist conformations of hERαLBD and 
hERαLBD 
Two absolute ethanol solutions, respectively containing either 60 μM ICI or 60 μM E2, were prepared.  To 
two test tubes, 500 μL E2 was added and 500 μL ICI was added to two more.  Next, the solutions were 
evaporated under a stream of nitrogen at 45°C.  In two separate test tubes, 10-mL solutions of hERαLBD 
and hERαLBD-f were prepared at 5 μg/mL.  Three millilitres of these solutions were transferred to the 
respective E2 or ICI containing test tubes.  The test tubes were sealed with laboratory film and stored over 
night at 4°C with gentle rocking.  Subsequent, 50 μL volumes of these solutions were added to the wells a 
96-well Nunc MaxiSorp™ ELISA plate as outlined in Figure 4.6.  The plate was covered, wrapped in 
plastic cling film and stored at 4°C for twelve hours. 





Figure 4.6 ELISA plate layout in Ab specificity assessment.  Anti-ERh12 monoclonal antibodies were assayed with 
different conformations of recombinant hERα LBD proteins in the presence or absence of the agonist E2 
and the antagonist ICI. 
Next, the protein/steroid solutions were aspirated from the wells and the plate was patted dry.  To each well, 
casein blocking buffer (150 μL) was added and the plate was incubated for one hour at 37°C.  Following 
aspiration of the blocking buffer, 50 μL hybridoma culture which exhibited high affinity when titrated 
against the recombinant proteins was added to the wells of individual rows at 1:200 dilution in casein.  To 
all wells of row G, 50 μL PBS were added.  The plate was incubated for one hour at 37°C, following which 
it was washed three times with PBST.  To each well, 50 μL HRP-conjugated goat anti-mouse IgG was 
added (1:50,000).  The plate was again incubated and washed as before.  TMB was added at 50 μL per well 
and following 30 minutes’ incubation in the dark an equal volume 1 N H2SO4 was added to stop the 
reaction.  The absorbance of each well was determined at 450 nm.  Results of the ELISA were analysed by 
GraphPad Prism’s integrated ordinary two-way ANOVA function with Tukey’s correction for multiple 
comparisons (α = 0.001). 
4.2.8.2 Dot blot assays against hERαLBD and hERαLBD-f with anti-ERh12 culture 
supernatants 
The high affinity anti-ERh12 culture growth media was also used to assess whether differences in antibody 
binding to the recombinant hERα LBD proteins could be observed in the presence or absence of ligand 
when these proteins were applied directly to nitrocellulose membranes.  In preparation, 200-μL solutions of 
absolute ethanol containing either 10 μM E2 or 10 μM ICI was added to individual test tubes and 
evaporated under nitrogen at 45°C.  To each tube, 200 μL PBS containing 5 μg/mL hERαLBD or 
hERαLBD-f was added after which they were gently rocked at 4°C for 24 hours.  Subsequently, the protein 
solutions were applied as 5 mm bands onto Amersham™ Protran™ 0.45 μm NC nitrocellulose blotting 
membrane at 0.1 nL per second using a CAMAG Linomat 5 TLC spotter under the control of winCATS 
version 1.4.8 software (CAMAG Chemie-Erzeugnisse & Adsorptionstechnik AG, Muttenz, Switzerland).  
The protein bands contained either 500 ng, 1,000 ng or 1,500 ng of protein.  The membranes were 
incubated overnight at 4°C in casein blocking buffer and to membranes onto which ligand-treated proteins 
were applied, 10 μM E2 or 10 μM ICI was added.  Once removed from the blocking buffers, the 
membranes were washed three times with PBST and cut into strips.  Next, individual strips were incubated 




with 3 mL anti-ERh12 high affinity culture supernatants diluted in casein (1:200) for 90 minutes at 37°C.  
Thereafter, the membranes were washed three times with PBST following which 3 mL HRP-conjugated 
goat anti-mouse IgG in casein (1:50,000) was added to each membrane strip.  The membrane strips were 
incubated for 90 minutes at 37°C after which they were washed as before.  Subsequently, 1 mL Clarity ECL 
solution was added to each strip.  Following incubation at room temperature for 5 minutes, the 
chemiluminescent signal produced on the membranes were captured with the a myECL digital 
transilluminator imager following one-minute exposure for the hERαLBD and 45 seconds exposure for the 
hERαLBD-f. 
4.2.8.3 Establishment of detection limits of anti-H12(HA1A6) culture supernatant for 
recognition of hER LBD proteins by means of dot blot arrays 
Dot blot arrays for the detection of the hERαLBD and hERαLBD-f were produced by application of the 
recombinant proteins onto Amersham™ Protran™ 0.45 μm NC nitrocellulose blotting membrane at 0.1 nL 
per second using a CAMAG Linomat 5 TLC spotter.  The 5 mm bands contained between 25 ng and 300 ng 
protein.  Following application of the protein, the membranes were incubated in casein buffer at room 
temperature for 90 minutes, followed by 30 minutes at 37°C.  Next, the membranes were incubated in 3 mL 
dilutions of anti-ERh12 (HA1A6) culture supernatant ranging between 1:200 and 1:1,200 for one hour at 
37°C.  Following three wash cycles with PBST, the membranes were incubated with HRP-conjugated goat 
anti-mouse IgG (1:50,000) for one hour at 37°C.  After washing as before, 1 mL Clarity ECL substrate was 
added to each membrane and reacted for 5 minutes at room temperature.  The chemiluminescent signal 
generated by each treatment was captured as before. 
4.3 RESULTS AND DISCUSSION 
4.3.1 The generation of antigen-specific populations of murine B lymphocytes 
To generate an immune response, a suitable foreign antigen which stimulates the adaptive immune system 
must be introduced to the animal.  BALB/c mice were challenged with various antigens during this project.  
The carrier protein-conjugated synthetic peptide antigens ERh12, αII and PolyHis have proven to be highly 
immunogenic (Figure 4.7).  The αII-peptide, coupled to mcKLH via the EDAC conjugation method, 
yielded suitable pre-fusion titres at day 28 following initial immunisation.  Extending the immunisation 
protocol for this antigen to 48 days markedly increased the polyclonal antibody titre to over 1 in 25,600.  
Similarly, high titres were easily obtained against the synthetic peptide analogous to the twelfth helix of the 
hERα LBD.  The peptides and peptide-conjugates were well soluble in aqueous media, however, ERh12 
required the addition of 20% DMSO to facilitate dissolution.  The PolyHis peptide, also, was readily 
solubilised in aqueous buffers; however, in complex with the mcKLH carrier protein, precipitates generally 
formed following the conjugation procedure.  These insoluble complexes, nevertheless, were still able to 
elicit immune responses within immunised animals.  Purified recombinant hERαLBD protein, however, 




proved to be poorly immunogenic as an antigenic challenge in BALB/c mice.  Immune responses suitable 
for the fusion of splenocytes to myeloma cells could only be achieved for the whole protein, following 
96 days of fortnightly challenges (Figure 4.7).  The human and murine analogues ERα share 97% sequence 
identity in the E-domains.  It is likely, therefore, that the perceived immunological tolerance may be 
accounted for due to the highly conserved nature of mammalian ERα LBDs (274). 
 
Figure 4.7 Composite image of ELISA plates indicating immune responses raised in BALB/c mice following 
challenge with antigen in TiterMax Gold adjuvant.  All assays were performed one day prior to fusion of 
spleen cells with Sp2/0-Ag14 murine myeloma cells.  Fusion of αII, ERh12, PolyHis and hERαLBD 
immune-stimulated splenocytes occurred on days 48, 35, 54 and 96, respectively, following initial 
immunisation. 
4.3.2 Fusion of immune-stimulated splenocytes with Sp2/0-Ag14 murine 
myeloma cells 
To detect changes in the conformation of receptor molecules following ligand-binding requires sensitive 
molecular probes which can distinguish between different structural motifs on the protein surface.  
Monoclonality is a prerequisite for this purpose if antibodies are to be used to indicate the alteration in 
three-dimensional structure.  Following the elicitation of immune responses in BALB/c mice, challenged 
with various antigens, splenic B cells secreting an immense variety of different antibodies were obtained.  
By using the polyethylene glycol method (352), these cells were fused (Figure 4.8) with an immortal 
murine cancer cell line.  Following fusion of cells, the HAT medium system was used for selection of 
somatic hybrids.  Hypoxanthine, aminopterin and thymidine are the key constituents of the medium that 
regulates the DNA synthesis in the cell.  Synthesis of nucleotides (Figure 4.9) can either start from the de 
novo synthesis of purines and pyrimidines, or by recycling of the free bases, termed the ‘salvage pathway’.  
The folic acid analogue, aminopterin, is a potent inhibitor of dihydrofolate reductase (DHFR), an enzyme 
involved in purine and pyrimidine synthesis.  During de novo synthesis, DHFR catalyses the reduction of 
dihydrofolic acid to tetrahydrofolic acid, using NADPH as electron donor.  This reaction is important for 
the interconversion of deoxyuridine monophosphate (dUMP) to thymidine monophosphate (TMP) during 
pyrimidine synthesis.  During purine biosynthesis, it is also involved in the conversion of 5-aminoimidazole 
carboxamide ribonucleotide (AICAR) to 5-formyl aminoimidazole carboxamide ribonucleotide (FAICAR). 





Figure 4.8 Selection of hybridoma cells. 
 
Figure 4.9 Diagram of DNA synthesis via de novo and the salvage pathways.  




Treatment of cells with aminopterin inhibits de novo synthesis of DNA by occupation of the DHFR active 
site, thus imposing nucleic acid auxotrophy on cells grown in its presence (364).  Tissues and cells 
containing the enzymes thymidine kinase (TK) and hypoxanthine guanine phosphoribosyl transferase 
(HGPRT) can, however, utilise a different biosynthetic route to synthesise DNA.  HGPRT is the most 
common selectable marker utilised during the fusion of B cells to an immortal cell line. Many of the 
immortal fusion partners available for hybridisation with B cells have been genetically engineered to be 
HGPRT negative.  As such, these cells cannot use hypoxanthine as a source for nucleic acid biosynthesis 
and will die in culturing environments containing aminopterin.  Cells, such as B cells or the hybridomas 
produced during this study are both HGPRT and TK positive and can therefore utilise the salvage pathway 
to synthesise DNA when hypoxanthine and thymidine is present (365, 366).  Consequently, only B cells 
that have successfully fused with the engineered immortal cells will survive in culture when grown in HAT 
medium, since the parental cells either have a limited lifespan, or are deficient in the enzymes required to 
survive in the selection medium. 
Following fusion procedures, robust growth was generally observed in the presence of aminopterin 
(Figure 4.10).  The removal of the DHFR inhibitor from culture media, 110 hours post fusion, led to a 
marked decrease in cell proliferation time. 
 
Figure 4.10 Micrographs of cells following fusion procedures.  (A) Immediately following the PEG procedure, small 
clusters of fusing splenocytes myeloma cells can be observed (red arrows) within a field of smaller red 
blood cells.  In panels (B) 100x magnification and (C) 400x magnification, an emerging hybridoma cell 
population is visible 110 hours post fusion.  Note the surrounding cellular debris from apoptotic cells.  
Following selection cell populations originating from single cells become evident.  In panel (D) a small 
cluster is visible at 100x magnification that has undergone two rounds of replication. 
  




4.3.3 Selection and clonal expansion of antigen-specific monoclonal antibody-
producing hybridomas 
4.3.3.1 The αII-peptide 
Following four rounds of clonal selection and expansion, hybridoma cultures secreting high affinity 
antibodies to the αII peptide could be established.  Growth media supernatant from these anti-αII hybrid cell 
cultures exhibited consistently higher recognition of the αII peptide when conjugated to BSA in comparison 
to positive serum controls.  From the available clones at the time, three strains were selected for 
maintenance and larger scale propagation.  Titration of these cell strains revealed recognition of the αII-
epitope at dilutions above 25,600-fold (Figure 4.11, A).  However, the binding characteristics observed for 
all three strains suggest that it is likely the antibodies produced by all three strains may have arisen from the 
same parental lineage (Figure 4.11, B). 
 
Figure 4.11 Titrations of anti-αII hybridoma culture supernatants.  (A) ELISA plate indicating the extremely high titres 
produced by cultures expressing antibodies against the αII peptide (αII-BSA: 5 μg/mL).  (B) Absorbances 
of diluted culture supernatants. 
According to Kong et al. (25), the αII peptide interacts with the hERα LBD at a site distal and distinct from 
AF-2.  Purportedly, the peptide can bind to the LBD in the presence of ligand, whether agonist or 
antagonist, yet is unable to recognise the αII binding surface when the receptor is in the apo conformation.  
Therefore, following the successful generation of mAbs capable of αII recognition, experiments were 
designed to assess whether αII-BSA could be used as an intermediate to detect conformational changes in 
the hERαLBD following ligand-binding.  In one instance, αII-BSA was immobilised to a solid surface to 
serve as a capturing agent for the receptor LBD in the presence of ligand.  Since a singular epitope is 
available for αII interaction on the activated hERαLBD, the hypothesis was that anti-αII antibodies would 
be inhibited from binding to surface immobilised αII-BSA if these binding sites were occupied by the 
ligand-bound receptor.  In the absence of a ligand, the conformational change required for αII-hERαLBD 
interaction would not occur, thus the LBD would not interact with αII-BSA and the antibody would be able 
to bind to the conjugate.  Consequently, the conjugate-antibody interaction would then be visualised by a 




colourimetric enzymatic reaction (Figure 4.5, panel A).  In an alternative format, immobilisation of the 
receptor to the solid substrate would be followed by interaction of the αII-conjugate in the presence of 
ligands to the receptor.  The peptide conjugate, which contains multiple αII-epitopes, would then act as 
intermediary to the immobilised hERαLBD and anti-αII antibodies, resulting in colour formation if ligand 
was present (Figure 4.5, panel B).  However, binding of anti-αII antibodies to the immobilised hapten-
conjugate could not be inhibited by pre-incubation of the antigen with recombinant hERαLBD in the 
presence of an agonist or an antagonist (Figure 4.12, panel A).  Antibodies were still able to bind to the 
immobilised peptide-protein conjugate, indicating that the complex was not obscured from this interaction 
by hERαLBD.  Equally, pre-incubation of hERαLBD coated NUNC Maxisorp™ plates with the αII-BSA 
conjugate also failed to generate responses which would indicate interaction between the hapten-conjugate 
complex and the immobilised receptor LBD (Figure 4.12, panel B). 
 
Figure 4.12 Binding inhibition studies with anti-αII antibodies.  (A) Assessment whether anti-αII antibodies are 
inhibited from interaction with the peptide by competition with the hERαLBD protein.  (B) No interaction 
between αII-BSA and the surface immobilised receptor LBD was detected by the anti-αII antibodies.  In 
columns 9 and 10, anti-hERαLBD serum enabled visualisation of the surface immobilised recombinant 
protein.  As expected, no binding occurred between hERαLBD immobilised to the plate and anti αII-
antibodies (column 11), whilst binding was evident when anti-αII antibodies were added to wells coated 
with BSA-αII. 
During the study by Kong et al. in 2005, the peptide was biotinylated and conjugated to the SPR sensor 
chip via interactions with streptavidin.  Also, following crystallisation studies it was revealed that the 
peptide adopts an extended conformation that closely matches the surface topology of the LBD which is 
mediated by several hydrogen-bonded and nonpolar interactions (25).  EDAC-mediated conjugation of αII 
to carrier proteins is non-directional and thus probably inhibits this conformational interaction with the 
hERαLBD.  When conjugating peptides to carriers, both the peptide ant the proteins may contain multiple 
carboxyl and amine moieties and polymerisation of the two macromolecules may occur.  This is normally 
not detrimental for purposes of immunisation since polymerised peptide will also be immunogenic (367).  
However, considering the use of a conjugate for interaction with a protein via a defined protein-protein 
binding site, polymerised peptide may have been a limiting factor.  Since the peptide is not free to conform 
to the receptor surface the conjugate may not have been able to interact with the hERαLBD via the αII 
binding surface to serve as an intermediate. 




A possible solution to this problem may be to synthesise the αII peptide to contain a terminal cysteine 
moiety, thus enabling the directional coupling of the peptide to a carrier for use as an intermediary between 
ligand-bound hERα LBDs and an anti-αII antibody. 
4.3.3.2 hERαLBD 
Differences in the response obtained, following incubation of culture media with immobilised antigen 
treated with 10 μM of either an ERα agonist, E2, to induce the holo configuration, or ICI, an ERα 
antagonist, and the apo form were initially observed with regards to hybridomas raised to secrete antibodies 
against the hERαLBD protein (Figure 4.13, top panels – well A11).  However, after four rounds of 
successive selection, typical results yielded no difference during ELISAs of culture supernatants treated 
with an agonist or antagonist, as compared to the control to which no ligand was added (Figure 4.13, 
bottom panels). 
 
Figure 4.13 Assessment of hybridoma culture medium for conformation-dependent antibodies.  Sera obtained pre-
euthanasia and -immunisation were incubated as positive and negative controls, respectively in wells A1 
and B1.  Assay of P2 anti-hERαLBD hybridoma cultures (top panels) revealed a single well (P3E2A11) 
containing antibodies which recognise the recombinant protein only in the presence of the agonist 
(encircled in red).  Continued selection of clones from this well, however, resulted in loss of ligand-
dependent differential detection of the hERαLBD.  During selection of P5 hybridomas for expansion, no 
observable differences in colourimetric response could be recorded. 
The fusion of splenocytes to myeloma cells produces millions of hybrid cells, some expressing antibodies 
against the antigen used during immunisation protocols, some of which produce irrelevant antibodies and 
some of which are non-secretors.  Selection of hybrids occurring via limiting dilution requires titration of 
these hybridomas to low seeding densities.  Thus, a clone which produces the required antibody may be lost 
via non-selection or may be overgrown by a clonal population which express an antibody which either does 
not recognise a conformational change in the LBD structure, produces irrelevant antibodies, or does not 
produce any immunoglobulins at all.  It is highly probable that this was the case with the desired 
conformational dependent antibodies raised against the recombinant hERαLBD protein.  





The loss of anti-hERαLBD clones which could possibly distinguish between ligand-bound and apo 
conformations of the hERα LBD proteins resulted in the need to formulate an alternative strategy to target 
an epitope on the LBD surface which may indicate a conformational change.  Building on the fortuitous 
results reported by Weigel et al. (344) following generation of mAbs against the C-terminal amino acid 
residues of the PR, a synthetic peptide analogous to H12 of the hERα LBD was designed and used as an 
immunogen.  H12 is involved in the conformational changes which occur in the receptor LBD following 
ligand binding.  In the apo state, H12 distends away from the main LBD body.  However, when bound to 
agonists the helix shifts to a position almost perpendicular to helix 11 to form the AF-2 co-activator binding 
site.  Conversely, AF-2 is obscured by H12 in the presence of antagonists.  The change in the position of 
H12 may thus obscure availability of recognition epitopes on the helix surface.  Therefore, antibodies 
recognising H12 could possibly indicate such conformational changes by interaction with the receptor in 
the only the apo, holo or antagonistic conformations. 
Following five rounds of selection, eleven anti-ERh12 cell lines were clonally expanded to larger cultures 
and cryogenically frozen (Table 4.1).  Marked differences in the affinity of the antibodies expressed by 
these cell lines for the hERαLBD were, however, observed.  Based on the antibodies’ ability to detect the 
hERα LBD proteins at 200-fold dilutions, the cell lines were assigned to either high (HA), moderate (MA) 
or low (LA) affinity groupings.  All eleven of these lines detected ERh12-BSA with affinities exceeding 
that of the control during the pre-final round of selection.  During titration following final selection all 
antibodies, apart from clone HA1A4, recognised ERh12-BSA at below 1:1,000 dilutions. 
The main antigenic region of the ERh12 peptide was determined by the Kolaskar-Tongaonkar (357) method 
to be between the aspartic acid residue at position four and the methionine at position fourteen of the 
polypeptide sequence.  The amino acid alterations to H12 were designed to flank the degenerate LxxLL 
motif whilst still retaining this antigenic determinant.  Since the motif interacts with the defining surface of 
the LBD which constitutes AF-2 in the antagonist conformation, the hypothesis was that antibodies binding 
to the LxxLL region may be incapable of doing so when the motif is engaged with the LBD surface.  Anti-
ERh12 antibodies which exhibit low to moderate affinity for the hERαLBD most probably bind to epitopes 
on the peptide that is towards either the N- or C-terminal of the LxxLL motif.  Since amino acid 
substitutions have been made at these positions within the peptide structure that is not reflected in H12 of 
the LBD the low affinity exhibited by these antibodies are most probably due to the altered sequences.  The 
HA antibodies, however, binds to ERh12 in between these altered amino acid residues and is therefore 
directed at the LxxLL antigenic determinant region of H12 the hERα LBD. 
Even though these antibodies were quite capable of indicating the presence of ERh12, titration of the LA 
and MA antibodies revealed that their ability to recognise the hERα LBD proteins is much lower than was 
expected (Figure 4.14).  Almost no detection of the LBD proteins was evident at dilutions of 200-fold and 
below.  A slight increase in the response was observable for the MA strains as compared to the LA strains 




at 200-fold dilution, yet the absorbance values for these responses were not quantifiably more than the 
background.  Resultantly, no further experimentation was performed with the antibodies present in LA and 
MA hybridoma growth media supernatant.  
 
Figure 4.14 Titration curves of culture growth media from eleven hybridoma cell lines secreting monoclonal antibodies 
against the synthetic peptide ERh12.  All titrations were conducted in duplicate (SD: n = 2) against the 
peptide conjugated to BSA (grey), hERαLBD (red) and hERαLBD-f (blue).  Antibodies from all cultures 
detected the ERh12-BSA conjugate at low dilutions.  Depending on intensity of the response observed 
against the hERα LBD proteins at 200-fold dilution, the hybrid cell lines were assigned to low, medium or 
high affinity groups.  






Figure 4.15 Titration curves for monoclonal antibodies contained in hybridoma culture media which detect the hERα 
LBD proteins with high affinity.  Titrations were conducted in duplicate (SD: n = 2).  All antibodies detect 
the hERαLBD-f (blue) to a greater degree as compared to hERαLBD (red).  




Titration of the HA cell lines at lower dilutions (Figure 4.15) revealed functional titres of the antibodies for 
recognition of the hERα LBD proteins in an ELISA format of between 1:320 and 1:1,280.  Interestingly, the 
antibodies obtained from all clones exhibit significant greater affinities toward the hERαLBD-f than to the 
hERαLBD (P < .05).  Clone HA1A6 had the greatest affinity for both the hERαLBD and the hERαLBD-f 
with logEC50 values of -1.894 and -2.062, respectively.  All the obtained antibodies were of the IgG1 
isotype (Figure 4.16). 
Table 4.1 Designations given to anti-ERh12 hybridoma cell strains following five rounds of selection.  Six high 
affinity producers (HA), three medium affinity (MA) and two low affinity (LA) strains were clonally 
expanded and cryogenically stored.  The logEC50 values for HA strains were calculated from dose-
response curves of titrations with dilutions between 5-fold and 5,120-fold.  The response obtained over 
positive control sera at the final selection (P10) against hERαLBD is indicated with selection against 
ERh12 at P8.  The response obtained for parental strains of final HA strains against hERαLBD during P8 







% Response of 
P10 over control 
during final ELISA 
against hERαLBD 
% Response of P8 
over control 




HA1A4 High -1.446 -1.719 1A4(D3)1A5 2,800 145 
(1,053) HA1D4 High -1.479 -1.936 1D4(A11)1A5 2,825 
HA1C5 High -1.434 -1.570 1C5(H11)2A2 2,942 150 
(1,015) HA1D5 High -1.340 -1.618 1D5(F12)2A2 2,777 
HA1A6 High -1.894 -2.062 1A6(G1)2A3 2,750 143 
(1,010) HA2C1 High -1.621 -1.886 2C1(G11)2A3 2,928 
MA1A2 Medium   1A2(E2)1A3 530 135 
(359) 
MA2A2 Medium   2A2(C7)2A6 448 
147 
(416) 
MA2D2 Medium   2D2(A12)3A4 441 140 
(480) 
LA2B3 Low   2B3(A10)3A5 75 145 
(123) 




Figure 4.16 Image depicting the results of isotype determination of monoclonal antibodies contained in hybridoma 
growth media.  Isotyping was performed by means of a sandwich ELISA.  All antibodies are of the IgG1 
class.  




4.3.4 Conformation studies with anti-ERh12 monoclonal antibodies 
4.3.4.1 ELISA of anti-ERh12 against apo, holo and antagonist conformations of hERαLBD and 
hERαLBD-f 
To confirm a change in conformation following treatment of the LBD proteins with suitable ligand, a 
colourimetric response would be expected under one condition while being completely absent in another.  
Pre-incubation and activation of the hERα LBD proteins with a known agonist and antagonist failed to 
enable a visual elucidation of ligand-binding.  Spectroscopic measurement of colour development 
(Figure 4.17) confirmed that, for most part, the antibodies are unable to distinguish between activated and 
ligand-free hERαLBD or hERαLBD-f.  However, a general trend could be observed indicating slight 
decreased detection of the hERαLBD-f protein in the presence of E2, for all antibodies, and ICI, for 
antibodies from HA1C5, HA1D5, and HA2A3. 
 
Figure 4.17 Bar graph indicating the absorbances observed following ELISA of hER LBD proteins in the presence or 
absence of an ER agonist, E2, and an antagonist, ICI.  Statistically, only antibodies from clone HA1D4 
could distinguish the apo and holo conformations of hERαLBD-f.  Some distinction was obtained between 
the holo conformation of hERαLBD and receptor in the apo and antagonistic state by HA2A3.  However, 
visually no conclusions could be drawn from the colour that developed following substrate addition.  All 
measurements were taken in duplicate (SD: n = 2). Data was analysed by ordinary two-way ANOVA 
implementing Tukey’s correction for multiple comparisons.  The family wise significance and confidence 
level was set to 99.9% (α = 0.001); * P < .005. 
However, antibodies produced by clone HA2A3 detected the protein slightly better in the presence of E2 
than when incubated with ICI or when not activated by ligand (P < .005).  In the presence of E2, antibodies 
from clone HA1D4 detected the hERαLBD-f to a lower degree than in its absence or when the LBD was 
incubated with ICI.  Although not statistically significant, similar trends were observed for all treatments 
involving the hERαLBD-f following incubation with E2.  It may be that the F-domain of the hERαLBD-f 
does cause some steric hindrance to the binding of anti-ERh12 mAb.  Further optimisation of assay 
conditions may yet indicate some distinction.  




Nevertheless, analyses of binding of HA anti-ERh12 antibodies to apo and ligand-bound hERα LBD when 
immobilised to nitrocellulose membranes returned equivalent results (Figure 4.18).  Visually, no differences 
in chemiluminescence was observed between protein samples containing no ligand and those treated with 
either 10 μm E2 or 10 μM ICI.  Also, within treatments there seemed to be no difference in the signal 
generated for the three protein quantities, 500 ng, 1,500 ng and 1,500 ng.  However, comparable to results 
obtained following titration of the growth media with ELISA, anti-ERh12 HA1A6 seemed to recognise 
both proteins to a greater degree than the five other HA anti-ERh12 culture supernatants.  Also, all the mAb 
formulations detected hERαLBD-f to a greater degree than hERαLBD; the camera exposure required to 
capture the chemiluminescent signal during digital imaging of hERαLBD-f was limited to three quarters of 
the time needed for hERαLBD imaging. 
 
Figure 4.18 Dot blots of hERα LBD proteins applied to nitrocellulose membranes in the presence and absence of the 
ER agonist, E2, or antagonist, ICI, and detected with 1:200 dilutions of high affinity anti-ERh12 
antibodies.  The antibodies were unable to distinguish between different conformations induced to the 
protein structure by the inclusion of ligand. 
4.3.5 Detection limits of anti-ERh12 for the hERα LBD proteins 
The titres and limits of determination and detection of the various anti-ERh12 mAbs for the hERα LBD 
proteins are given in table 4.2. 
Table 4.2 Titres and quantitative limits determined at 450 nm by means of ELISA.  Limits of detection and 
determination was calculated from the mean background absorption as per equation 4.1 and equation 4.2.  
The functional titre is the reciprocal of the last dilution that exhibited an absorbance above three times 
that of the YD. 
Monoclonal 
antibody 
Quantitative limits at 450 nm (AU) Titre 
Limit of detection 
YL 






HA1A4 0.048 0.060 0.179 640 1,280 
HA1D4 0.075 0.133 0.399 320 640 
HA1C5 0.047 0.061 0.183 640 1,280 
HA1D5 0.058 0.091 0.272 320 640 
HA1A6 0.056 0.085 0.256 640 1,280 
HA2C1 0.051 0.070 0.211 640 1,280 




The chemiluminescent signals generated during the dot blot presented in figure 4.18 was not indicative of 
differences in protein conformation due to the presence or absence of ligand.  Regardless, as with the results 
of ELISAs for titration (Figure 4.15) and conformation studies (Figure 4.17), mAbs produced by clone 
HA1A6 exhibited greater affinity for the both hERα LBD proteins compared to the mAbs from the other 
five HA cell lines.  Figure 4.19 represents the results obtained following titration of native hERα LBD 
proteins applied directly to nitrocellulose membranes as distinct bands.  As had been previously shown in 
Figure 4.15 and Figure 4.18, anti-ERh12 HA1A6 is more sensitive in the detection of the hERαLBD-f than 
the hERαLBD.  The mAbs enabled visualisation of the hERαLBD-f protein at lower dilutions and at lower 
protein concentrations when compared with the hERαLBD.  The chemiluminescent signal generated for the 
detection of 25 ng hERαLBD was lost at dilutions exceeding 1:400.  This quantity of protein was still 
visible for the hERαLBD at anti-ERh12 HA1A6 dilutions of 1:1,200. 
 
Figure 4.19 Image of a dot blot array indicating the limits of detection of recombinant hERα LBD proteins by anti-
ERh12 HA1A6 monoclonal antibodies.  The hERα related proteins were applied directly to nitrocellulose 
at equivalent concentrations.  Anti-ERh12 HA1A6 can detect 50 ng hERαLBD at a 1:1,200 dilution.  The 
same antibody can detect the hERαLBD-f at half that quantity, 25 ng by using the same titre. 
  





The changes which occur in the three-dimensional structure of nuclear receptor LBDs following ligand-
binding have been well characterised in several publications (21, 318, 320, 368, 369).  Therefore, in this 
study an attempt was made to produce a method for the easy assessment of the presence of small molecules 
capable of inducing such conformation changes.  Two strategies, both of which required the generation of 
specific mAbs were investigated and described in this chapter. 
In one strategy, an 11-residue peptide, referred to as αII, was used as immunogen.  The peptide has been 
reported in literature as capable of hERαLBD receptor binding in the presence of both agonists and 
antagonists at a surface which may be a possible coregulator recruitment site (24, 353).  Replacing the 
nuclear box LxxLL sequence of a known hERα coactivator with the αII sequence, Kong et al. (25) were 
able to recruit the mutated protein to the receptor surface in the presence of ligand, but not in the absence 
thereof.  It was thus hypothesised that such a protein-protein interaction may be used to indicate ligand-
binding to the receptor by using a protein-intermediate.  Binding of both the receptor and anti-peptide mAb 
may be possible if multiple αII epitopes are present.  Conjugated to a protein carrier, αII proved to be highly 
immunogenic and elicited an immune response yielding serum titres of over 1:25,600.  Fusion of B-cells 
from an immunised mouse with murine myeloma cells led to the establishment of hybrid cells secreting 
antibodies of extremely high affinity for the peptide sequence.  However, even though conjugation of the 
peptide to the immunising carrier by means of EDAC was extremely efficient in providing αII recognising 
antibodies, conjugation of the peptide to an intermediate protein by EDAC does not allow for αII-hERα 
LBD interaction.  Alterations to the conjugation method to facilitate a directed attachment of the peptide to 
a carrier may overcome this problem and will be the subject of further inquiry in future.  Furthermore, the 
generated antibodies will be used to investigate whether co-regulatory proteins containing the αII sequence 
are expressed in various ERα positive cell lines. 
A main aim of this work, however, focused on the possible generation of a hybridoma cell line that secretes 
a mAb capable of distinguishing directly between apo and ligand-bound conformations of the hERα LBDs.  
In the first attempt at producing such a cell line, the full-length hERαLBD protein, heterologously 
expressed in T. ni insect cells, was used as immunogen.  Fusion of B-cells from a mouse immunised with 
the hERαLBD protein initially indicated the production of antibodies in culture which exhibited low levels 
of discrimination between the apo- and ligand-bound conformations of the receptor LBD.  Following 
successive selection and clonal expansion protocols, however, possible clones producing such antibodies 
were lost.  In general, conformational epitopes are discontinuous in nature.  Apart from certain complicated 
endeavours, such as the design of stapled peptides or presentation of multiple peptides on a synthetic 
molecular scaffold (370, 371), which may or may not resemble the protein’s three-dimensional structure, 
there are currently no means of specifically directing the generation of an antibody against a discontinuous 
epitope.  Thus, the failure to select a clone capable of indicating hERα LBD conformation prompted the 
initiation of an alternative method, directed to produce mAbs against a defined epitope on the hERαLBD 




surface, helix 12, which is known to be involved in conformational changes that occurs in the protein three-
dimensional structure following ligand-binding (320).  A synthetic peptide resembling H12 was designed 
and synthesised with alterations to the N- and C-terminal ends.  In this manner, selection of hybrid cell lines 
was designed to obtain hybridomas secreting antibodies to the central, degenerated LxxLL-motif of H12.  
Consequently, several such hybridoma cell lines were established.  However, as for the full-length receptor, 
none of these secrete mAbs capable of conformation-dependent hERα indication.  An interesting 
observation was made, however, that the antibodies produced by the anti-ERh12 HA cell lines seem to 
exhibit higher affinity for recognition of the hERαLBD-f compared to the hERαLBD.  Culture growth 
media containing anti-ERh12 mAbs from clone HA1A6 were able to detect the hERαLBD-f protein at 
25 ng when diluted 1:1,200.  At this dilution the hERαLBD was detectable to 50 ng. 
Although the desired mAbs capable of indicating a protein conformation change could not be obtained 
during these investigations, several mAb secreting cell lines could be established that release high affinity 
antibodies which bind to a defined epitope on the hERα LBD surface.  The availability of antibodies with 
directed antigen binding capabilities in essentially unlimited supply can still be utilised in the fabrication of 
a novel EDC detection system.  However, because it is currently not possible to distinguish between the 
apo and ligand-bound forms of the hERα, alternative methods for the antibody-based detection of 
heterogeneous oestrogenic substances will need to be devised.  Since the mAbs produced to date bind 
indiscriminately to the hERα LBD, such a system would require that receptors which are bound by ligand 
be separated from unbound receptors in some way. 
A typical lateral flow assay device, with some modification, may provide a method to facilitate such a 
separation.  In the following chapter, a way in which a LFIA may be constructed, capable of the detection 
of structurally dissimilar ligands by indication of receptor LBDs, will be described. 
  





Initial investigations into the feasibility of an EDC detecting 
immunochromatographic assay using a receptor-based 
approach 
5.1 INTRODUCTION 
The development of low-cost analytical instruments is expected to play a key role in improving global 
public health by providing POC diagnostic and monitoring methods.  Lateral flow immunochromatographic 
assays are highly attractive tools for the indication of the presence or absence of target analytes of concern 
due to their simplicity of use, low manufacturing cost, user-friendliness and result rapidity.  Furthermore, 
the portability afforded to these devices by using dry reagents incorporated into a membrane-based design 
makes LFIA ideal for use in remote settings or developing countries where simple bioassays are essential in 
disease detection, the monitoring of food- and water-borne toxins and the detection of environmental 
contaminants.  The realisation that several man-made and natural compounds can disrupt the functioning of 
the endocrine system has spurred the development of numerous LFIA for the detection of hormones (372, 
373), hormone analogous (374), environmental toxins (129, 375) and other EDCs (150).  These devices are 
highly specific for the indication of the analytes they were respectively designed for.  Yet, there are 
multiple other compounds which also exhibit endocrine disruptive capabilities which remain undetected 
due to lack of knowledge of their chemical structures, unavailability of specific tests or lack of sufficient 
analytical infrastructure. 
One possible solution to this problem is to design a system which provides a mechanism of analysis of the 
biological effects of a class of compounds, thus circumventing the need for individual chemical analysis.  
Vitellogenin is a large phospholipoglycoprotein synthesised in the livers of female egg-laying vertebrates, 
such as fish, amphibians, reptiles and birds.  The oestrogen-induced production of the protein increases 
markedly during oocyte development since VTG is a precursor of egg-yolk protein.  In the plasma of 
sexually mature female fish, VTG is present at concentrations ranging between 1 mg/mL and 15 mg/mL 
(376–378).  In males and juveniles, however, it is usually not expressed or occurs in undetectable low 
concentrations (379, 380), even though the VTG gene is present.  Nevertheless, the synthesis of the protein 
can be elicited in males by oestrogens, oestrogen mimics and P450 aromatase inducers (381, 382).  Exposed 
to such compounds, male fish are capable of synthesising ample quantities of VTG – concentrations within 
the serum may reach values equal to that observed in females.  Vitellogenin presence in males is 
consequently often used as a sensitive biomarker to assess the exposure of environmental oviparous 
populations to exogenous oestrogenic compounds.  Mandich et al. (383) developed an sandwich LFIA to 
simplify VTG assessment which exhibited good cross-reactivity with VTG from several species of fish.  
Accordingly, the use of an in vitro VTG LFIA (270) allows for a sensitive means to quantify exposure to 




oestrogenic endocrine disruptors by analysis of a single biomolecule, the production of which is can be 
induced by heterogenous chemical compounds.  However, use of VTG as a biomarker still requires the 
maintenance of oviparous organisms in a laboratory environment or the need for capture of such sentinels in 
the wild for environmental assessment. 
Nevertheless, the principles of LFIA technology may also enable the assembly of a device for the direct 
assessment of endocrine disruptive capability by evaluating binding capacity to nuclear receptor LBDs.  
There are several mechanisms by which such a LFIA may be assembled.  Figure 5.1 represents one iteration 
of a possible LFIA that uses recombinant NR LBDs in a format based on a ‘competitive immunometric’ 
assay.  Incorporating an additional element into the LFIA design at a position immediately after the sample 
application pad allows storage of recombinant receptor LBDs immobilised by a cognate ligand.  In high 
enough concentrations, competitor compounds in a sample will lead to displacement of the LBDs from their 
immobilised position.  At the next element within the LFIA, labelled anti-LBD mAbs will interact with the 
receptor proteins within the capillary stream.  Migration of the LBD/mAb complex will continue until it is 
bound at the test line by an alternate membrane-bound anti-LBD antibody.  As with other LFIA devices, a 
species-specific antibody will serve as a control mechanism to capture excess labelled antibody, thus 
indicating a functional test. 
 
Figure 5.1 Schematic of a LFIA in which hERα LBDs are sequestered immediately after the sample application pad 
by means of covalently membrane-bound ligands which are cognate to the receptor.  Displacement of the 
LBDs results in recognition by labelled mouse anti-ERh12 antibodies under capillary flow.  At the test 
zone, the ERα LBD/mAb-AuNP complex is bound by a different anti-ERα antibody indicating a positive 
result.  By means of an assay control, anti-mouse antibodies bind to the labelled antibody at the control 
zone, indicating the functionality of the assay. 
  




In this chapter, the production of an essential component of the proposed system, the labelled conjugate, is 
described.  Based on its greater ability to detect the recombinant hERα LBD proteins, mAbs secreted by 
clone HA1A6 were selected for further purification and labelling with coloured particles.  Succeeding 
isolation from growth culture supernatant, the purity of the mAbs was determined by SDS-PAGE and IgG 
of murine origin was affirmed with western blot analysis.  Following conjugation, covalent bond formation 
between the AuNP and pure mAbs was confirmed by multiple analyses.  Finally, the capture of the 
hERαLBD-f from solution and following migration under capillary flow is demonstrated. 
5.2 MATERIALS AND METHODS 
5.2.1 Purification of monoclonal antibodies 
5.2.1.1 Growth of hybridoma cells and preparation for chromatography 
For the purification of copious amounts of anti-ERh12 mAbs, HA1A6 cells were revived from cryogenic 
storage by rapid thawing at 37°C and washed with 20 mL complete RPMI-1640 medium.  The cells were 
collected by centrifugation at 200 xg for five minutes, suspended in 5 mL complete medium and incubated 
at 37°C a 5% CO2 atmosphere incubator maintained at 98% relative humidity.  The cultures were expanded 
to four 75-cm2 culture flasks at 4 x 104 cells/cm2.  Upon reaching confluency all cells were passaged a ten-
layered HYPERFlask® in 560 mL full RPMI-1640 containing FBS depleted of bovine IgG by a process 
adapted from Darby et al.1 (384).  Incubation was continued until the cells completely covered all growth 
surfaces after which the growth medium was collected and centrifuged at 4,400 xg for 15 minutes for 
clarification.  Clarified growth medium, 385 mL, was decanted to two 75 cm long 45 mm flat width 12 –
 14 kDa MWCO Spectra/Por® 2 dialysis membrane tubes that had been preconditioned in reverse osmosed 
water for 30 minutes at room temperature and rinsed.  The tubes were suspended in 20 L dialysis buffer 
(20 mM sodium phosphate, 150 mM NaCl, pH 7.0).  The growth medium was dialysed against this buffer, 
overnight with gentle stirring at 4°C.  The next day, the dialysis buffer was exchanged for 20 L fresh buffer 
and dialysis was continued for a further 24 hours. 




1 To remove bovine IgG for mAb secretion from hybridomas prior to affinity isolation, FBS was filtered with sterile 
0.45 μm pore size syringe filters and applied to a HiTrap Protein G column which had been equilibrated with filter 
sterilised solutions of 20% ethanol in PBS, followed by PBS at pH 7.0 connected to a Bio-Rad NGC Quest™ 10 Plus 
FPLC system.  Unfractionated effluent from the column was passed through the column a further two times, with 
elution of bovine IgG in between applications with 100 mM glycine-HCl and subsequent re-equilibration with PBS.  
Due to the high viscosity of serum, low flow rates of 0.125 mL/min to 0.5 mL/min was used to limit excessive 
backpressure. 




5.2.1.2 Isolation of monoclonal antibodies from in vitro cultivation system 
Isolation of anti-ERh12 antibodies was performed on a Bio-Rad NGC Quest™ 10 Plus FPLC system under 
the control of ChromLab software version 4.0.0.25 (Bio-Rad Laboratories, Inc.).  Prior to chromatography, 
the dialysed antibody containing buffer was filtered through a 0.45 μm pore size membrane filter under 
vacuum and degassed for 20 minutes.  The filtered sample, 50 mL, was applied onto a 1-mL HiTrap Protein 
G column equilibrated with 20 mM sodium phosphate, 150 mM NaCl, pH 7.0.  Following washing of the 
column with binding buffer, 10 column volumes, elution of mAbs were facilitated by changing the mobile 
phase to 100 mM glycine-HCl, pH 2.7.  Several separations were performed and the IgG containing peak 
from every run was collected, two 1 mL fractions, in ice-cooled tubes containing 100 μL 1 M Tris-HCl, 
pH 9.0. 
These fractions were pooled and transferred to 10 mm flat width, 12 – 14 kDa MWCO dialysis tubing, 
which had been preconditioned in reverse osmosed water for 30 minutes.  The sealed tubes were transferred 
to 2 L mAb storage buffer (10 mM sodium phosphate, 150 mM NaCl, pH 7.0) for 62 hours during which 
time the dialysis buffer was changed once.  Upon completion of dialysis, the solutions were transferred to 
sterile polypropylene tubes and stored at 4°C. 
Alternatively, buffer exchange of protein G purified mAbs were also performed with HiTrap Desalting 
columns as described in section 3.2.1.2.  In this case, the 5-mL column was equilibrated with mAb storage 
buffer. 
5.2.2 Concentration and titre determination following purification 
5.2.2.1 Protein concentration determination 
The concentration of the purified mAbs was estimated with the micro Bradford assay using BGG as a 
reference standard.  Bovine gamma globulin was analytically reconstituted from lyophilised powder to a 
concentration of 2 mg/mL in mAb storage buffer.  This stock solution was used to generate an eight-point 
standard curve with concentrations ranging between 0.0 mg/mL and 2.0 mg/mL.  The concentration of the 
purified mouse anti-ERh12 IgG1 from clone HA1A6 was determined in relation to the standard curve. 
5.2.2.2 Antibody titrations 
5.2.2.2.1 Checkerboard titrations of antibody binding to recombinant LBDs 
Following determination of the concentration of mAb obtained following purification, the titre of active 
antibody was determined by checkerboard assays and serial dilution ELISA.  Carbonate buffer solutions 
containing 20 μg/mL hERαLBD or hERαLBD-f was added to row A of Nunc Maxisorp™ ELISA plates at 
100 μL per well.  These solutions were subsequently serially diluted by sequential transference of 50-μL 
volumes to rows B – H.  The plates were incubated at 37°C for 90 minutes, after which the coating buffer 




was aspirated.  The plate was rinsed once with PBST, 150 μL casein buffer added and incubated overnight 
at 4°C. 
The following morning, the plates were washed once with PBST and to each well of column 1, 100 μL 
purified anti-ERh12 HA1A6, diluted to 10 μg/mL in casein buffer, was added.  The contents were serially 
diluted across the plate to reach a final concentration of 5 ng/mL in column 12, with a volume of 50 μL per 
well.  The plates were incubated at 37°C for 90 minutes, washed three times with PBST after which 50 μL 
HRP-conjugated goat anti mouse IgG was added to each well.  Incubation was continued at 37°C for 
90 minutes after which wells were washed as before.  Fifty microliters TMB was added to each well and 
after 30 minutes’ incubation in the dark the colourimetric reaction was quenched with an equal volume of 
1 N H2SO4.  Absorbance of was determined at 450 nm with a plate reader. 
5.2.2.2.2 Serial dilution ELISA 
A comparison of the increased activity achieved following purification of the antibody was achieved by a 
two-fold serial dilution titration of the purified stock and the original culture growth medium.  A Nunc 
Maxisorp™ ELISA plate was coated with 50 μL per well carbonate buffer solutions containing 5 μg/mL 
hERαLBD in rows A – D and 5 μg/mL hERαLBD-f in rows E – H at 37°C for 90 minutes.  The coating 
buffer was aspirated, and the plate was rinsed once with PBST.  To each well, 150 μL casein buffer was 
added, the plate sealed and incubated overnight at 4°C.  Once rinsed with PBST, 100 μL purified anti-
ERh12 HA1A6 antibody solution diluted 1 in 5 in casein buffer was added to wells A1, B1, E1 and F1; and 
100 μL culture medium from clone HA1A6, diluted 1 in 5 in casein buffer, was added to wells C1, D1, G1 
and H1.  The solutions were serially diluted across the plate to column 11, which contained a final dilution 
of 1:5120, in a volume of 50 μL per well.  To the wells of column 12, 50 μL casein was added.  The plate 
was incubated at 37°C for 90 minutes and washed as before.  Diluted HRP-conjugated goat anti-mouse IgG 
(1:50,000), 50 μL, was added to each well.  Incubation was continued at 37°C for 90 minutes, after which 
the wells were washed and 50 μL TMB was added.  Following 30 minutes incubation in the dark, the 
reactions were quenched with an equal volume of 1 N H2SO4, followed by spectroscopic determination at 
450 nm. 
5.2.3 Electrophoretic analysis 
5.2.3.1 SDS-PAGE and western blot of anti-ERh12 antibodies 
The purity of the isolated monoclonal antibodies was assessed by SDS-PAGE and the identity confirmed as 
murine antibodies by western blot.  Purified antibodies were diluted 1:1 with Laemmli SDS-PAGE 
treatment buffer and heated to 95°C for 10 minutes.  The treated sample, 35 μL, containing 4.0 μg of 
protein, was loaded to 15% hand-cast SDS-acrylamide gels.  Duplicate gels were prepared, and 
electrophoresis was carried out at 4°C for 70 minutes at 200 V.  Protein bands were visualised with 
Coomassie R-250 after staining and destaining. 




Proteins on the second gel were transferred to nitrocellulose by electrophoresis at 110 V for 90 minutes.  
The membrane was subsequently incubated in casein blocking buffer for 60 minutes at 37°C.  Next, the 
membrane was incubated in casein containing 1:5,000 ImmunoPure® HRP-conjugated goat anti-mouse IgG 
(H+L) antibodies for a further 90 minutes at 37°C.  Following three five-minute wash cycles with PBST, 
the membrane was submerged in 5 mL Clarity ECL chemiluminescent substrate solution.  After a five-
minute incubation period in in the substrate, the chemiluminescent signal was photographed following 
exposure for seven seconds with a myECL digital imager. 
5.2.3.2 Western blot detection of SDS denatured hERαLBD and hERαLBD by anti-hERαLBD-
H12 1A6(HA) 
The ability of purified anti-ERh12 antibodies to detect the recombinant hERα LBD proteins in denatured 
form was assessed by western blot.  Each protein, 5 μg, was loaded into the wells of a 10% SDS-acrylamide 
gel following denaturation with 2x Laemmli sample buffer for 10 minutes at 95°C.  The proteins were 
resolved by electrophoresis and transferred to nitrocellulose as above.  Visualisation of the protein was 
achieved by incubation with 1 μg/mL anti-ERh12 HA1A6 antibody in casein buffer followed by washing 
and incubation with HRP-conjugated goat anti-mouse IgG (1:50,000).  Chemiluminescence was captured 
following washing and incubation with Clarity ECL chemiluminescent substrate solution.  At the same 
time, Hsc70 and Hsp40 was visualised as previously reported. 
5.2.4 Anti-ERh12 HA1A6 labelling 
5.2.4.1 Concentration of antibodies 
The conjugation of proteins to the surfaces of carboxyl-modified gold nanoparticles requires concentrations 
of 0.05 – 0.5 mg/mL protein within a suitable buffer.  The concentration of antibodies purified from clone 
HA1A6 growth media was greater than this requirement, yet too low to facilitate conjugation due to the 
presence of phosphates which is known to detrimentally affect the coupling reaction.  According to the 
manufacturer of InnovaCoat® GOLD-Carboxyl 40OD, proteins in PBS may be conjugated to the particles if 
the concentration of the antibodies are greater than 10 mg/mL.  Thus, the interfering buffer components had 
to be removed or diluted to an extent that the conjugation reaction would not be negatively impacted upon.  
Consequently, purified anti-ERh12 HA1A6 mAbs were centrifugally concentrated with a 10 kDa MWCO 
AbPure™ spin cartridge.  The purified anti-ERh12 antibody, 500 μL, was added to the spin cartridge and 
centrifuged at 12,250 xg until the volume had decreased to between 50 and 100 μL.  The procedure was 
repeated multiple times, the retentate transferred to a clean polypropylene tube and the concentration 
determined by the micro Bradford assay against a BGG reference standard. 
  




5.2.4.2 Validation of antibody binding activity following concentration 
Prior to attempting conjugation reactions, it was prudent to reassess the binding activity of the concentrated 
antibodies to ensure that no loss of antigen recognition was incurred due to the concentration procedure.  
Activity was assessed by indirect ELISA as previously described. 
5.2.4.3 Conjugation of antibodies to colloidal gold 
Following validation of antibody activity, the concentrated mAbs were diluted in 10 mM MES (pH 5.0) to 
concentrations of 0.25 mg/mL, 0.20 mg/mL, 0.15 mg/mL and 0.10 mg/mL.  Ten microliters 100 mM MES 
(pH 5.0), 20 μL concentrated anti-ERh12 HA1A6 and 20 μL 1 mM EDAC in ultrapure water was added to 
50 μL InnovaCoat® Gold Carboxyl.  The mixtures were incubated at room temperature for 20 minutes with 
constant agitation after which 1 mL Tris-buffered saline (TBS; 50 mM Tris-HCl, 150 mM NaCl, pH 8.0) 
containing 0.05% Tween-20 (TBST) was added to the reaction.  The colloidal suspension was centrifuged 
at 2,500 xg for 15 minutes to pellet the antibody-conjugated AuNP.  The supernatant was carefully 
aspirated and 90 μL TBST, containing 0.5 % BSA, was added to the pellet.  The colloidal pellet was gently 
suspended in the buffer and stored at 4°C. 
5.2.4.3.1 Gel retardation assay using agarose gel electrophoresis 
Gel electrophoresis is a common analytical technique that separates macromolecules or particles based on 
their size, shape and charge.  Analysis of the surface modification of the AuNP-antibody conjugates was 
performed by gel retardation.  Each AuNP-conjugate, 8 μL, was added undiluted to an equal volume 
denaturing agarose gel electrophoresis sample buffer (0.5% TAE (20 mM Tris base, 1 mM EDTA, 10 mM 
acetic acid, pH 8.3), 0.25% SDS, 30% glycerol, 20% Ficoll Orange), heated to 50°C for 10 minutes after 
which it was cooled to room temperature.  Each prepared conjugate, 15 μL, was loaded to a well on a 0.5% 
denaturing agarose gel (0.5% D1 LE molecular grade agarose in 1x TAE, 0.5% SDS).  As control, 7 μL of 
unconjugated InnovaCoat® GOLD Carboxyl 40OD in the same denaturing buffer was loaded to a well.  
Electrophoresis of AuNPs was conducted with a potential gradient of 15 V/cm, maintained for 3 minutes 
and subsequently lowered to 8 V/cm for 60 minutes.  The migration of AuNP in the gel was easily 
monitored due to their intrinsic colour.  Electrophoreses was halted when the particles had migrated across 
80% of the gel. 
5.2.4.3.2 Determination of colloid concentration 
The maximum absorbances of each AuNP suspension was measured at 530 nm with a Cary 60 UV-Vis 
spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) to determine the effective conjugate 
concentrations.  InnovaCoat® Gold-Carboxyl was diluted, 1 in 40, and each conjugate was diluted 1 in 20 
with TBST.  The visible spectra for all sample was obtained between 800 nm and 400 nm 
  




5.2.4.3.3 Confirmation of surface functionalisation by means of ATR-FTIR 
Attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy is a powerful spectral 
method to determine the chemical makeup of molecules.  In preparation for ATR-FTIR, 200 μL 
unconjugated InnovaCoat® GOLD Carboxyl and 200 μL of a 0.20 mg/mL anti-ERh12-AuNP conjugate was 
frozen in liquid nitrogen and lyophilised for eight hours.  The procedure was performed on a Nexus infrared 
spectrometer equipped with a Smart Golden Gate attenuated total reflectance diamond (Thermo Nicolet) 
with ZnSe lenses.  Each spectrum was scanned 32 times with 4.0 cm-1 resolution.  Data analysis was 
performed with Omnic Software version 7.2. 
5.2.5 Visualisation of recombinant hERα LBD proteins with anti-ERh12-AuNP 
Antibodies labelled with colloidal gold provide a facile means to visualise the presence of an antigen.  The 
ability of the anti-ERh12-AuNP to concentrate on and visualise hERα LBD proteins localised on 
nitrocellulose membranes were therefore assessed.  The concentration of the purified receptor proteins was 
increased by ultra-filtration using 10 kDa MWCO spin columns to allow the application of distinct protein 
bands on the membrane with minimal diffusion.  The recombinants were sprayed onto NC with a CAMAG 
Linomat 5 TLC spotter at an application rate of 1 nL/second as 5 mm bands 6 mm apart, containing 
between 25 ng to 1000 ng protein and dried at room temperature.  The membrane was cut into four sections 
and incubated in casein blocking buffer for one hour at 37°C.  Following blocking, the sections were 
transferred to casein solutions containing OD 0.3 of the respective anti-ERh12 conjugates for four hours at 
37°C, after which it was incubated overnight at 4°C.  The membranes were briefly rinsed with PBST, dried 
and photographed. 
Densitometrical analysis was performed with the freeware software package GelAnalyzer 2010a (Istvan 
Lazar and Dr Istvan Lazar) implementing valley-to-valley baseline subtraction.  The obtained pixel 
densities were plotted against the quantity of hERα LBD protein applied to the membranes and fitted with a 
one-site specific binding isotherm with GraphPad Prism. 
5.2.6 Capturing of hERαLBD-f by membrane immobilised anti-ERα antibodies 
and visualisation with anti-ERh12-AuNP 
5.2.6.1 Sandwich capture from solution 
The ability to capture antigen to a test line is a requirement for the fabrication of a direct LFIA.  Triplicate 
5 mm bands of rabbit anti-ERα polyclonal antibodies (sc-543) were applied to NC at quantities ranging 
between 200 ng and 1,200 ng to investigate whether the hERαLBD-f could be visualised in this manner.  
The membrane was blocked in casein after which it was incubated with 5 μg/mL hERαLBD-f for one hour 
at 37°C.  Once washed with PBST, the membrane was transferred to a solution of casein containing OD 0.3 
of a 0.20 mg/mL anti-ERh12-AuNP conjugate.  The membrane was incubated for four hours at 37°C, 
rinsed with PBST, dried and photographed. 




5.2.6.2 Capturing of receptor-AuNP-antibody complexes following migration under lateral 
flow 
A further requirement for the fabrication of a LFIA is the migration of antigens across the membrane 
element of the test to be captured at the test line.  The migration of hERαLBD-f across NC was visualised 
by chemiluminescence and AuNP.  First, sc-543 rabbit anti-ERα in PBS was applied as two 5 mm bands, 
containing 150 ng or 300 ng, onto a nitrocellulose membrane.  The membrane was blocked with casein, 
washed with PBST and dried.  Next, the bottom 5 mm of the membrane was suspended in a 3-mL PBS 
solution containing 5 μg/mL hERαLBD-f.  As control, a similarly treated membrane was suspended in a 
solution of hERαLBD-f pre-incubated for one hour at room temperature with 1 nM ERh12.  The solutions 
migrated up the membranes under capillary flow until completely saturated.  The membranes were washed 
as before and incubated at 37°C for one hour in 5 mL casein containing 1 μg/mL mouse anti-ERh12 
HA1A6.  Once washed, the membranes were incubated with 1:50,000 HRP-conjugated goat anti-mouse 
IgG in casein for one hour at 37°C.  Following washing chemiluminescence was initiated with Clarity ECL 
chemiluminescent substrate.  The chemiluminescent signal was photographed following exposure for 
25 minutes with a myECL digital imager. 
A single 5 mm band containing 250 ng sc-543 rabbit anti-ERα was also applied to NC, non-specific sites 
were block in casein and the membrane was washed and dried as before.  A pad of Whatman® no. 1 filter 
paper was affixed to the end of the membrane with a metal staple to serve as a wicking reservoir.  The 
bottom 5 mm of the membrane was suspended in a casein solution containing OD 0.6 of 0.20 mg/mL anti-
ERh12-AuNP conjugate.  The assembly was incubated at 37°C until a pink band was noticeable after 
approximately two hours. 
5.3 RESULTS AND DISCUSSION 
5.3.1 Purification of anti-ERh12 antibodies from HA1A6 cultures 
Depending on the source of antibodies, different techniques may need to be applied for their purification.  
Traditionally, physicochemical fractionation by means of ammonium sulphate precipitation, size-exclusion 
chromatography or adsorption chromatography using ion exchange resins or hydroxyapatite has been used 
for antibody isolation with various degrees of success (385). 
In general, very little of total IgG present in mouse serum is specific to the antigen used for immunisation.  
Therefore, the isolation and enrichment of specific antibodies from serum generally requires the use of 
antigen-specific affinity separation to prevent the co-purification of irrelevant or non-specific 
immunoglobulins.  In contrast, mAb produced in cell culture can be isolated without the need for antigen-
specific purification methodologies, since the target antibody is the only immunoglobulin produced.  
Affinity chromatography of mAbs from hybridoma cell culture growth media using S. aureus derived 




protein A or Group G streptococci derived protein G conjugated to Sepharose resin is a rapid and easy 
procedure which, in most cases, provide pure antibody preparations in a single chromatographic step. 
The affinity ligand contained in HiTrap™ Protein G columns is a recombinant protein that has been 
expressed in E. coli and coupled to Sepharose High Performance resin by the N-hydroxy succinimide 
activation method.  Native protein G contains an albumin binding region which may bind albumin from 
FBS-containing growth media.  This binding region has been deleted from the recombinant protein G 
protein, thus avoiding cross-reactions with albumin (386).  Protein G is preferable to protein A in the 
isolation of IgG1, since it exhibits greater affinity for the immunoglobulin.  Thus, being of the IgG1 isotype 
and subclass, high affinity murine anti-ERh12 HA1A6 antibody purification could be approached by 
affinity chromatography using Sepharose immobilised protein G.  Reproducible separation of the 
monoclonal immunoglobins was achieved in 20 minutes following sample application (Figure 5.2). 
 
Figure 5.2 Affinity chromatography of anti-ERh12 HA1A6 mAbs.  Chromatograms represent three independent 
purifications from hybridoma cell culture supernatant. 
Elution of antibodies from protein G requires lowering of the pH to 2.7 to alter the protonation state of the 
affinity protein, thus breaking the protein-protein interaction.  However, the harsh elution conditions may 
induce acidic conformational changes in the antibodies causing aggregation (387).  Antibodies were thus 
eluted into a volume of a high molarity Tris-HCl solution at pH 9.0 to prevent this.  Removal of unwanted 
buffer salts via dialysis compared to the use of desalting columns did not seem to impact upon antibody 
activity and was therefore the preferred method of buffer exchange (Figure 5.7). 
The total amount of purified antibody following purification was determined by means of the Bradford 
microtiter assay.  Yields of 2.20 mg/mL were obtained following buffer exchange and no contaminating 
proteins, apart from a feint high molecular weight band of unknown identity above 250 kDa, was observed 
during electrophoresis (Figure 5.3).  Protein G is much smaller at 17 kDa and was not observed on 
Coomassie stained gels and thus, no leakage of the ligand was observed from the affinity chromatography 
column. 





Figure 5.3 Analysis of anti-hERαLBD antibodies.  (1) Image of purified protein, 4.0 μg, electrophoresed on a 15% 
SDS-PAGE gel depicting apparent MW of 25 kDa and 50 kDa, the approximate sizes of antibody heavy 
and light chains.  (2) Antibodies of murine origin was confirmed by western blot with HRP-conjugated 
goat anti-mouse (heavy and light chain) IgG (1:1,000). 
5.3.2 Titration of purified anti-ERh12 HA1A6 monoclonal antibodies 
The functional titre of the purified antibodies, in relation to the hERα LBD proteins, was determined by 
indirect checkerboard ELISA (Figure 5.4).  Following purification of the antibody, the results obtained in 
chapter 4 for culture medium titrations was corroborated.  The purified anti-ERh12 antibodies are capable 
hERαLBD-f detection at lower dilutions than for the hERαLBD; 40 ng/mL compared to 80 ng/mL.  
Furthermore, the use of checkerboard ELISA also indicated that hERαLBD-f can be detected at lower 
concentrations of LBD protein than hERαLBD; 160 ng/mL versus 630 ng/mL. 
 
Figure 5.4 Checkerboard ELISAs of surface immobilised hERαLBD (left) and hERαLBD-f (right) detected with 
purified anti-ERh12 mAbs.  The red line indicates the functional titre of the antibody towards the 
respective proteins. 
  




In comparison to culture media supernatant, two-fold increases were observed for detection of both the 
hERαLBD and hERαLBD-f (Figure 5.5).  The functional titre of detection for the hERαLBD increased 
from 1:640 to 1:1,280, while the hERαLBD-f was still detectable at 1:2,560, or 100 ng anti-ERh12/mL. 
 
Figure 5.5 Determination of Ab titre.  Recombinant hERα LBD proteins, 5 μg/mL, were detected by indirect ELISA 
of anti-ERh12 HA1A6 culture media and purified preparation. Fold dilutions for both culture media 
supernatant and purified antibodies are given at the top of the image.  The concentrations indicated at the 
bottom refers to purified anti-ERh12 HA1A6 mAbs only. 
5.3.3 Detection of recombinant hERα LBD proteins by western blot 
Anti-ERh12 HA1A6 antibodies recognise a continuous epitope on the hERα LBD protein structure.  
Denaturation of the proteins with SDS and subsequent electrophoresis by SDS-PAGE and western blot 
indicate major band formation at the predicted sizes for the two recombinant proteins (Figure 5.6).  These 
bands correlate well with the banding patterns observed following western blot analysis of the proteins with 
a commercial anti-hERα antibody (Figure 3.2).  Lower molecular weight bands than the expected 35.2 kDa 
protein were also observed for the hERαLBD-f protein.  These bands may indicate some degradation of the 
protein following purification or storage.  However, considering that no degradation products are evident 
for the hERαLBD protein, which was treated in the exact same fashion, early cessation of translation during 
protein synthesis may be a feasible explanation.  Furthermore, these truncations are possibly localised in the 
C-terminal F-domain, since purification of the protein is accomplished by binding of the N-terminal 
histidine tag to the IMAC column.  In this image, a doublet band is evident relating to Hsp40 which was not 
evident on previous blots transferred from higher percentage gels.  The higher molecular weight band is due 
to the farnesylation of Hsp40 which occurs in all eukaryotic cells, including insect cells (388).  
Farnesylation of the co-chaperone has been shown to affect the overexpression of soluble recombinant 
proteins significantly by serving to localise Hsp40 to the endoplasmic reticulum and the perinuclear 
membranes (389). 





Figure 5.6 Image of a western blot of recombinant hERα LBD.  Proteins, 5.0 μg, were electrophoresed on a 10% SDS-
PAGE gel and transferred to nitrocellulose, which was exposed to co-incubation with anti-ERh12 
(1 μg/mL), anti-Hsp40 (1:10,000) and Hsc70 (1:1,000) antibodies. 
5.3.4 Conjugation of anti-ERh12 to colloidal gold nanoparticles 
AuNP is the most widely used label in commercial immunochromatographic flow assays.  It has an intense 
colour and generally no developmental process is needed for visualisation.  Moreover, it has high stability 
in both liquid and dried forms.  Although it can be prepared in the laboratory at low cost, there are many 
commercial sources available which specialise in its production, characterisation and functionalisation. 
InnovaCoat® Gold Carboxyl is a AuNP suspension of colloidal gold with a mean diameter of 40 nm to 
which carboxyl groups have been introduced by means of a proprietary coating.  According to Innova 
Biosciences (390), the coated AuNPs have been optimised for single step EDAC covalent coupling of 
proteins to the carboxyl moiety, without the aggregation that is traditionally associated with the process if 
N-hydroxy succinimide pre-activation is not employed.  To formulate an amide, EDAC reacts with 
carboxylic acid groups at pH 4.0 – 6.0 to form an active O-acylisourea intermediate (Figure 5.7).  The O-
acylisourea, which can be viewed as a carboxylic ester with an activated leaving group, is easily displaced 
by nucleophilic attack from primary amino groups in the reaction mixture, thus yielding the desired amide 
and an EDAC by-product, released as a soluble isourea derivative (391).  Moreover, the O-acylisourea 
intermediate can also react with an additional carboxylic acid to give an acetic anhydride intermediate and 
an isourea derivative.  The anhydride can react further with primary amines to also give the desired amide.  
However, since EDAC can mediate the formation of phosphoramidate linkages between phosphates and 
amines (367), the presence of inorganic phosphate moieties should be kept to a minimum during the 
reaction. 





Figure 5.7 Mechanism of carbodiimide mediated amide bonds formation.  The acid (1) will react with the 
carbodiimide to produce the key intermediate: An O-acylisourea (2), which can be viewed as a carboxylic 
ester with an activated leaving group. The O-acylisourea will react with amines to give the desired amide 
(3) and urea (4).  In a side reaction, the O-acylisourea (2) react with an additional carboxylic acid (1) to 
give an acid anhydride (5), which can react further to give the desired amide (3). 
Bearing this in mind, Hermanson (367) asserts that 100 mM sodium phosphate may be used as conjugation 
buffer to facilitate coupling reactions with EDAC, provided that the procedures are conducted under neutral 
conditions.  Once purified, mAbs were transferred to a 10-mM phosphate buffer for storage via 
chromatographic separation on Sepharose G-25 column or via dialysis.  The concentration of the purified 
antibodies was 2.2 mg/mL and, since the reaction is carried out at 0.05 mg/mL to 0.5 mg/mL, conjugation 
to carboxyl-modified AuNP by EDAC would probably not have been problematic.  However, as per the 
manufacturer’s instructions, optimal results are assured for antibody concentrations above 10 mg/mL if 
stored in PBS.  Consequently, the purified mAbs were concentrated using 10 kDa MWCO spin columns to 
concentrations exceeding 18.5 mg/mL.  As a result, the maximum amount of phosphate present during any 
conjugation reaction between anti-ERh12 and the carboxyl-modified AuNP was less than 150 nM. 
Once concentrated, it was prudent to establish whether the increase in concentration would affect the bio-
activity of the antibody for the recombinant proteins negatively (Figure 5.8).  Concentrated, dialysed and 
desalted antibodies were diluted to the equivalent concentrations and applied to an ELISA plate coated with 
5 μg/mL hERα LBD proteins.  No differences were observed between any of the mAbs for binding to the 
two recombinant proteins, apart from the continued greater recognition of hERαLBD-f. 





Figure 5.8 Indirect ELISA of recombinant hERαLBD and hERαLBD-f.  Proteins, 5 μg/mL, were detected with 
purified anti-ERh12 mAbs. 
Concentrated monoclonal antibodies were diluted in 10 mM MES to varying concentrations prior to 
assembly of the reaction mixtures to facilitate the conjugation reaction in the presence of diminished levels 
of interfering substances.  Following two hours incubation, further reaction was quenched by the addition of 
the primary amine-containing buffer salt, Tris, thus excess EDAC was bound while simultaneously raising 
the pH to physiological levels.  Rapid addition of the quenching buffer, however, resulted in some 
precipitation of elemental gold from solution (Figure 5.9).  By slow addition of TBST to the reaction vial 
the formation of a metal film could mostly be reduced, even though some of the AuNP clearly still adhered 
to the polypropylene sides. 
 
Figure 5.9 Photograph of a conjugation reaction between mAbs and AuNPs.  Rapid addition of TBST resulted in the 
precipitation of a thin film of elemental gold on the liquid surface.  Dropwise addition of the buffer reduced 
the formation of the elemental metal to a minimum. 
  




5.3.4.1 Confirmation of mAb conjugation to AuNP 
5.3.4.1.1 Gel retardation assays 
Gel electrophoresis is a common analytical technique that separates macromolecules or particles based physical 
characteristics such as size, shape and charge.  Since these molecular features affect the migration of a particle within 
the gel matrix, gel electrophoresis is a rapid and easy method to assess surface modification of AuNPs.  Furthermore, 
due to the distinct colour of the particles, migration of the particles in the matrix can be observed directly.  The 
conjugation of proteins to the AuNP surface increases the molecular volume of the conjugate as compared to the 
native particles, thus a retardation of the migratory behaviour can be detected.  Furthermore, the method can be used in 
the optimisation of conjugation conditions by revealing the point of saturation beyond which increased loading of 
proteins causes no further migration shift of the band.  Figure 5.10 indicates the migration shifts observed during 
agarose gel retardation assays conducted following mAb conjugation to AuNP.  The inverse correlation between 
increased protein concentration during conjugation and decrease in migration distance through the gel due to an 
increase in size and alterations to the negative charge of the conjugate, can be seen – note the change in migration 
pattern between the native particles in lane 1 and antibody functionalised samples in lanes 2 – 5.  Inclusion of the 
chaotropic detergent SDS in the system not only denatured the conjugated mAbs but also served to indicate that 
covalent bonds between the protein and AuNP did indeed form since disruption of non-covalent linkages would result 
in similar migration patterns for all particles. 
 
Figure 5.10 Agarose gel analysis of 40 nm colloidal gold functionalised covalently with anti-ERh12 HA1A6 mAbs.  
Lane 1: native particles; lanes 2 – 5: 0.10 mg/mL, 0.15 mg/mL, 0.20 mg/mL and 0.25 mg/mL antibody 
functionalised conjugates.  




5.3.4.1.2 Confirmation of covalent surface functionalisation by means of ATR-FTIR 
Covalent bond formation was further confirmed by the differential ATR-FTIR spectra obtained for the 
naked AuNP and biofunctionalised conjugate (Figure 5.11).  In the absence of the protein coating, a 
prominent broad O-H stretch is observed between 3,200 cm-1 and 3,700 cm-1 indicating the presence of a 
carboxylic acid functionality (Figure 5.11, black).  The presence of the carboxylic acid moieties on the 
naked particles are further confirmed by the C=O stretch at ~1,630 cm-1.  Following conjugation, however, 
these prominent transmission peaks are depressed and instead the emergence of stretches indicative of the 
presence of amides are observed.  In the conjugate trace (Figure 5.11, blue), an amide A stretch at 
~3,170 cm-1 is visible along with amide I, II, and III stretches, respectively at ~1,630 cm-1, 1,550 cm-1 and 
1,290 cm-1, indicating the presence of peptide bonds and thus, protein. 
 
Figure 5.11 ATR-FTIR spectra of native InnovaCoat® Gold Carboxyl AuNP (black) and particles conjugated to anti-
ERh12 HA1A6 mAbs (blue).  The characteristic O-H stretch (1) of the carboxylic acid moiety on the naked 
particles, as well as the C=O stretch (2) disappears following conjugation.  In the spectrum for the 
conjugate, stretches indicating the presence of amides (3 – 6) is visible while a noticeable increase in C-H 
stretch (7) absorption occurred. 
5.3.4.2 Spectroscopic determination of conjugate concentration 
The concentration of AuNP needs to be determined to enable their use in immunoassays.  Localised surface 
plasmon resonance induces a strong absorption maximum in 40 nm AuNPs at approximately 530 nm.  The 
concentration of particles in solution can resultantly be inferred by spectrophotometry since the collective 
oscillations of surface plasmons increase as the particle density increases.  Indicated in figure 5.12 are the 
absorbance spectra obtained for non-functionalised AuNP and conjugates produced from different 
concentrations of mAb.  The concentration obtained is only dependent on the number of particles in 
suspension and is not influenced by the surface functionalisation.  Each of the conjugates were diluted 
20-fold for calculation of their respective OD.  InnovaCoat® Gold Carboxyl was diluted 40-fold to yield an 
OD of 1.0, serving as a reference for the accuracy of the determination.  The calculated OD from the 
measured absorbance at peak maximum is presented in table 5.1. 





Figure 5.12 Absorbance spectra for naked AuNP and AuNP conjugates. 
The obtained spectrum is dependent on both the size and shape of the particles.  Larger diameter particles 
incur an increase in peak absorbance wavelength due to alterations to the resonance of surface plasmons.  
Similarly, a shift in peak absorbance can also be used to evaluate the surface functionalisation of the 
AuNPs.  Conjugation of proteins to the AuNP surface leads to an increase in the molecular volume of the 
particle.  Thus, a shift in the total local refractive index occur at the AuNP particle surface which is 
visualised as a small red shift during spectrophotometry.  Following conjugation of mAbs to the particle 
surface, a marginal red shift from 527.5 nm to 528.0 nm was observed for particles functionalised with 
0.200 mg/mL and 0.250 mg/mL. 
Table 5.1 Absorbance maximums (nm) and concentration determinations for AuNP-mAb conjugates from spectral 
scans between 800 nm and 400 nm. 
 Anti-ERh12 HA1A6 AuNP conjugate InnovaCoat® 
Gold 
Carboxyl  0.100 mg/mL 0.150 mg/mL 0.200 mg/mL 0.250 mg/mL 
Absorbance 
maximum 
527.5 527.5 528.0 528.0 527.5 
Absorbance 0.906 0.950 0.762 0.873 1.016 
Dilution 20 20 20 20 40 
OD 18.1 19.0 15.2 17.5 40.6 
  




5.3.5 Visualisation of recombinant hERα LBD proteins with anti-ERh12-AuNP 
Various bioassays utilise AuNP-antibody conjugates as molecular probes.  It is therefore not only important 
to ensure a stable conjugation has taken place but also to confirm that the conjugate retained the bioactivity 
of the antibody.  The simplest method to achieve this is via immunoblotting.  Therefore, the ability of the 
conjugates to detect the hERα LBD proteins was initially investigated by direct application of the 
recombinant proteins to nitrocellulose, followed by visualisation of the protein bands by concentration of 
the conjugates to the applied bands.  As can be clearly seen in figure 5.13, anti-ERh12 HA1A6 mAbs 
retained binding activity to the hERα LBD proteins following covalent conjugation to AuNPs.  However, 
the level of recognition of the hERαLBD-f in comparison to the hERαLBD is striking.  Previous 
investigations of the interaction of the mAb with the recombinant proteins during ELISA and 
chemiluminescent immunoblotting did reveal the difference in binding activity.  Yet, the sensitivity of those 
analysis seems to have masked the immense disparity of detection between recognition of the two proteins 
by the same mAb.  Band formation can be observed for the hERαLBD-f as low as 25 ng, even for the 
0.100 mg/mL conjugate, albeit the colour intensity is feint.  Conversely, the lowest level of detection for the 
hERαLBD by the human eye was at 125 ng, with some indication of protein presence down to 50 ng 
following incubation with the 0.200 mg/mL and 0.250 mg/mL conjugates. 
 
Figure 5.13 Digitally enhanced immunoblots of recombinant hERα LBD proteins.  Clear distinctions are observable for 
the detection of the hERαLBD-f over the hERαLBD, with visual detection limits of 25 ng and 125 ng, 
respectively, at higher conjugated concentrations. 
Using densitometric analysis following digital imaging of the immunoblots, both proteins could be detected 
above background to 25 ng (Figure 5.14).  All curves were normalised against the highest signal recorded 
and fitting of a one-site binding model to the data revealed that no distinction can be made between 
detection of either the hERαLBD or the hERαLBD-f at the two highest conjugate concentrations.  However, 
marked differences were observed in the colourimetric signal generated at higher quantities of protein, 




especially regarding the hERαLBD-f.  All subsequent analyses were thus performed with conjugates 
produced with 0.200 mg/mL purified antibody.  
 
Figure 5.14 Densitometric curves produced from single value pixel densities of hERαLBD (left panel) and hERαLBD-f 
(right panel) blots developed with AuNP labelled anti-ERh12 mAbs. 
To improve the strength of analysis obtained from the results presented in figure 5.13, replicate 
immunoblots were produced for the detection of recombinant protein by including more data points at 
concentrations between 12.5 ng and 400 ng.  Since no difference was observed in the detection of the hERα 
LBD proteins by the two higher concentration conjugates, the experiment was conducted with the 
0.200 mg/mL conjugate (Figure 5.15).  hERαLBD-f was clearly visualised at 12.5 ng protein; the signal 
observed for hERαLBD was poor in comparison with nearly three-fold less pixel density recorded at the 
highest protein quantity tested (Figure 5.16). 
 
Figure 5.15 Immunoblot of replicate protein bands of hERα LBD proteins detected with anti-ERh12-AuNP. 





Figure 5.16 Densitometric data represented as binding curves.  Data were normalised against the calculated maximal 
obtainable pixel volume of the hERαLBD-f by fitment of a one-site specific binding model. 
The differential detection by the same mAb of analogous proteins, differing by only 42 amino acid residues, 
raises certain questions.  During selection of the HA1A6 strain, both the synthetic peptide and the 
hERαLBD were used as screening tools.  Detection of the hERαLBD-f protein by the mAb was only 
performed once the strain had been established.  It is therefore unlikely that anti-ERh12 HA1A6 
preferentially binds to an epitope that is only partially available at the C-terminal of H12 of the LBD and 
fully present when the additional F-domain is present.  Furthermore, the H18K amino acid substitution 
would result in selection against an epitope that is located at the very C-terminal end of H12 during 
screening with the hERαLBD.  A logical conclusion can therefore be drawn that the additional F-domain 
imposes a conformational bias on H12 which exposes the binding epitope to anti-ERh12 HA1A6. 
The effect that the F-domain has on the activation of the receptor by various ligands, endogenous and 
otherwise, has been reported previously (298, 299, 392).  However, to the best of our knowledge the 
consequences of the presence of the F-domain on the molecular structure of the LBD has not been reported 
in literature.  A search of the RCSB Protein Data Bank (393) reveals that attempts at the crystallisation of 
recombinant forms of the receptor has, to date, only been performed with truncated forms of the LBD.  
Moreover, no nuclear magnetic resonance studies have been undertaken to investigate structural 
characteristics in solution.  The increased availability of this epitope supports the idea that the F-domain is 
naturally involved in an intra-receptor interaction which allows presentation of H12 to the solvent 
environment (299).  Models describing receptor activation, such as the mousetrap model, have focussed on 
the allosteric shift of H12 following receptor activation within an otherwise stable LBD structure.  
However, the specific translocation of the F-domain in relation to the LBD surface is yet to be elucidated.  
What is currently known is that the additional domain affects the binding of coregulatory elements in a 
ligand-specific manner.  In transactivation assays, deletion of the C-terminal domain altered the activation 
behaviour towards the receptor by antagonists (298, 299, 392, 394) and mutations of H12 or the F-domain, 
or complete deletion thereof, results in interference of co-regulator recruitment following agonist or 




antagonist binding (299, 395, 396).  Moreover, the domain is known to impact upon receptor dimerisation 
(306, 394). 
Furthermore, as far as we are aware, the mAbs produced in the current study are the first that have been 
specifically targeted at H12 of the hERα LBD.  Thus, it would be interesting to see whether anti-ERh12 
could inhibit coactivator recruitment in the presence of ERα agonists.  Such considerations, however, fall 
outside of the current purview of this study. 
5.3.6 Capturing of hERαLBD-f and visualisation of the protein by anti-ERh12 mAb 
5.3.6.1 Sandwich capture from solution 
The LFIA format requires the migration of an analyte across the membrane to be captured by a second 
binding partner immobilised at the test line.  Triplicate bands containing between 200 ng and 1,200 ng of 
commercial polyclonal anti-hERα antibodies (sc-543, which has been raised against an epitope at the very 
C-terminal of the hERα) were applied to nitrocellulose membrane to show that the recombinant 
hERαLBD-f can be captured in such a fashion.  Incubation of the membrane with the recombinant protein 
and subsequent application of the anti-ERh12-AuNP conjugate led to the development of distinct red bands 
indicating the successful capture of the protein from solution (Figure 5.17). 
 
Figure 5.17 Visualisation of hERαLBD-f protein captured in a sandwich format between commercial anti-hERα 
antibodies and anti-ERh12 HA1A6 AuNP mAbs. 
  




5.3.6.2 Capturing of receptor-AuNP-antibody complexes following migration under lateral 
flow 
In the development of any immunochromatographic assay utilising lateral flow, effective migration of the 
analyte across the test membrane is of course a prerequisite.  Thus, the movement of the protein across NC 
and its capture by a membrane-immobilised anti-hERα antibody was approached in the presence and 
absence of an AuNP labelled mAb (Figure 5.18). 
 
Figure 5.18 Blot analysis of migration and capture of the hERαLBD-f protein by immobilised anti-hERα antibodies 
following migration across nitrocellulose.  A: Pre-incubation of anti-ERh12 antibodies with the synthetic 
peptide; B: incubation of the membrane with mAb in absence of peptide; and C: co-incubation of the 
hERαLBD and AuNP labelled mAb. 
As can be seen from figure 5.18, the hERαLBD-f protein migrated across the membrane to be bound by the 
commercial antibody.  During the use of post-migration detection with chemiluminescence, both the 150 ng 
and 300 ng band indicated the presence of the recombinant proteins (Figure 5.18, panel B).  When pre-
incubated with the ERh12 peptide, however, the anti-ERh12 mAb could not bind the H12 epitope of the 
hERαLBD-f and therefore no signal was observed (Figure 5.18, panel A).  Moreover, co-incubation of the 
hERαLBD with labelled mAbs prior to protein migration resulted in the formation of a single band at a 
position on the nitrocellulose membrane to which 250 ng sc-534 anti-hERα antibodies had been applied 
(Figure 5.18, panel C). 
5.4 CONCLUSION 
Molecules used for biorecognition form a central part of all LFIA devices.  This chapter described the 
purification of anti-hERα specific mAbs from hybridoma culture media and the subsequent 
functionalisation of these antibodies with colloidal AuNP.  The unique properties of AuNP, which include 
their well-characterised surface chemistry, low toxicity and easy synthesis have promoted their use in a 
variety of biomedical and analytical applications.  Traditional methods utilised for the conjugation of 
antibodies to AuNP, however, requires extensive optimisation of reaction conditions to facilitate passive 
conjugation by means of electrostatic and hydrophobic interactions.  Moreover, these non-covalent binding 




interactions have numerous significant weaknesses including a requirement of high concentrations of 
antibody for the preparation of conjugates, random orientation of antibodies at the AuNP surface and since 
permanent bonds are not formed the interaction can be broken by other molecules in sample fluids and 
down-stream reaction conditions.  On the other hand, covalent attachment provides greatly increased 
conjugate stability over passive adsorption, since the antibody becomes permanently bound to the 
nanoparticle and is unable to detach from it. 
Binding activity at the test and control lines is a defining factor in LFIA development.  The typical binding 
capacity of NC for IgG is more than 100 μg/cm2 (38).  However, when antibodies are used in a test line in 
an immunometric LFIA, they are normally applied at a ratio of 1.0 – 3.0 μg per centimetre across the width 
of the strip.  A 4.0 mm lateral flow strip with a test zone of 1.0 mm and a relatively shallow bed volume of 
0.13 μm will therefore contain between 4.0 and 12.0 μg antibodies (168).  Assuming a mean application of 
8.0 μg capture antibody at the test line, with a 75% activity retention following immobilisation, 
approximately 6.0 μg antibody would be available to bind a maximum 2.8 μg hERαLBD-f in the assay 
format proposed in figure 5.1.  hERαLBD-f, with a Bmax of 3.312 fmol/mg protein would therefore require 
9.3 pmol high affinity ligand to lead to saturation of the LFIA system.  Considering that the hERαLBD-f 
protein could be effectively visualised with AuNP-mAbs following capture to 250 ng sc-534 anti-hERα 
antibodies immobilised to NC (Figure 5.18), an LFIA utilising recombinant receptor LBD may be highly 
effective at the indication of EDCs in concentrated environmental samples. 
  





General conclusions and future perspectives 
6.1 INTRODUCTION 
Many chemicals are released into the environment due to industrial, agricultural, medical and municipal 
practices, poor waste management, and lacking infrastructure (267).  Increasingly, the presence of 
compounds that were not traditionally viewed as environmental contaminants are being detected in soils, 
sediments, groundwater and ecosystems far removed from their original sites of production or use (268).  
These EPs encompass a wide array of natural and man-made chemicals, including medical and veterinary 
pharmaceuticals, hormones, pesticides, cosmetics, personal and household care products, industrial 
compounds and others.  Even though a mass of scientific data highlighting the potential threats posed to 
public and environmental health has been collected over the last decades, limited information concerning 
the ecotoxicity, concentration, and distribution of most of these compounds are available, severely 
confounding their ecological regulation, detection, and removal.  Many of these compounds are routinely 
identified in water sources and waste effluents destined for reticulation to points of human consumption.  
Moreover, since several of these compounds have been shown to elicit physiological responses via 
endocrine mechanisms, elucidation of their chemical identity and biological activity is important to 
facilitate the formulation of successful remedial action plans. 
The endocrine system is responsible for the regulation of vitally important processes within the human 
body.  These processes include growth and development, homeostasis, cell differentiation, osmoregulation, 
reproductive function, as well as neurological function and metabolism.  The neuroendocrine system is a 
vast, intricately interconnected web of intra- and extracellular signal transducing receptors which regulate 
biochemical processes at cellular and organismal levels via their interaction with cognate ligands.  
Structural complementarity of a ligand to the three-dimensional arrangement of the LBP results in high 
affinity coordinated binding between the two molecules.  As a result, hormones elicit cellular events at very 
low concentrations.  However, with increasing global industrialisation and the increased usage of chemicals 
in industry, commerce and agriculture, research into the fate of these chemicals has revealed a growing 
body of evidence as to their effect on biological systems (10, 271–273).  Consequently, a specific class of 
these compounds, which exhibits deleterious effects on the endocrine system, has come to light.  EDCs are 
natural and synthetic compounds that can disrupt the endocrine system.  Resultantly, the US-EPA defines 
these compounds as: “exogenous agent(s) that interferes with the synthesis, secretion, transport, binding, 
action, or elimination of natural hormones in the body that are responsible for the maintenance of 
homeostasis, reproduction, development, and/or behaviour” (269). 




The link between developmental irregularities and man-made EDCs has been extensively documented in 
both humans and wildlife (4–13).  Human exposure to EDCs can lead to various diseases and syndromes.  
Examples include a decrease in sperm count and sperm quality, hypothyroidism, cryptorchidism, 
hypospadias, malignancies in the male and female reproductive tracts, as well as tumours of the breast and 
other cancers.  The potential biological effect of EDCs is known to occur at concentrations ranging from 
parts per billion to parts per trillion (397).  An accurate and efficient testing method therefore needs to be 
developed to allow for the detection of EDCs in reservoirs that serve as sources of water for human and 
animal consumption.  Current research has inclined towards studying the effects of EDCs on sex hormone 
receptors, i.e. the ER and AR, with compounds which can potentially interfere with ER and AR activities 
respectively designated as oestrogenic and androgenic EDCs. Several other routes of endocrine disruption 
have also been described, including xenobiotic modulation of other nuclear receptors which govern the 
molecular actions of the progestins, mineralocorticoids, glucocorticoids, thyroid hormones and ligands 
which bind the aryl hydrocarbon and peroxisome proliferator-activated receptors.  Moreover, numerous 
studies have indicated the disruptive actions that exogenous compounds may have on the activity of 
enzymes involved in signalling pathways and hormonal conversion (7, 279, 398, 399).  Considering the 
complexity of the endocrine system and the possible interactions of EDCs at every biological level, four 
general mechanisms of EDC interaction with the endocrine system are: by mimicking endogenous 
hormones, antagonising the effects of endogenous hormones, disrupting the synthesis and metabolism of 
endogenous hormones and disrupting the synthesis of the hormone receptors.  The current project focussed 
on the utilisation of the ER in the production of a novel EDC detection system. 
EDCs are defined by their biological activity, not necessarily by their chemical structure, and there are 
several shortcomings involved in the use of conventional analytical techniques, such as mass spectrometry 
or nuclear magnetic resonance, commonly employed in chemical analysis.  A relevant deficiency of 
conventional analytical techniques in EDC analysis is that no information about potential endocrine 
disrupting activity can be determined from a compound if no prior research has indicated that it is capable 
of endocrine disruption.  Other relevant examples of shortcomings include, but are not limited to, chemical 
compounds may have EDC activity at levels lower than the accepted ‘No Observable Adverse Effect 
Level’, analytical techniques are unable to determine the effects of a combination of EDCs and the 
expertise, cost and time required to operate technical equipment and the unfeasibility of rapid, on-site 
testing.  This does not mean that such techniques are not important in the monitoring of EDCs.  In fact, 
traditional analytical techniques play a vital role in the validation of biological assays.  Current research in 
EDC detection and monitoring has tended to move towards in vivo- or in vitro-based biological assays.  
Most in vivo detection methods use rodents or aquatic animal species and function by exploiting cellular 
mechanisms sensitive to EDCs (e.g. cellular proliferation, reproductive changes and VTG induction).  In 
vitro-based assays, on the other hand, make use of ligand-binding, reporter molecules such as luciferase and 
immunochemical methods which employ antibodies.  These assays may be qualitative or quantitative.  In 
vitro assays are extremely relevant in the rapid detection of small molecules and assessment of their 




endocrine disruptive capabilities.  However, these methods require access to laboratory infrastructure which 
is generally not available in rural or resource limited locations. 
6.2 PROTEIN PRODUCTION 
The ability to recombinantly express and purify nuclear receptor proteins with which EDCs interact enables 
the rapid screening of compounds for possible endocrine activity.  In contrast to work conducted by other 
research groups (400–403) which have reported the functional expression of truncated hERα derived 
proteins in prokaryotic production platforms such as E. coli, research in our own laboratory have found that 
the hydrophobic nature of these proteins severely limited the quantities which could be produced in a 
soluble state, even following extensive optimisation of induction and lysis conditions (15).  Transferral of 
the DNA encoding these gene to the baculovirus genome thus allowed for the expression of soluble hERα 
LBD proteins in eukaryotic cells in which the transcription machinery closer resemble that of human cells.  
The association between steroid receptors and Hsps and their roles in regulating the assembly, trafficking 
and transcriptional activity of hERα have been documented in the past, with the association with Hsp90 
receiving much attention (275–277, 404–406).  In general, the association between steroid receptors and 
Hsps are mostly weak and transient in nature (405).  Yet, as described by Pratt and Toft (275), Hsc70, 
unlike Hsp90, remains associated with the LBD of steroid hormone receptors in the presence of high salt 
concentrations and ligand.  This observation was confirmed during this study since it was found that the 
recombinant receptors remained in complex with Hsps following purification.  Most notably, the F-domain 
containing construct, hERαLBD-f, exhibited greater association with Hsc70 as compared to hERαLBD.  
However, interestingly the greater association of Hsp70 with hERαLBD-f did not lead to a concomitant 
increase in the levels of Hsp40 observed on western blots.  In fact, from the results presented in figure 5.6, 
the co-chaperone Hsp40 does not seem to favour association with one recombinant protein over the other.  
Proteomic studies by Dhamad et al. (407) recently revealed that Hsc70 is one of four predominant Hsps that 
associates with wildtype hERα in MCF7 cells.  Interestingly, they found that Hsp40 was not abundant in 
complexes involving hERα.  However, where Hsp40 was detected in such complexes, its interaction with 
the hERα appeared to occur indirectly via Hsp70 only.  Following an in-cell protein cross-linking method, 
Dhamad et al. proposed that over and above non-specific hydrophobic interaction commonly associated 
with Hsc70, the association between the chaperone and hERα can also occur in a site-specific manner 
(407).  Due to the greater association observed with the hERαLBD-f, the results obtained from this study 
may suggest that such a specific interaction could be localised to the F-domain of the receptor. 
6.2.1 Ligand-binding activity 
Heat shock proteins are essential for the normal functioning of steroid hormone receptors since these 
chaperones maintain their ‘client’ proteins in a correctly folded and ligand responsive state (406).  In this 
study, radioligand-binding assays were adapted to 96-well formats to rapidly, accurately and reproducibly 
indicate the ligand-binding capabilities of compounds to the two heterologously expressed hERα LBD 




proteins.  The truncation of the 42 additional amino acid residues constituting the F-domain of the hERα 
resulted in a slight loss in affinity of approximately 1.5-fold for the natural ligand, E2 (KD = 1.525 nM as 
compared to 0.9688 nM for hERαLBD-f).  Interestingly, the ratio of Bmax values calculated for the two 
proteins also equated to an estimated 1.5-fold increase in the maximum binding capacity of hERαLBD 
versus hERαLBD-f for the same concentration of protein.  The seemingly reciprocal change in binding 
behaviour, however, equates to roughly the same BP for E2.  Not only does the F-domain mediate 
transcriptional responses via modulation of coregulator recruitment depending on ligand identity (301), it 
also seems to act as gatekeeper for access of ligand to the LBP of the LBD.  Therefore, absence of the F-
domain from the hERαLBD may allow unencumbered access to the LBP, thus increasing the total amount 
of ligand molecules bound at any given time.  Yet, the turnover rate of these binding events may be much 
greater in comparison to the hERαLBD-f, for which binding events may be slower to occur but more stable 
due to the conformational stabilisation afforded to the protein structure by intra-protein molecular binding.  
This trend was also observable during competitive binding assays.  Compound KIs for binding to the 
hERαLBD-f were generally lower than for the hERαLBD, indicating that in all cases, bar BPA, the strength 
of binding was enhanced by the additional C-terminal domain of the receptor. 
It was subsequently also shown that these receptors could be used in the biofunctionalisation of synthetic 
membranes for the specific sequestration and concentration of compounds with ER binding capabilities.  
The principle of non-covalent immobilisation of truncated steroid receptors forms a central part of the 
conformation-change EDC detection method envisaged in this project.  The directional binding of histidine-
tagged hERαLBD to the PVP-PSMI membrane and ability of the immobilised receptor to bind E2 was 
investigated by scintillation counting and competitive binding assays were conducted to determine the 
ability of the immobilised receptor to bind two known EDCs, DES and BPA.  The immobilised hERαLBD 
maintained steroid binding capabilities, a proportional level of radioligand-binding was observed upon an 
increase in protein charging of the affinity membrane, and the hERαLBD bio-functionalised PVP-PSMI 
membrane proved successful in the sequestration of the two model estrogenic EDCs during competitive 
ligand-binding experiments.  Even so, these assays still necessitate access to a laboratory and other forms of 
expensive infrastructure, while requiring multiple reaction steps and prolonged incubation periods prior to 
generation of a result.  One of the chief aims of this thesis, therefore, was to investigate possible alternatives 
to laboratory-based assays for EDC detection by producing reagents which may be used in biologically-
based devices.  In principle, such membranes should be useful in environmental monitoring provided a 
reliable, safe and economical visualisation method can be developed. 
  




6.3 PROTEIN CONFORMATION-DEPENDENT EDC DETECTION BY MEMBRANE 
DIPSTICK 
Several studies describe the successful generation and isolation of mAbs which recognise three-dimensional 
epitopes on protein surfaces; i.e. proteins must be correctly folded and in the correct conformation for 
antibody-binding to take place.  Antibodies that recognise discontinuous epitopes have therefore been 
applied to the study of aggregation-state pathologies in amyloid-related and infectious diseases (408–413), 
cancer (414), enzymology (415, 416), toxicology (417) and genetics (418). However, very few examples 
exist of antibodies that can discern an alteration to the three-dimensional conformation of a protein which is 
not concomitant with a physical modification to the protein structure.  By immunising test animals with 
polylysine-coupled peptides relating to the μ-opioid receptor, Gupta et al. (419) raised receptor specific 
mAbs to regions proximal and distal to the N-terminal domain of the protein.  Recognition of the proximal 
region could be significantly increased by treatment of cells transfected to express the receptor with 
agonists, but not antagonists.  The gain in fluorescence observed in receptor recognition following 
activation could, however, be reduced to baseline levels by incubation with peptide:N-glycanase, which 
suggests that receptor glycosylation is required to induce the conformational switch needed for increased 
antibody binding.  Yet, even in the absence of agonists, some detection of the receptor still occurred with 
OD490 of approximately 0.4 for untreated controls.  By immunoprecipitating radioligand-PR complexes, 
Weigel et al. (344) could clearly show decreased recognition by a PR-H12 mAb towards the PR in the 
presence of an agonist (approximately 10% that of the control antibody).  Although not as sensitive in 
analysis, the immunoprecipitated complexes still yielded around 50% of the signal generated by unliganded 
or antagonist-bound PR when examined by autoradiography western blots.  In this study, a mAb against the 
twelfth helix of the hERα LBD, HA1D4, could also discriminate between the E2-bound and apo-state of 
hERαLBD-f when analysed by ELISA; 67% in the agonist-treated sample as compared to the no-ligand 
control.  Yet, when the same samples were visualised with chemiluminescent immunoblots the difference 
could not be distinguished with the naked eye (Figure 4.18).  Considering the requirement for visual 
discernment of results in the development of a colourimetric EDC detection assay, the mAbs produced 
during this inquiry proved to be insufficient. 
Selection of mAbs is an extremely labour-intensive process and no guarantees can be submitted that the 
intended hybridoma clone will be identified at the end.  Epitope mimicking techniques such as phage 
display (420–423) or peptide stapling (370, 371) may in future be viable options to enable the identification 
of mAbs capable of detecting one conformational state without cross-reaction to another.  At present, 
however, such antibodies have proven elusive.  Yet the principle of an EDC detection method based on the 
alteration of NR LBD conformation following ligand-binding is still valid.  The interaction between nuclear 
receptors and coregulatory proteins have been described in multiple publications (22, 424–428).  Nishikawa 
et al. (429) applied three methods exploiting the interaction between the ER and steroid receptor 




coactivators to assess EDC binding: a yeast two-hybrid assay, a GST pull-down assay and surface plasmon 
resonance.  In the yeast two-hybrid assay and in vitro binding studies alike, the coactivators RIP140, 
SRC-1, TIF1 and TIF2 all interacted with the ERα in a cognate agonist-dependent manner.  Subsequently, 
Nishihara et al. (430) utilised the TIF2 two-hybrid assay to rapidly screen 517 compounds for ERα binding 
capacity enabling the establishment of theories regarding common structural elements of oestrogenic 
compounds.  However, apart from a requirement to culture yeast cells, a disadvantage to the method is the 
potential for false negative results due to exclusion of chemicals from the cytosol by membrane transport 
mechanisms.  An in vitro dipstick assay utilising a coactivator protein as indicator of ligand-binding would 
not suffer this drawback.  Furthermore, expression and purification of recombinant coregulatory proteins 
would abolish the need to raise highly specialised and elusive mAbs against a conformational epitope on 
the LBD surface.  Coregulatory proteins may either be conjugated to nanoparticles, expressed as fusion 
constructs with enzymatic reporters or probed by immunochemical methods to visualise the protein-protein 
interaction.  Moreover, by employing corepressor proteins such N-CoR and SMRT as conformation 
indicators (328, 431–433), it may be possible to distinguish between agonists and antagonists; although in 
vitro evidence suggests weak physical interaction between agonist bound hERα LBD and corepressors 
(434) .  Alternatively, recombinant proteins engineered to contain αII-motifs or other peptide sequences in 
lieu of the LxxLL-nuclear box may indicate ligand-binding irrespective of chemical agonism or antagonism 
(25). 
6.4 LATERAL FLOW IMMUNOCHROMATOGRAPHIC ASSAY 
One other receptor-based assay has been developed by McKim (435) who recently registered a patent for a 
column-based EDC detection system utilising recombinant receptors attached to a solid bead support.  The 
IONTOX endocrine field tester employs a column filled with beads to which hormone receptors had been 
attached.  The immobilised receptors are charged with a cognate ligand prior to the application of sample 
fluid to the column.  Displacement of the cognate ligand by EDCs in the sample results in elution of the 
ligand from the column.  In a collection vial, a ligand responsive reagent causes a colour change or other 
measurable response proportionate to the amount of hormone present.  Numerous compounds have been 
described which yield coloured products when reacted with sterols.  Reagents such as the Liebermann-
Burchard (H2SO4-Ac2O-HOAc), Zak (H2SO4-HOAc-Fe3+) and others have been implemented historically in 
the development of thin-layer chromatography analyses of steroids (436–438).  The redox reactions 
involved in such analyses may not translate well to use in a LFIA format; yet, the competitive displacement 
of steroids bound to NR LBDs could be adapted to indicate the presence of EDCs in a membrane-based 
system.  In this study, displacement of 3HE2 was used to prove that recombinant hERα LBD could bind 
multiple compounds of diverse chemical origins.  Thus, as presented in figure 5.1, a competitive-
immunometric assay may assembled by transient immobilisation of NR LBDs to a region immediately 
proximal to the sample addition pad of a LFIA strip.  Displacement of recombinant receptor LBDs by 
EDCs in sample fluid can be detected with labelled anti-LBD antibodies at the test line.  Alternatively, the 




receptor itself may be labelled and used as reporter molecule when stored at the conjugated pad 
(Figure 6.1).  As with traditional competitive LFIA, capture of unliganded NR LBDs may subsequently be 
facilitated by cognate ligand immobilised at the test line.  In this way, the quantity of EDC in the sample 
will be inversely proportional to the signal generated.  Furthermore, multiple cognate ligands may be 
immobilised at the test zone, with various affinities for the NR LBD in question.  Thus, an indication of the 
severity of EDC contamination may be gathered from the intensity of the lines formed at positions to which 
ligands of known affinity had been immobilised.  In the absence of ligand in the sample liquid, all lines 
would be expected to have the same depth of colour.  However, as EDC load in the sample increases, a 
decrease of line intensity will be observed, starting with the position where low affinity ligands are 
immobilised.  The mAbs produced during this study, being of high affinity towards the hERα LBD, would 
thus be a source of antibodies which can be used at the control line.  Yet, the diversity of LFIA construction 
may allow for multiple modes to analyse EDC interaction with receptor LBD.  As with dipstick assays, the 
utilisation of coregulatory proteins as binding partners to LBDs following ligand-binding may also be a 
viable option to exploit in EDC LFIA design. 
 
Figure 6.1 A format of LFIA for the detection of hormonally active compounds based on competition between 
xenobiotics in sample fluid and immobilised cognate ligands at a test zone.  Multiple ligands with varying 
degrees of receptor affinity may be applied, allowing differential analysis of EDC affinity.  As a control, 
anti-receptor antibodies are immobilised at the control line.  Resultantly, positive test results (middle panel) 
generated by multiple competitive reactions may be used in quantitation of environmental EDC load in 
relation to ligands of known activity (such as E2 or BPA equivalents).  Conversely, no differentiation 
should be observed between test and control lines when negative results are to be recorded (bottom panel) 
since all control lines should reach saturation in the absence of EDCs. 




6.5 COMPARISON BETWEEN THE TWO MEMBRANE-BASED ASSAYS 
Depending on the geographical location, multiple sources contribute to the continual augmentation of 
environmental EDC load.  Continuous exposure to the elements, dilution within large areas and microbial 
metabolic action naturally degrade these compounds over time.  Yet, the persistent nature of many of these 
organic pollutants results in constant exposure, concentration in trophic levels of the food chain and 
bioaccumulation in animals.  Even so, most analytical techniques are generally not sensitive enough to 
directly detect compounds in sample matrices.  Thus, from aqueous environments especially, where 
chemical compounds may have diluted in vast volumes, the establishment of proper extraction protocols 
prior to analysis is an important initial requirement.  Once retrieved from a sample matrix, analytes must be 
dissolved in a solvent suitable to the method of analysis.  Both proposed membrane-based methods utilise 
biological components which are sensitive to the presence of organic solvents.  Furthermore, the membrane 
elements themselves are generally better suited for use with aqueous buffer systems.  Table 6.1 highlights 
some of the broader similarities and differences between the possible membrane-based technologies for 
EDC detection presented in this dissertation. 
Table 6.1 Comparison between dot-ELISA dipsticks and LFIA for the detection of EDCs in aqueous matrices. 
Dipstick LFIA 
• Based on receptor conformation change 
following ligand-binding 
• Multiple reagent format 
• Highly specialised biorecognition 
molecules required 
• Adaptation of established technology 
• Enzymatic visualisation may be optimal 
• May be quantitative if suitable digital 
readers are developed 
• User friendly 
• Conformation dependent mAbs required 
for every receptor if used 
• Receptor coregulatory proteins may be 
promiscuous to multiple receptor LBDs 
• Based on receptor-ligand interaction 
• Single step required 
• Biorecognition molecules are only needing to 
detect protein 
• Multiple formats may be viable 
• Based on proven technology 
• Nanoparticle visualisation may be optimal 
• May be quantitative if suitable digital readers 
are developed 
• May be adaptable to multiple receptors 
• Design of device can be altered to increase 
sensitivity; increase of sample volume or 
signal enhancement (VFIA) 
• Extremely user friendly 
• Once technology is established, it should be 
easy to adapt to other receptors 
• Preconcentration of environmental samples required 
• Further work required to achieve functional prototypes 
 




6.6 FUTURE PERSPECTIVES 
During this study it was shown that recombinant NR LBDs of human origin, expressed in insect cells can 
not only be purified from lysate to high homogeneity, but that these proteins could be maintained in 
solution and retained ligand-binding capabilities.  Furthermore, the hexahistidine fusion tag incorporated at 
the N-terminal end of the recombinant proteins, which facilitated purification by means of a simple one-
step procedure, also enabled the facile immobilisation of the proteins to a metal chelation membrane.  The 
ability to directionally immobilise recombinant NR LBDs to IMAMs may hold promise in the development 
of a membrane-based dipstick for the detection of EDCs.  At the very least, biofunctionalised PVP-PSMI 
can be developed into a rapid HTS laboratory-based method for the characterisation of suspected 
hormonally active compounds based on competitive displacement of radioactive, fluorescent or luminescent 
ligands to nuclear receptors.  However, a reasonable alternative to produce a test amenable to laboratory 
and field-use may still be to gauge the three-dimensional conformation of the LBD following ligand-
binding by means of a measurable visual response.  Further investigation into the feasibility of such a 
system would require the heterologous expression and purification of recombinant proteins which carry 
motifs that can interact with NR LBDs at defined protein-protein interfaces.  Following purification, these 
proteins may be conjugated to reporter particles, enzymes or biotin for visualisation of protein-protein 
interaction by a variety of means.  Alternatively, NR LBD-binding proteins may be expressed as fusion 
constructs with HRP, AP or light emitting proteins such as green fluorescent protein. 
In conclusion, there are multiple ways by which a LFIA capable of EDC detection may function.  All these 
iterations will require specialised membrane components to produce the strip, all of which are commercially 
available.  Most of the biological component which may be necessary for the assembly of such a device 
have been produced during this project to date.  However, an essential component, of which the 
manufacture still needs further investigation, is the cognate ligands coupled to proteins required for 
transient immobilisation of receptor molecules in the direct-competitive format or the capture of labelled 
LBD in the competitive LFIA.  Several methods to facilitate the conjugation of small molecular haptens to 
carriers proteins have been described (439), and the implementation of these procedures in the development 
of novel LFIA devices will be researched in future. 
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ADDENDUM A: DETAILS OF REAGENT SUPPLIERS 
The following is a list of reagents used during the procedures described in this thesis and the manufacturers 
and/or suppliers from whom they were procured. 
The baculovirus transfer plasmid used for construction of the vector, pAB-6xHis, the linearised baculovirus 
DNA, ProFold®-C1 and titrated reference viruses used as infection controls and titration aides, Green 
Control (GFP expression) and No-expression Control (polyhedrin deletion): 








Spodoptera frugiperda Sf9 (Sf9; CVCL_0549) and Trichoplusia ni BTI-Tn-5B1-4 (T. ni; CVCL_C190) 
insect cell lines: 









Clarity ECL substrate solution: 












The BacPAK™ qPCR Titration Kit: 









The mammalian expression vector, pSGhERα66, containing the DNA encoding the alpha isoform of the 
human oestrogen receptor, was a generous gift from the laboratories of Ann Louw and Donita Africander: 
o Department of Biochemistry 




Amersham™ Protran™ 0.45 μm NC nitrocellulose blotting membrane and HiTrap Chelating and Desalting 
columns: 
o GE Healthcare Bio-Sciences AB 
Uppsala 
Sweden 
The synthetic peptide αII, SGSGLTSRDFGSWYA: 




o Greiner Bio-One 
Frickenhausen 
Germany 
InnovaCoat® GOLD-Carboxyl 40OD and 10 kDa MWCO AbPure™ spin cartridges: 
o Innova Biosciences 
Cambridge 
UK 




Oligonucleotide primers used during the amplification of DNA encoding domains E and E/F of the hERα 
LBD: 




HRP-conjugated goat anti-rat IgG: 








The murine myeloma cell line, SP2/0-Ag14, was generously donated by Prof Edmund Pool: 
o Medical Bioscience Programme 
Faculty of Natural Science 
University of the Western Cape 
Cape Town 
RSA 
Deionised water was prepared to 18.2 MΩ with a Milli-Q deionising system; bovine serum albumin, 
methanol and sodium bicarbonate: 
o Merck KGaA 
Darmstadt 
Germany 
Radiolabelled steroid [2,4,6,7-3H(N)]-oestradiol (3HE2; lot #: 2112785, 3,478 GBq/mmol, 37 MBq/mL), 
6-mL polypropylene liquid scintillation pony vials and FlowScint III liquid scintillation cocktail: 









Female BALB/c mice, five-weeks of age: 
o Research Animal Facility 
Faculty of Health Sciences 
University of Cape Town 
Cape Town 
RSA 
Rabbit anti-ERα polyclonal antibodies (sc-543): 




Acrylamide, activated charcoal, amphotericin B, antipain, aprotinin, atrazine, bisphenol A, bisphenol S, 
bovine gamma globulins, bovine serum albumin, Bromophenol Blue, carbamazepine, casein, 
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate hydrate, Coomassie Brilliant Blue R-250, 
α-cypermethrin, p,p’-dichlorodiphenyl-dichloroethylene, p,p’-dichlorodiphenyl-trichloroethane, di-n-butyl 
phthalate, dimethyl sulphoxide, dithiothreitol, endosulfan, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide, ethylenebis-(oxyethylenenitrilo)-tetraacetic acid, ethylenediaminetetraacetic acid disodium 
dihydrate, 17α-ethynyloestradiol, Ficoll Orange, genistein, gentamicin, glacial acetic acid, glycerol, glycine, 
HAT and HT media supplements, heparin, horseradish peroxidase-conjugated goat anti-mouse IgG, Fab 
specific, horseradish peroxidase-conjugated goat anti-rabbit IgG hydrochloric acid, imidazole, ISO-2 mouse 
monoclonal antibody isotyping reagents, lactalbumin, Laemmli SDS-PAGE treatment buffer, 
lipopolysaccharides from Salmonella enterica, serotype enteritidis, leupeptin, β-mercaptoethanol, 2-(N-
morpholino) ethanesulphonic acid, nickel sulphate, Nonidet-P40, 17β-oestradiol, oestriol, oestrone, 
PenStrep, pepstatin A, phenylmethanesulphonyl fluoride, phosphate salts, poly-L-histidine, RPMI-1640, 
sodium bicarbonate, sodium carbonate, sodium chloride, sodium dodecyl sulphate, sodium metabisulphite, 
sodium metavanadate, sucrose, 4-tert-octylphenol, 3,3’,5,5’-tetramethylbenzidine, TiterMax Gold® 
adjuvant, tris(hydroxymethyl) aminomethane, Tween-20, Whatman® no. 1 filter paper, zearalenone and 





45 mm 12 – 14 kDa MWCO Spectra/Por® 2 dialysis membrane tubes: 








Tissue culture flasks, centrifuge tubes, cell strainers and other laboratory disposables: 
o SPL Life Sciences 
Pocheon-si 
South Korea 
GlutaMAX™, Grace’s insect cell medium, Imject™ maleimide-activated BSA, Imject™ maleimide-
activated mariculture keyhole limpet haemocyanin, ImmunoPure® HRP-conjugated goat anti-mouse IgG 
(H+L) antibodies, rat anti-ERα IgG, Nunc-Immuno™ F96 Maxisorp™ 96-well microtiter plates, the 
restriction enzymes, Cfr9I an EcoRI, Trypan Blue and 2-mL 7K MWCO Zeba™ spin desalting columns: 




D1 LE molecular grade agarose: 
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